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SYSTEMATIC REVIEW

Effects of neonatal nutrition interventions on neonatal
mortality and child health and development outcomes: A
systematic review
Aamer Imdad1 | Faseeha Rehman2 | Evans Davis3 | Deepika Ranjit4 |
Gamael S. S. Surin4 | Suzanna L. Attia5 | Sarah Lawler6 | Abigail A. Smith7 |
Zulfiqar A. Bhutta8
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Abstract
Background: The last two decades have seen a significant decrease in mortality for
children <5 years of age in low and middle‐income countries (LMICs); however,
neonatal (age, 0–28 days) mortality has not decreased at the same rate. We assessed
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three neonatal nutritional interventions that have the potential of reducing mor-
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Objectives: To determine the efficacy and effectiveness of synthetic vitamin A,
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bidity and mortality during infancy in LMICs.
dextrose oral gel, and probiotic supplementation during the neonatal period.
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Search Methods: We conducted electronic searches for relevant studies on the
following databases: PubMed, CINAHL, LILACS, SCOPUS, and CENTRAL, Cochrane
Central Register for Controlled Trials, up to November 27, 2019.
Selection Criteria: We aimed to include randomized and quasi‐experimental studies.
The target population was neonates in LMICs. The interventions included synthetic
vitamin A supplementation, oral dextrose gel supplementation, and probiotic supplementation during the neonatal period. We included studies from the community
and hospital settings irrespective of the gestational age or birth weight of the
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neonate.
Data Collection and Analysis: Two authors screened the titles and extracted the
data from selected studies. The risk of bias (ROB) in the included studies was assessed according to the Cochrane Handbook of Systematic Reviews. The primary
outcome was all‐cause mortality. The secondary outcomes were neonatal sepsis,
necrotizing enterocolitis (NEC), prevention and treatment of neonatal hypoglycaemia, adverse events, and neurodevelopmental outcomes. Data were meta‐analyzed
by random effect models to obtain relative risk (RR) and 95% confidence interval
(CI) for dichotomous outcomes and mean difference with 95% CI for continuous
outcomes. The overall rating of evidence was determined by the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach.
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Main Results: Sixteen randomized studies (total participants 169,366) assessed the
effect of vitamin A supplementation during the neonatal period. All studies were
conducted in low‐ and middle‐income (LMIC) countries. Thirteen studies were
conducted in the community setting and three studies were conducted in the hospital setting, specifically in neonatal intensive care units. Studies were conducted in
10 different countries including India (four studies), Guinea‐Bissau (three studies),
Bangladesh (two studies), and one study each in China, Ghana, Indonesia, Nepal,
Pakistan, Tanzania, and Zimbabwe. The overall ROB was low in most of the included
studies for neonatal vitamin A supplementation. The pooled results from the community based randomized studies showed that there was no significant difference in
all‐cause mortality in the vitamin A (intervention) group compared to controls at
1 month (RR, 0.99; 95% CI, 0.90–1.08; six studies with 126,548 participants,
statistical heterogeneity I2 0%, funnel plot symmetrical, grade rating high), 6 months
(RR, 0.98; 95% CI, 0.89–1.07; 12 studies with 154,940 participants, statistical heterogeneity I2 43%, funnel plot symmetrical, GRADE quality high) and 12 months of
age (RR, 1.04; 95% CI, 0.94–1.14; eight studies with 118,376 participants, statistical
heterogeneity I2 46%, funnel plot symmetrical, GRADE quality high). Neonatal vitamin A supplementation increased the incidence of bulging fontanelle by 53%
compared to control (RR, 1.53; 95% CI, 1.12–2.09; six studies with 100,256 participants, statistical heterogeneity I2 65%, funnel plot symmetrical, GRADE quality
high). We did not identify any experimental study that addressed the use of dextrose
gel for the prevention and/or treatment of neonatal hypoglycaemia in LMIC. Thirty‐
three studies assessed the effect of probiotic supplementation during the neonatal
period (total participants 11,595; probiotics: 5854 and controls: 5741). All of the
included studies were conducted in LMIC and were randomized. Most of the studies
were done in the hospital setting and included participants who were preterm
(born < 37 weeks gestation) and/or low birth weight (<2500 g birth weight). Studies
were conducted in 13 different countries with 10 studies conducted in India, six
studies in Turkey, three studies each in China and Iran, two each in Mexico and
South Africa, and one each in Bangladesh, Brazil, Colombia, Indonesia, Nepal, Pakistan, and Thailand. Three studies were at high ROB due to lack of appropriate
randomization sequence or allocation concealment. Combined data from 25 studies
showed that probiotic supplementation reduced all‐cause mortality by 20% compared to controls (RR, 0.80; 95% CI, 0.66–0.96; total number of participants 10,998,
number needed to treat 100, statistical heterogeneity I2 0%, funnel plot symmetrical,
GRADE quality high). Twenty‐nine studies reported the effect of probiotics on the
incidence of NEC, and the combined results showed a relative reduction of 54% in
the intervention group compared to controls (RR, 0.46; 95% CI, 0.35–0.59; total
number of participants 5574, number needed to treat 17, statistical heterogeneity I2
24%, funnel plot symmetrical, GRADE quality high). Twenty‐one studies assessed
the effect of probiotic supplementation during the neonatal period on neonatal
sepsis, and the combined results showed a relative reduction of 22% in the intervention group compared to controls (RR, 0.78; 95% CI, 0.70–0.86; total number of
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participants 9105, number needed to treat 14, statistical heterogeneity I2 23%,
funnel plot symmetrical, GRADE quality high).
Authors' Conclusions: Vitamin A supplementation during the neonatal period
does not reduce all‐cause neonatal or infant mortality in LMICs in the community
setting. However, neonatal vitamin A supplementation increases the risk of
Bulging Fontanelle. No experimental or quasi‐experimental studies were available from LMICs to assess the effect of dextrose gel supplementation for the
prevention or treatment of neonatal hypoglycaemia. Probiotic supplementation
during the neonatal period seems to reduce all‐cause mortality, NEC, and sepsis
in babies born with low birth weight and/or preterm in the hospital setting. There
was clinical heterogeneity in the use of probiotics, and we could not recommend
any single strain of probiotics for wider use based on these results. There was a
lack of studies on probiotic supplementation in the community setting. More
research is needed to assess the effect of probiotics administered to neonates
in‐home/community setting in LMICs.

1 | P L AI N LAN G U A G E S U M M A RY

1.1.2 | What studies are included?

1.1 | Neonatal probiotic supplementation can
improve infant illness and reduce death, but vitamin
A does not, and may have adverse effects

Sixteen studies that assessed the effect of vitamin A supplementation
during the neonatal period were included. Thirteen of these studies
were conducted in the community setting and three studies were
conducted in the hospital setting. All the included studies on neonatal

Nutritional support during the 1st month of life is vital for the short‐ and

vitamin A supplementation were conducted in LMICs. Most of the

long‐term survival of the newborn. Neonatal nutrition interventions have

studies had a low ROB.

the potential to decrease death and illness in young infants in LMICs.

No experimental studies were found that evaluated the use of
dextrose for the prevention or treatment of low blood sugar during
the neonatal period.

1.1.1 | What is this review about?

Thirty‐three studies assessed the use of probiotics during the 1st
month of life. All included studies on probiotic supplementation were

This review assesses the efficacy of synthetic vitamin A, dextrose, and

randomized and conducted in LMICs. Most of the included studies

probiotic supplementation during the neonatal period. These interven-

had a low ROB. The probiotics studies mainly included babies born

tions were assessed separately and not in combination with each other.

early and/or with low birth weight, and these studies were mostly
conducted in hospital settings.

What is the aim of this review?
This Campbell systematic review assesses the

1.1.3 | Key results

efficacy of three neonatal nutritional interventions that have the potential of reducing mor-

Combined results from thirteen vitamin A studies conducted in the

bidity and mortality during infancy in LMICs:

community settings showed that there was no significant effect of

synthetic vitamin A, dextrose, and probiotic

vitamin A supplementation for reduction of death in young infants at

supplementation.

1, 6, or 12 months of age. Neonatal vitamin A supplementation increases the risk of bulging fontanelle by 53%. The pooled data from
probiotics studies showed that this intervention reduced the risk of
death by 20% compared to controls. Further analysis showed that

1.1.4 | What are the main findings of the review?

compared to controls, probiotic supplementation reduced the risk of
a severe form of gastrointestinal illness in neonates called NEC by

Combined results from thirteen vitamin A studies conducted in the

54%. Probiotic supplementation also reduced the risk of blood in-

community settings showed that there was no significant effect of

fection called sepsis by 22% compared to controls. The quality grade

vitamin A supplementation for reduction of death in young infants at

ratings for these outcomes were “high.”
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1, 6, or 12 months of age. However, neonatal vitamin A supple-

births happen at home and the prevalence of maternal malnutrition

mentation increased the incidence of bulging fontanelle by 53%.

and incidence of low birth weight (birth weight <2500 g) and preterm

The pooled data from probiotics studies showed that this interven-

birth (gestational age <37 weeks) is high (Bhutta et al., 2013; Lee

tion reduced the risk of death by 20% compared to controls. Further

et al., 2017; WHO, 2017b). This review focused on three nutritional

analysis showed that compared to controls, probiotic supplementation

interventions during neonatal periods that have the potential to re-

reduced the risk of a severe form of gastrointestinal illness in neonates

duce illness and death during infancy in LMIC.

called NEC by 54%. Probiotic supplementation also reduced the risk of
blood infection called sepsis by 22% compared to controls. The quality
grade ratings for these outcomes were “high.”

2.1 | Description of the condition
The approach to nutritional management of newborn depends on

1.1.5 | What do the findings of this review mean?

maternal nutritional status, comorbidities during pregnancy (such as
gestational diabetes), pregnancy duration (term vs. preterm birth),

Vitamin A supplementation during the 1st month of life does not

events at birth (such as birth asphyxia), birth weight (low birth weight

reduce the risk of death during the 1st year of life in LMICs. How-

vs. normal birth weight) and available resources for postpartum

ever, neonatal vitamin A supplementation increases the risk of bul-

care of the mother and the baby (such as skilled birth attendant,

ging fontanelle, which may cause damage to the brain.

home vs. facility birth, availability of neonatal intensive care) (Bhutta

We did not find any experimental studies from LMICs that as-

et al., 2013; WHO, 2015, 2017a, 2017b). The most important nu-

sessed the use of dextrose gel supplementation during the 1st month

tritional intervention after birth is breastfeeding, which is covered in

of life for the prevention or treatment of low blood sugar.

a separate Campbell review of this series. There are a number of

Probiotic supplementation during the 1st month of life to babies

other nutritional interventions that have been proposed in addition

born preterm and/or low birthweight can reduce the risk of death,

to breastfeeding. It is beyond the scope of this review to compre-

blood infection and bowel sickness (NEC).

hensively evaluate all the possible nutritional interventions during

There was clinical heterogeneity in the use of probiotics and we

the neonatal period. We limited our review to the following three

could not recommend any single strain or combination of probiotics

interventions: neonatal synthetic vitamin A supplementation, oral

for wider use based of these results.

dextrose gel supplementation, and probiotic supplementation during

There is a lack of studies on probiotic supplementation in the 1st

the neonatal period in LMIC. Below in this section and in the rest

month of life in community settings. More research is needed to

of the introduction, we describe the rationale and importance of

assess the effect of probiotics administered to neonates in home/

reviewing these interventions.

community settings in LMICs.

2.1.1 | Neonatal vitamin A deficiency (VAD)
1.1.6 | How up‐to‐date is this review?
Globally, about 190 million children and 19.1 million pregnant woThe review authors searched for studies published up to
November 2019.

men are vitamin A deficient based on serum retinol levels (i.e., serum
retinol <0.70 μmol/L) (WHO, 2009a). VAD is most prevalent in South
Asia and Africa (Stevens et al., 2015). VAD is associated with
increased risk of blindness, infections, and mortality (Imdad

2 | BACKGROUND

et al., 2017). Most of the newborns are vitamin A deficient and rely
on supplementation from maternal breast milk (Haider et al., 2017).

The decline in rates of neonatal (age, 0–28 days) mortality has been

High prevalence of maternal VAD in LMICs increases the risk of

slower than the decline in child mortality between 1990 and 2016

neonatal VAD. There has been interest in vitamin A supplementation

(Alkema et al., 2014; Bhutta et al., 2015). Neonatal mortality ac-

during neonatal period to assess if it reduces risk of illness and death

counted for 46% of child mortality in 2016 compared to 40% of all

(Haider et al., 2017; WHO, 2009b), as it has been shown to reduce

under‐five mortality rates in 1990 (WHO, 2017a). Globally, the

morbidity and mortality in children 6–59 months of age (Imdad

percentage of neonatal mortality is the highest in South Asia and

et al., 2017).

Sub‐Saharan Africa (Alkema et al., 2014). Optimal nutritional support
during the neonatal period is vital to the short and long term survival
of the newborn (Bhutta et al., 2013; WHO, 2017b). Poor nutritional

2.1.2 | Hypoglycemia during the neonatal period

status of neonates is a major cause of illness and can lead to poor
growth, increased risk of infection, bleeding, and neonatal death

Hypoglycemia (low blood sugar) is common during the immediate

(Bhutta et al., 2013; WHO, 2017b). The risk of morbidity and mor-

neonatal period. The definition of neonatal hypoglycaemia varies. The

tality during the neonatal period is higher in LMICs where many

American Academy of Pediatrics defines neonatal hypoglycaemia as

IMDAD
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blood glucose below 47 mg/dl (2.61 mmol/L); however, other socie-

causes inflammation that may contribute to neonatal sepsis and/or

ties such as the Pediatric Endocrine Society define neonatal

NEC (Arrieta et al., 2014; Deshmukh et al., 2014; Gewolb et al., 1999;

hypoglycaemia as blood glucose <50 mg/dl (2.77 mmol/L; Thompson‐

Panigrahi et al., 2017). There is an increasing interest in correction of

Branch & Havranek, 2017; Thornton et al., 2015). Recurrent, severe,

intestinal dysbiosis by probiotics to prevent NEC and neonatal sepsis.

and/or persistent hypoglycaemia can lead to complications such as

Data from early studies on probiotic use in neonates from LMIC is

death; there is limited evidence to show that blood sugars below a

encouraging (AlFaleh & Anabrees, 2014; Rao et al., 2016).

certain level leads to long‐term brain damage (Kaiser et al., 2015;
McKinlay et al., 2017; Thornton et al., 2015). About 10–15% of
otherwise healthy newborns have low blood sugar, and the rate is

2.2 | Description of the intervention

much higher among infants with additional risk factors such as large
for gestational age, small for gestational age, low birth weight, pre-

2.2.1 | Neonatal vitamin A supplementation

term birth, infant of diabetic mother, and newborns with perinatal
asphyxia (Thompson‐Branch & Havranek, 2017). Additional risk fac-

Vitamin A is a term used for a subclass of the family of fat soluble

tors for neonatal hypoglycaemia include neonatal sepsis, prolonged

compounds named retinoic acids. Vitamin A is found in nature in two

labor, and maternal medication use such as use of β‐agonists and

forms, provitamin A carotenoids and preformed vitamin A, which is

β‐blockers (Thompson‐Branch & Havranek, 2017). The recommended

essential to human bodily function. Plant‐based foods are the main

initial intervention to treat neonatal hypoglycaemia is to offer feed-

source of provitamin A carotenoids, of which β‐carotene is the most

ing in the form of breastfeeding followed by formula feeding if

commonly known. Animal‐based foods are the main source of pre-

breastfeeding is unsuccessful. Persistent hypoglycaemia may require

formed vitamin A (Bates, 1995; Haider & Bhutta, 2011). Vitamin A

IV dextrose supplementation and admission to a neonatal intensive

from animal sources (retinol, retinal, retinoic acid, and retinyl esters)

Thornton

is the most active form, and synthetic vitamin A retinol has been used

et al., 2015). In LMIC, where a significant proportion of births happen

in most intervention trials in the past (Haider & Bhutta, 2011; Imdad

at home and incidence of low birth weight and preterm birth is high,

et al., 2017). Plant‐based foods may not be an adequate source of

prevention and treatment of hypoglycaemia encounters additional

vitamin A, as the gastrointestinal conversion ratio from carotenoid‐

challenges (Singhal et al., 1991, 1992; WHO, 2017b; Williams, 1997).

to‐retinol varies from 6:1 to 26:1 (US Institute of Medicine, Food and

The instruments to test blood sugar might not be available in low‐

Nutrition Board). VAD may, therefore, exist in areas even when there

resource settings; In addition, formula, IV dextrose, and intensive

is high consumption of plant‐based foods such as in South Asia and

care units might not be available to treat persistent and/or severe

Africa (Imdad et al., 2017; Stevens et al., 2015).

care

unit

(Thompson‐Branch

&

Havranek,

2017;

hypoglycaemia. Recent studies have tested simple interventions such
as oral dextrose gel to treat neonatal hypoglycaemia and to prevent
hypoglycaemia in high‐risk newborns (Hegarty et al., 2016; Weston
et al., 2016).

2.2.2 | Oral dextrose gel supplementation during
neonatal period
Dextrose gel is a thickened aqueous solution that contains the con-

2.1.3 | Neonatal sepsis and NEC

centrated simple carbohydrate dextrose. It can be administered by
direct application to oral, buccal, or sublingual mucosa and can in-

Neonatal sepsis and NEC are neonatal morbidities that can be fatal

crease blood sugars rapidly by absorption through the highly vas-

(Oza et al., 2015; WHO, 2017b). Neonatal sepsis is the presence of an

cularized and thin mucus membranes of the oral mucosa (Hegarty

infection leading to systemic illness. Bacterial sepsis is common in

et al., 2016). Detxrose gel is a low cost nonproprietary intervention,

LMIC and is a significant risk factor of morbidity and mortality

and the gel can be prepared in hospital pharmacies. The typical in-

in these countries (WHO, 2017a). NEC is a condition that occurs in

gredients include water, glucose, a gelling agent, and preservatives

newborns and can lead to intestinal injury and death. The extent of

(Hegarty et al., 2016). The decision to use dextrose gel in a neonate

injury may vary from mucosal injury to full thickness intestinal wall

should be taken on individual basis and should be avoided in neo-

injury. NEC happens most commonly in preterm babies and especially

nates with compromised neurological or respiratory status (Hegarty

in extremely preterm babies (<28 weeks gestational age; AlFaleh &

et al., 2016; Weston et al., 2016).

Anabrees, 2014; Patel & Denning, 2015). Multiple factors lead to the
development of NEC in preterm infants including altered bacterial
gut flora affecting the protective intestinal barrier, decreased intestinal motility, and the increased susceptibility of preterm infants

2.2.3 | Probiotic supplementation during neonatal
period

to inflammation and infections (Patel & Denning, 2015). Recent
studies have shown that an imbalance between commensal bacteria

Prebiotics are supplements that promote the growth of commensal

and pathogenic bacteria (intestinal dysbiosis) makes babies vulner-

bacteria (AlFaleh & Anabrees, 2014; Panigrahi et al., 2017). Probio-

able to pathogenic bacterial growth in the intestine which then

tics contain live bacteria that enrich pools of commensal bacteria

6 of 88
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(AlFaleh & Anabrees, 2014; Millar et al., 2003; Panigrahi et al., 2017).

that it does not require special skills (such as IV placement) and can

Synbiotics are a combination of prebiotics and probiotics and

be administered by community, lay health workers, or the caregiver

might have synergistic effect (Johnson‐Henry et al., 2016, Nandhini

herself. Potential adverse effects include vomiting, choking, gagging,

et al., 2016; Panigrahi et al., 2017). These supplements are meant to

respiratory distress, and delay of treatment for severe hypoglycae-

optimise gut health and their hypothesized mechanisms of actions in-

mia (Hegarty et al., 2016; Weston et al., 2016).

clude enhanced gut barrier function, inhibition of gut colonization with
pathogenic bacteria, improvement in colonization with healthy commensal bacteria that protect the infant from enteropathogenic infection
through production of acetate, enhanced innate immunity, and in-

2.4 | Probiotics supplementation during neonatal
period

creased maturation of the enteric nervous system (Rao et al., 2016).
Recent data have shown that probiotic supplements can prevent the

Newborn, and especially preterm, babies have immature intestines

incidence of NEC in preterm babies (AlFaleh & Anabrees, 2014; Millar

free of normal commensal bacteria that would normally protect them

et al., 2003; Patel & Denning, 2015; van den Akker et al., 2018). There is

from developing NEC and sepsis by inhibiting the growth of patho-

also promising data on use of probiotocs/synbiotics for prevention

genic bacteria in the intestines (AlFaleh & Anabrees, 2014; Patel &

of neonatal sepsis (Rao et al., 2016; Panigrahi et al., 2017). The

Denning, 2015; Rao et al., 2016). Probiotics are used to proactively

most commonly used strains of probiotics include Lactobacillus and

colonize the intestines with beneficial bacteria such as Lactobacillus

Bifidobacterium (Rao et al., 2016).

species (Millar et al., 2003; Patel & Denning, 2015). Probiotics
therefore reduce the growth of pathogenic bacteria which would
otherwise increase the risk of NEC and sepsis. Also probiotics pro-

2.3 | How the intervention might work

mote gut immunity by increasing IgA levels and contributing to improved mucosal barrier function (Patel & Denning, 2015). These

2.3.1 | Neonatal vitamin A supplementation

protective mechanisms reduce intestinal permeability by producing a
protective mucosal barrier against bacteria and increase the pro-

Vitamin A has an effect on cell differentiation and helps maintain

duction of anti‐inflammatory cytokines (Deshpande et al., 2017;

normal functioning of epithelial cells (Bates, 1995; Bhutta

Millar et al., 2003). Probiotics are especially protective in preterm

et al., 2013; Haider & Bhutta, 2011). It is considered anti‐infective

babies with immature intestinal microbiomes and neonates on anti-

because it helps to maintain the protective epithelial barrier of the

biotics; antibiotics may reduce bacterial diversity in the intestine and

skin and mucosa, which protects the body from infections. Vitamin A

thus also dispose to colonization by pathogenic bacteria causing NEC.

helps in the regeneration of the epithelium and therefore maintains

Prebiotics and probiotics can be given together in the form of a

the integrity of the body's first line of defence. These mechanisms

synbiotic to improve the gut flora and can potentially reduce all‐

may help prevent infections in newborns (McCullough et al., 1999;

cause neonatal mortality (Johnson‐Henry et al., 2016; Panigrahi

Wolbach, 1933). Synthetic vitamin A supplementation has been

et al., 2017). Probiotics are considered safe; however, there are

shown to reduce morbidity and mortality in children 6–59 months of

concerns regarding probiotic supplementation in extremely pre-

age (Imdad et al., 2017). The potential side effects of synthetic vi-

mature or immunocompromised neonates. A few cases of neonatal

tamin A supplementation include vomiting and bulging fontanelle

sepsis have been reported that were thought to be caused by

(Imdad et al., 2016, 2017; Haider & Bhutta, 2011; Haider

probiotics (Dani et al., 2016).

et al., 2017). Excess vitamin A supplementation can cause toxicity
that presents in the form of a bulging fontanelle in children under
1 year, headaches, vomiting, diarrhea, loss of appetite, and irritability

2.5 | Why it is important to do this review

(Haider et al., 2017; Imdad et al., 2017).

2.5.1 | Neonatal vitamin A supplementation
2.3.2 | Oral dextrose gel supplementation during
neonatal period

Randomized trials on neonatal vitamin A supplementation have
produced conflicting results with some studies (mostly from South
Asia) showing a mortality benefit while no major benefit in other

The absorption of dextrose gel through the oral mucosa leads to

studies (mostly from Africa) (Haider et al., 2017) and some studies

entry of glucose into lingual veins and into the internal jugular vein.

showing even an increased risk of infant mortality in certain popu-

This pathway provides almost immediate delivery of glucose to the

lations (Smith et al., 2016).The exact reason for this difference in

systemic circulation and bypasses first pass liver metabolism through

results is not clear. Previous reviews (Haider et al., 2017; Gogia &

the portal circulation. If proven effective in preventing and treating

Sachdev, 2009) and a WHO technical consultation (WHO, 2009b)

hypoglycaemia, dextrose gel can avoid the need of intravenous glu-

have hypothesized on what factors may explain these varied results.

cose and reduce separation of baby from mother (Hegarty

Our group has previously published a Cochrane review on the evidence

et al., 2016; Weston et al., 2016). The intervention is simple enough

on neonatal vitamin A supplementation (Haider & Bhutta, 2011), and

IMDAD
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cluded studies conducted in the community setting. In this review, we
considered studies conducted in both the community and the hospital

4.1 | Criteria for considering studies for this review

setting in LMIC. We also included neurodevelopment outcomes for this
review that were not covered in the previous Cochrane review.

4.1.1 | Types of studies
We included the following study designs:

2.5.2 | Oral dextrose gel supplementation during
neonatal period

• Randomized controlled trials (RCTs), where participants were
randomly assigned either individually or in clusters to intervention

Oral dextrose gel has been studied in the prevention and

and comparison groups. Cross‐over designs were also eligible for

treatment of neonatal hypoglycaemia in high‐income countries

inclusion.

(Hegarty et al., 2017; Weston et al., 2016); however, it was not

• Quasi‐experimental designs, which include:

clear if similar studies were available from LMICs. Our objective
was to consider both randomized and nonrandomized observa-

a. Natural experiments: studies where nonrandom assignment was

tional studies with a control arm. We hypothesized that the use of

determined by factors that were out of the control of the in-

dextrose may be more beneficial in LMIC than in high‐income

vestigator. One common type includes allocation based on exo-

countries, as the incidence of neonatal hypoglycaemia might be
higher in these countries due to an increased rate of preterm and
low birth weight birth.

genous geographical variation.
b. Controlled before‐after studies (CBA), in which measures were
taken of an experimental group and a comparable control group
both before and after the intervention. We also require that appropriate methods were used to control for confounding, such as

2.5.3 | Probiotics supplementation during neonatal
period

statistical matching (e.g., propensity score matching or covariate
matching) or regression adjustment (e.g., difference‐in‐differences,
instrumental variables).

The effect of probiotic supplementation for the prevention of NEC and
neonatal sepsis has been assessed in previous reviews (AlFaleh &

c. Regression discontinuity designs; here, allocation to intervention/
control was based upon a cut‐off score.

Anabrees, 2014; Rao et al., 2016; van den Akker et al., 2018). Most of

d. Interrupted time series studies, in which outcomes were mea-

these reviews included studies from both high‐ and LMICs. Deshpande

sured in the intervention group at at least three time points be-

et al. (2017) reviewed studies from LMIC where neonates were sup-

fore the intervention and after the intervention.

plemented with probiotics. More studies (Amini et al., 2017;
Chowdhury et al., 2016; Guney‐Varal et al., 2017; Hernández‐Enríquez
et al., 2016; Hussain et al., 2016) have been published since the

4.1.2 | Types of participants

publication of Deshpande et al.'s (2017) review. Overall, our objective
was to assess the current evidence for the effect of probiotic

Participants for this review included neonates (aged 0–28 days) from

supplementation during the neonatal period in the hospital and

LMICs. We included neonates regardless of their health status. This

community setting in LMIC.

includes low birth weight and preterm babies. However, studies that
focused on neonates with congenital anomalies were excluded. We
considered studies that included older age population groups in ad-

3 | OBJECTIVES

dition to neonates only if we could disaggregate relevant data for the
neonatal population. For example, a study might include infants up to

3.1 | Primary objectives

6 months of age. We included such a study if the disaggregated data
were available for neonates (0–28 days). Even though we planned to

To determine the efficacy of the following interventions on neonatal

assess later childhood outcomes, we did not plan to include studies

morbidity and mortality:

that recruited participants after the neonatal period.

1. Synthetic vitamin A supplementation,
2. Oral dextrose gel supplementation, and

4.1.3 | Types of interventions

3. Oral probiotic supplementation.
The following interventions were included in the review:
A detailed description of background and methods for this
review was published in the form of a protocol as Imdad
et al. (2019).

1. Neonatal vitamin A supplementation compared to no supplementation or placebo: we considered only oral synthetic vitamin A
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Secondary outcomes

frequency of the medicine. The comparison group could include a

The secondary outcomes included:

ET AL.

placebo or standard of care.
2. Oral dextrose gel supplementation during the neonatal period
compared to no supplementation: we placed no limits on the dose

1. Sepsis‐specific mortality measured between 0 and 28 days, 0 days
and 6 months, and 0 days and 12 months of life

or frequency of the dextrose supplementation. We only con-

2. Neonatal sepsis (as defined by authors) in the first 6 weeks of life

sidered dextrose gel as the intervention and excluded dextrose

3. NEC as defined by authors

given in other forms such as intravenous, nasogastric tube, or

4. VAD

mixed with infant formula. The reason to exclude forms other

5. Prevention of Hypoglycemia (as defined by authors) during the

than dextrose gel was that administration of dextrose in those
forms may require special circumstances (like trained staff to
place an IV) or special delivery vehicles, such as formula, that may

neonatal period
6. Treatment of Hypoglycemia (recurrence of hypoglycaemia after
the episode treated)

not be available in LMIC. The comparison group included placebo

7. Any adverse reactions during the intervention period

or standard of care.

8. Serious adverse events

3. Neonatal oral probiotics/synbiotics compared to no probiotic supplementation: probiotics are live microbial organisms that are given

9. Neurodevelopmental outcomes at 12 and 24 months and at the
longest follow‐up.

to promote the growth of commensal gut bacteria and prevent the
growth of pathogenic bacteria. Prebiotics are dietary supplements

The term neurodevelopment is a composite term that refers to

that promote the growth of commensal bacteria. Synbiotics are a

cognitive, neurologic, and/or sensory outcomes. The term neurode-

combination of prebiotics and probiotics (Millar et al., 2003; Patel

velopment may include intellectual disability as measured on the

& Denning, 2015). We placed no limits on the dose or frequency of

Mental Developmental Index of the Bayley Scales of Infant Devel-

probiotics. We included studies that used probiotics and synbiotics

opment; gross motor delay measured on Gross Motor Function

supplementation and excluded studies that used only prebiotics.

Classification System, and hearing and vision loss requiring amplifi-

Comparison groups included placebo or standard of care.

cation devices.
In order to be eligible for inclusion in the review, a study should

Each of the above interventions (i.e., vitamin A, dextrose, or
probiotics) was summarized separately, and the interventions were

have reported at least one of the primary or secondary outcomes.
This was assessed at the full‐text review stage.

not compared to each other directly or indirectly.
Duration of follow‐up. We included all participants in eligible studies that had outcomes of interest measured. There were no re-

4.1.4 | Types of outcome measures

strictions based on the duration of exposure, duration of follow‐
up, or timing of the outcome measurement. If the duration of

Primary outcomes

treatment exceeded the neonatal period (i.e., 28 days), we con-

The primary outcomes were:

sidered another 2 weeks maximum but did not include studies in
which the treatment went beyond 6 weeks of supplementation.

1. All‐cause neonatal mortality (death between 0 and 28 days of life)
2. All cause infant mortality at 6 months (death between 0 days and
6 months of life)

We included mortality outcomes measured at 28 days, 6 months,
12 months of life, and at the longest follow‐up as reported by
authors.

3. All‐cause infant mortality at 12 months (death between 0 days
and 12 months life).

Type of settings. We included studies conducted in LMIC. Low‐income
countries were defined as those with a gross national income (GNI)

We anticipated that studies might not report the outcomes in the

per capita of USD 1005 or less in 2016, and middle‐income econo-

follow‐up period mentioned above for the primary outcomes. If a

mies were those with a GNI per capita between USD 1006 and 3955

study did not report mortality outcomes at day 28, 6 months, or

in 2016 (World Bank, 2017).

12 months, we contacted authors for data for the same. If segregated
data were not available from authors, we included mortality data as
follows: mortality in the first 6 weeks of life was included as neonatal

4.2 | Search methods for identification of studies

mortality at day 28; between 3 and 6 months was included as
6 months, and between 9 and 12 months was included as 12 months.

The identification of studies included various methods, such as

If the follow up was not clear, we included the mortality data at the

electronic and other sources. We did not exclude any based on the

longest follow‐up.

outcome at the screening stages.
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4.2.1 | Electronic searches
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contacted the experts and authors of the newest published studies to
ask about any additional studies. Duplicates were removed.

The electronic search for relevant studies was done in the following
databases: PubMed, CINAHL, LILACS, SCOPUS, and CENTRAL
(Cochrane Central Register for Controlled Trials).

4.3 | Data collection and analysis

Appendix 1 gives the search strategy for PubMed, CINAHL, LILACS, SCOPUS, and CENTRAL. It includes keywords and MeSH terms

4.3.1 | Selection of studies

as appropriate. This approach includes a search strategy for the population (neonates) and interventions of interest. We planned to run

Two authors independently screened titles/abstracts using pre-

searches for each intervention separately. We first ran the search for

specified inclusion/exclusion criteria. A full text was reviewed for the

the population, which is the same for each intervention. Then we ran

studies selected in the initial screening, and the same inclusion/ex-

the search for each intervention. We then combined both searches by

clusion criteria were applied. If there was a conflict about the in-

using “AND” and kept the searches in a separate EndNote file.

clusion of a study between the two reviewers, a third reviewer (ZAB)

An example of a search strategy for vitamin A for PubMed was as
follows:
(((((“Vitamin A”[Mesh]) OR (Vitamin A[tiab] OR Aquasol A[tiab]

was consulted. We used a web‐based software “Covidence”
(Covidence, 2019) to do both title/abstract and full‐text screening.
This software allows simultaneous independent screening of studies,

OR Retinol[tiab] OR All Trans Retinol[tiab] OR All‐Trans‐Retinol[tiab]

and inter‐reviewer reliability can be assessed by checking the num-

OR Vitamin A1[tiab] OR Vitamin A 1[tiab] OR 11‐cis‐Retinol[tiab] OR

ber of conflicts in the resolved conflict page following each stage of

11 cis Retinol[tiab] OR Tretinoin[tiab])AND Supplement*[tiab]))AND

screening.

((“Infant”[Mesh] OR “Premature Birth”[Mesh]) OR (Neonat*[tiab] OR
neo nat*[tiab]) OR (newborn* OR new Born*[tiab] OR newly born*

Description of methods used in primary research

[tiab]) OR (preterm[tiab] OR preterms[tiab] OR pre term[tiab] OR pre

We expected that the majority of the included studies would be

terms[tiab]) OR (premature*[tiab] AND (birth*[tiab] OR born[tiab]

randomized or cluster‐randomized. We extracted the information

OR deliver*[tiab])) OR (low[tiab] AND (birthweight*[tiab] OR birth

on study design explicitly and made a careful differentiation be-

weight*[tiab])) OR (lbw[tiab] OR vlbw[tiab] OR elbw[tiab]) OR infant*

tween experimental and observational studies. We aimed to

[tiab] OR (baby[tiab] OR babies[tiab])))) NOT (“Animals”[Mesh] NOT

analyze randomized and nonrandomized studies separately.

(“Animals”[Mesh] AND “Humans”[Mesh]))
We applied restriction of “humans” to searches. We did not apply

Criteria for determination of independent findings

any restrictions on searches based on outcomes, study design, or

We anticipated that authors might report the results of a study in

language. There was no restriction on date of publication.

multiple publications. We coded such trials as a single study to avoid

The searches were conducted for vitamin A on December 10,

double counting of the data and included all the relevant outcomes

2018 (updated on November 13, 2019); probiotics on February 8,

decided a priori for this review. If a pilot study was done before the

2019 (updated on November 27, 2019); and dextrose on April 25,

larger study, we included the two studies separately unless the data

2019 (updated on November 26, 2019).

from the pilot study was included in the main trial. When a clinical
trial registration number was available for a study, we searched that
number on PubMed to locate all the published studies linked to that

4.2.2 | Searching other resources

trial number.

Other resources included the search for ongoing trials at www.
clinicaltrials.gov and WHO's ICTRP trials database. We also searched

4.3.2 | Data extraction and management

websites of international agencies such as WHO (including WHO's
Reproductive Health Library), UNICEF, Global Alliance for Improved

Details of study coding categories

Nutrition (GAIN), International Food Policy Research Institute, In-

The data from included studies were abstracted into a standardized

ternational Initiative for Impact Evaluation (3ie), Nutrition Interna-

data abstraction form by two authors. We extracted data in dupli-

tional (NI), World Bank, USAID and USAID affiliates (e.g., FANTA,

cates, and any discrepancies were resolved by discussion firs. A third

SPRING), and the World Food Programme.

reviewer (ZAB) was consulted if the conflict existed after the initial

Grey literature search sources included NI, GAIN, International
Food Policy and Research Institute (IFPRI), and the WHO library

discussion.
The data extraction sheet had the following information.

database (WHOLIS).
We searched the reference lists of all included studies. We did

• General study information: authors, publication year, study design

citation searches of included studies in Google Scholar and Web of

• Study setting: World Bank region, country, World Bank income

Science. We also searched the reference sections of previously

level, city/town, urban/urban slum/rural/mixed setting, duration of

published systematic reviews and the latest published studies. We

data collection, date of data collection
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• Study population: sample size recruited, sample size analysed, fe-

were presented as summary risk ratios with 95% CI. We combined

male (%), description of participants (i.e., inclusion/exclusion cri-

risk ratios (events per child) and rate ratios (events per child year) for

teria applied to recruitment)

incidence data because of their similar interpretation and scale.

• Intervention characteristics: type of intervention, duration of in-

For continuous outcomes, we presented the summary results as the

tervention, unit of randomization (where applicable), dose, fre-

mean difference with 95% CI when data were available on the

quency of provision, duration of follow up, attrition rate

same scale across the studies. We used the standardized mean dif-

• Quality assessment

ference with 95% CI when data were presented in different scales
across the studies.

Each quantitative outcome sheet contained the following:

To avoid reviewer bias, we planned to predetermine the preference for specific data for certain outcomes. For example, for

• Subgroup (if applicable)

mortality outcomes, we gave preference to denominators in the

• Subgroup sample size

following order: number with the definite outcome known, number

• Outcome type

randomized, and child‐years. For morbidity data such as neonatal

• Outcome units

sepsis where both survivors and nonsurvivors might have con-

• Outcomes

tributed data, we gave preference to child years, number with the
definite outcome known, and number randomized. For randomized

a. Outcome measure treatment group

trials, we gave preference to data that required the least manipula-

b. Outcome measure comparison group

tion by authors or inference by reviewers. We extracted the raw

c. Standard deviation

values (e.g., means and SDs) and built the intention‐to‐treat (ITT)
analysis where applicable.

• Effect size:

We anticipated that cause‐specific morbidity or mortality data
might not be readily available, as febrile illness due to respiratory,

a. Effect measure

urinary, or central nervous system infection during the neonatal

b. 95% CI

period are often categorized under a broader term of neonatal sepsis
(WHO, 2017b).

4.3.3 | Assessment of ROB in included studies
4.3.5 | Unit of analysis issues
We used the Cochrane ROB tool (Higgins & Green, 2011) for randomized studies. The Cochrane ROB tool includes the following

As we planned to include multiple interventions, all interventions and

items:

outcomes within those interventions, were meta‐analyzed separately.

• Selection bias: random sequence generation and allocation

randomized trials in the same analysis. We assessed analyses in the

For randomized trials, we meta‐analyzed individual and cluster‐
concealment

cluster‐randomized trials to ensure that clustering was appropriately

• Performance bias: blinding of participants and personnel

accounted for within the analysis of the primary study, such that

• Detection bias: blinding of outcome assessment

study precision was not over or under‐estimated within our analysis.

• Attrition bias: incomplete outcome data

If the authors adjusted for cluster randomization, no further adjust-

• Reporting bias: selective reporting

ment was made. In case a cluster‐randomized study was not adjusted

• Other sources of bias

by primary authors, we adjusted effect estimates by using the mean
cluster size (M) and the intra‐cluster correlation coefficient (ICC) to

Two authors independently performed the ROB assessments for

calculate the design effect as follows: design effect = 1 + (M − 1) ICC.

each study. A third reviewer was involved to resolve any disagree-

We then used the design effect to adjust the study data such that a

ments (ZAB). An overall score was not provided.

trial was reduced to its effective sample size or standard error of the
summary estimate was inflated. We used the ICC given in the published studies. If the ICC was not available from the published study,

4.3.4 | Measures of treatment effect

we contacted the authors for the same. If the ICC was not available
from the authors, we used ICC from the similar studies done in the

We performed a meta‐analysis for the synthesis of quantitative data

similar region and on a similar population or took it from the

when the included studies had comparable participants, interven-

previously published reviews (Haider et al., 2017).

tions, and outcomes. We did not assess the effect on outcome across
the interventions, such as is done in network meta‐analysis. Each

Multiple‐arm trials

intervention was analysed separately. We analysed continuous and

We included studies with multiple intervention arms, but we only

dichotomous data separately. For dichotomous outcomes, results

included the arms that were eligible for the review. We selected one

IMDAD
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pair (with appropriate intervention and control group) that satisfied

test to determine if there was a relevant difference in effect across

the inclusion criteria of the review and excluded the rest. In case

subgroups.

there were more than two groups eligible for inclusion, we combined

We assessed the quality of overall evidence using the GRADE

these groups into a single pair‐wise comparison. In multiple‐arm trials

approach. This method of quality assessment considers study type,

using two different doses of the same intervention, we combined the

within‐study ROB (methodological quality), directness of evidence,

two groups to avoid double counting the participants in the control

heterogeneity, precision of effect estimates, and risk of publication

group.

bias (Guyatt et al., 2011). We rated the quality of the body of evidence for each key outcome as “high,” “moderate,” “low,” or
“very low.”

4.3.6 | Dealing with missing data
Any missing data were noted including loss to follow‐up and dropouts. The reasons for the missing data were taken from the studies,

4.3.10 | Subgroup analysis and investigation of
heterogeneity

and if it was not mentioned in the studies, the authors were contacted for the same. If the authors reported the adjusted values for

Neonatal vitamin A supplementation

missing data, we used the adjusted values.

Although we had planned a number of subgroup analyses for neonatal vitamin A supplementation; however, a recent IPD analysis
(West et al., 2019) covered both individual and study level subgroup

4.3.7 | Assessment of heterogeneity

analyses, so we did not perform any subgroup analysis for vitamin A
supplementation at this stage

Statistical heterogeneity was assessed using τ2, I2, and significance of
the χ2 test. We also assessed statistical heterogeneity by visually
inspecting the forest plots.

Neonatal probiotic supplementation
1. Gestational age: term and preterm
2. Strains used in probiotics: single strain versus multiple strain and

4.3.8 | Assessment of reporting biases

of type of strain used in each probiotic
3. Strains used in probiotics: contains Lactobacillus versus Bifido-

A funnel plot and its symmetry were used to assess publication bias if

bacterium versus both

the number of included studies for intervention was more than 10. If

4. Settings: community‐based versus hospital setting

the funnel plot was suggestive of publication bias, we further in-

5. Type of feedings: breastmilk versus formula milk versus mixed.

vestigated the publication bias with the use of Egger's test (Higgins &
Green, 2011).

Oral dextrose gel supplementation
1. Gestational age: term and postterm versus late preterm (35–36

4.3.9 | Data synthesis

weeks) versus moderately preterm (30–34 weeks) versus extremely preterm (<30 weeks)

Synthesis procedures and statistical analysis

2. Dose: equal or <200 mg/kg versus >200 mg/kg

We used the software Review Manager 5.3 (Review Manager, 2019)

3. Frequency: one versus more than one dose

to conduct the statistical analysis. For randomized trials, we followed

4. Time of administration: ≤1 h of age versus after 1 h of age versus

the ITT analysis. If ITT was not available, and the author reported the

after 2 h of age.

analyses as specified in the protocol, we reconstructed the data to
create an ITT analysis.
We used a random‐effect model to account for expected het-

4.3.11 | Sensitivity analysis

erogeneity in the intervention, comparisons, or setting within studies
included in a given synthesis. We used the generic inverse variance

1. High quality studies versus low quality studies. The quality of

method of meta‐analysis for fixed effect models and random effect

study was subjectively based on the ROB assessment. Even

models. This method of meta‐analysis gives weight to studies based

though we considered all the domains included in the Cochrane

on their variance in a way that a study with low variance gets a high

ROB tool, we gave higher importance to sequence generation and

weight and vice versa.

allocation concealment, as most of the outcomes for this review

We interpreted the results of the meta‐analysis based on

were objective, and it was less likely that the results of the in-

p value at the 95% confidence level (a value <0.05 was considered

cluded studies would have been biased by a lack of blinding.

statistically significant) and reported both significant and non-

2. Random versus fixed effect models. We chose this sensitivity

significant results. For subgroup analysis, we used an interaction

analysis to assess if the summary estimates will change
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significantly based on use of random versus fixed effect model.

total of about 16,366 participants. All the studies were RCTs and

There is no exact criterion to choose between the two models,

published in a peer‐reviewed journal.

and we wanted to make sure that estimates were not significantly
different between the two models.

Dextrose gel supplementation during neonatal period
We did not identify any studies that assessed the use of dextrose gel

Treatment of qualitative research

supplementation during neonatal period for prevention or treatment

We did not plan to include qualitative research.

of hypoglycaemia in LMIC.

Probiotic supplementation during neonatal period

4.3.12 | Summary of findings and assessment of the
certainty of the evidence

Thirty‐three studies reported in 37 publications evaluated the effect
of probiotic supplementation during the neonatal period and included a total of 11,595 participants (probiotics, 5854 and controls,

Summary of findings' tables

5741; Amini et al., 2017; Braga et al., 2011; Chowdhury et al., 2016;

We constructed “Summary of findings” tables for all of the primary

Cooper et al., 2017; Cui et al., 2019; Dashti et al., 2014; Demirel

outcomes using the Grading of Recommendations Assessment, De-

et al., 2013; Dilli et al., 2015; Dongol Singh et al., 2017; Dutta

velopment and Evaluation (GRADE) criteria (GRADEpro GDT 2015).

et al., 2015; Fernández‐Carrocera et al., 2013; Hariharan et al., 2016;

These covered consideration of within‐study ROB (methodological

Hernández‐Enríquez et al., 2016; Huaxian, 2013; Hussain et al., 2016;

quality), directness of evidence, heterogeneity, precision of effect

Kaban et al., 2019, Mazumder et al., 2015; Nandhini et al., 2016;

estimates and risk of publication bias. We rated the certainty of

Guney‐Varal et al., 2017; Oncel et al., 2014; Panigrahi et al., 2017;

evidence for each key outcome as “high,” “moderate,” “low,” or “very

Rojas et al., 2012; Roy et al., 2014; Samanta et al., 2009; Shashidhar

low.” The GRADE evidence is described in Table 1. Nonrandomised

et al., 2017; Sinha et al., 2015; Sari et al., 2011; Serce et al., 2013;

studies were initially rated as “low” quality. If there were no serious

Shadkam et al., 2015; Saengtawesin et al., 2014; Tewari et al., 2015;

methodological flaws, we upgraded the evidence for studies with a

Xu et al., 2016).

large magnitude of effect; presence of a dose response relationship;
and effect of plausible residual confounding.
We used GRADE and prepared the summary of findings tables

Three of the studies were available in the form of abstracts
(Hariharan et al., 2016; Huaxian, 2013; Rehman et al., 2018). The rest
of the studies were published in a peer‐reviewed journal.

for the following primary outcomes:
• Stillbirth defined as baby born with no signs of life at or after 28

5.1.2 | Included studies

weeks' gestation
• Perinatal mortality (stillbirth and deaths ≤7 days)

The characteristics of included studies are available in the table

• Neonatal mortality (death < 28 days)

Characteristics of included studies.

• Infant mortality (deaths between 0 and 12 months)
• Under‐five mortality (deaths between 0 and 59 months)

Vitamin A supplementation during neonatal period

• Miscarriage

Type of studies. All the included studies were RCTs. Thirteen studies

• Mean maternal body mass index

were individually randomized (Ahmad et al., 2019; Basu et al., 2019;
Benn et al., 2008, 2010, 2014; Edmond et al., 2015; Giridhar
et al., 2019; Humphrey et al., 1996; Malaba et al., 2005; Masanja

5 | RESULTS

et al., 2015; Mazumder et al., 2015; Rahmathullah et al., 2003), and
three studies were cluster‐randomized (Klemm et al., 2008; Soofi

5.1 | Description of studies

et al., 2017; Sun et al., 2019; West et al., 1995). Three trials had
multiple arms of interventions (Benn et al., 2010, 2014; Malaba

5.1.1 | Results of the search

et al., 2005).

Figure 1 shows the PRISMA flow diagram for our literature search.

Country. Studies were conducted in 10 different countries with four

Vitamin A supplementation during neonatal period

Mazumder et al., 2015; Rahmathullah et al., 2003), three studies in

Sixteen studies reported in 45 publications assessed the effect of neo-

Guinea‐Bissau (Benn et al., 2008, 2010, 2014), two studies in Ban-

studies conducted in India (Basu et al., 2019; Giridhar et al., 2019;

natal vitamin A supplementation (Ahmad et al., 2019; Basu et al., 2019;

gladesh (Ahmad et al., 2019; Klemm et al., 2008), and one each in

Benn et al., 2008, 2010, 2014; Edmond et al., 2015; Giridhar et al., 2019;

China (Sun et al., 2019), Ghana (Edmond et al., 2015), Indonesia

Humphrey et al., 1996; Klemm et al., 2008; Malaba et al., 2005; Masanja

(Humphrey et al., 1996), Nepal (West et al., 1995), Pakistan (Soofi

et al., 2015; Mazumder et al., 2015; Rahmathullah et al., 2003; Soofi

et al., 2017), Tanzania (Masanja et al., 2015), and Zimbabwe (Malaba

et al., 2017; Sun et al., 2019; West et al., 1995). These studies included a

et al., 2005).
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T A B L E 1 Effect of probiotic supplementation during neonatal period: Subgroup analysis
No. of studies

Effect estimate:
relative risk

Test for subgroup
difference

Hospital based

22

0.78 [0.65, 0.94]

p = .31

Community based

3

1.25 [0.51, 3.05]

I2 = 0%

Preparation contain a single strain of probiotics

9

0.80 [0.61, 1.05]

p = .95

Preparation contained multiple strains of probiotics

12

0.80 [0.58, 1.09]

I2 = 0%

Preparation contained synbiotics
(prebiotics + probiotics)

5

0.69 [0.29, 1.61]

Outcome or subgroup
All‐cause mortality: subgroup analysis: settings

All‐cause mortality: subgroup analysis: type of probiotics

All‐cause mortality: subgroup analysis: type of participants
Study include preterm/low birth weight babies

24

0.79 [0.65, 0.95]

p = .47

Study included term infants only

1

1.38 [0.31, 6.08]

I2 = 0%

p = .44

All‐cause mortality: subgroup analysis: type of feedings
Baby received breastmilk only

14

0.81 [0.62, 1.05]

Baby received formula milk only

1

1.38 [0.31, 6.08]

Baby received both both breastmilk and formula milk

8

0.69 [0.48, 0.99]

Type of feeding was unclear

3

1.33 [0.63, 2.81]

I2 = 0%

All‐cause mortality: subgroup analysis: probiotics preparation
Preparation contained Lactobacillus

10

0.82 [0.63, 1.05]

Preparation contained Bifidobacterium

1

0.43 [0.17, 1.09]

Preparation contained both Lactobacillus and
Bifidobacterium

13

0.71 [0.47, 1.08]

Preparation contained Saccharomyces boulardii only

2

1.12 [0.46, 2.71]

p = .47
I2 = 0%

Necrotizing enterocolitis: subgroup analysis: probiotic preparation
Preparation contained Lactobacillus

13

0.39 [0.25, 0.61]

Preparation contained Bifidobacterium

1

0.20 [0.09, 0.47]

Preparation contained both Lactobacillus and
Bifidobacterium

14

0.49 [0.36, 0.68]

Preparation contained S. boulardii only

2

0.94 [0.45, 1.95]

p = .05
I2 = 60.5%

Necrotizing enterocolitis: subgroup analysis: type of feeding
Baby received breastmilk only

13

0.43 [0.31, 0.59]

Baby received formula only

1

0.21 [0.03, 1.76]

p = .74

Baby received both breastmilk and formula milk

9

0.55 [0.33, 0.92]

Type of feeding was unclear

7

0.41 [0.17, 1.00]

Preparation contained a single strain of probiotics

12

0.48 [0.30, 0.76]

p= .50

Preparation contained multiple strains of probiotics

15

0.48 [0.35, 0.67]

I2 = 0%

Preparation contained synbiotics
(prebiotics + probiotics)

3

0.28 [0.12, 0.67]

I2 = 0%

Necrotizing enterocolitis: subgroup analysis: type of probiotics

Neonatal sepsis: subgroup analysis: probiotic preparation
Preparation contained Lactobacillus

11

0.74 [0.62, 0.87]

Preparation contained Bifidobacterium

1

0.81 [0.60, 1.09]

Preparation contained both Bifidobacterium and
Lactobacillus

6

0.83 [0.68, 1.02]

Preparation contained S. boulardii only

3

0.73 [0.57, 0.94]

Baby received breastmilk only

8

0.71 [0.61, 0.83]

Baby received formula milk only

2

0.59 [0.22, 1.56]

Baby received both formula and breastmilk only

6

0.77 [0.65, 0.90]

Type of feeding was unclear

4

0.95 [0.82, 1.09]

p = .79
I2 = 0%

Neonatal sepsis: subgroup analysis: type of feeding

Neonatal sepsis: type of probiotics

p = .04
I2 = 65%
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Outcome or subgroup

No. of studies

Effect estimate:
relative risk

Test for subgroup
difference

Preparation contained single strain of probiotics

8

0.84 [0.74, 0.96]

p = .21

Preparation contained multiple strains of probiotics

9

0.81 [0.68, 0.97]

I2 = 35%

Preparation contained synbiotics
(prebiotics + probiotics)

4

0.67 [0.54, 0.83]

Hospital based

19

0.83 [0.76, 0.91]

p = .19

Community based

2

0.67 [0.49, 0.91]

I2 = 42%

Neonatal sepsis: subgroup analysis: settings

Settings. Thirteen studies were conducted in the community

analysis (Niekerk et al., 2015 (HIV exposed); Niekerk et al., 2015

setting, while three studies were conducted in the hospital setting

(HIV nonexposed).

(Basu et al., 2019; Giridhar et al., 2019; Sun et al., 2019).
Country. Studies were conducted in 13 different countries with 10 stuParticipants. Most of the studies included live born infants who were

dies conducted in India (Dutta et al., 2015; Hariharan et al., 2016;

otherwise healthy. One study included only low birth weight babies

Mazumder et al., 2015; Nandhini et al., 2016; Panigrahi et al., 2017;

(Benn et al., 2010), two studies included newborns with very low

Roy et al., 2014; Samanta et al., 2009; Shashidhar et al., 2017; Sinha

birth weight (Basu et al., 2019; Giridhar et al., 2019), and one study

et al., 2015; Tewari et al., 2015), six studies in Turkey (Demirel

included extremely premature babies (Sun et al., 2019). The sample

et al., 2013; Dilli et al., 2015; Guney‐Varal et al., 2017; Oncel et al., 2014;

size of each study ranged from 120 (Giridhar et al., 2019) to 44,948

Sari et al., 2011; Serce et al., 2013), three studies each in China (Cui

(Mazumder et al., 2015).

et al., 2019; Huaxian, 2013; Xu et al., 2016) and Iran (Amini et al., 2017;
Dashti et al., 2014; Shadkam et al., 2015), two each in Mexico

Dose. Most of the included studies for the use of neonatal vitamin A

(Fernández‐Carrocera et al., 2013; Hernández‐Enríquez et al., 2016) and

supplementation used a dose of 50,000 IU. Rahmathullah et al.

South Africa (Cooper et al., 2017; Niekerk et al., 2015 (HIV exposed)),

(2003) gave 24,000 IU daily, and Benn et al. (2010) used 25,000 IU.

and one each in Bangladesh (Chowdhury et al., 2016), Brazil (Braga

Benn et al. (2014) compared doses of 50,000 IU versus 25,000 IU.

et al., 2011), Colombia (Rojas et al., 2012), Indonesia (Kaban et al., 2019),

Basu et al. (2019) used a daily dose of 1,500 IU.

Nepal (Dongol Singh et al., 2017), Pakistan (Hussain et al., 2016), and
Thailand (Saengtawesin et al., 2014).

Comparison. In all the included studies for neonatal vitamin A
supplementation a placebo was given to the control group.

Settings. All the studies were conducted in the hospital setting except for
three studies where participants were followed in the community setting

Probiotic supplementation during neonatal period

(Cooper et al., 2017; Dongol Singh et al., 2017; Panigrahi et al., 2017).

Type of studies. All the studies that evaluated the effect of probiotic supplementation during the neonatal period were individual

Participants. Only one study (Cooper et al., 2017) included neonates

RCTs. Two studies had multiple intervention groups (Dilli

that were full term. The rest of the studies included participants that

et al., 2015; Dutta et al., 2015). One of these studies compared

were either low birth weight, preterm, or both. The participants were

different combinations of probiotics with prebiotics (Dilli

recruited from neonatal intensive care units except in three studies

et al., 2015), and the other study compared different doses of

(Cooper et al., 2017; Dongol Singh et al., 2017; Panigrahi et al., 2017),

probiotics (Dutta et al., 2015). For the study by Dilli et al. (2015),

where participants were recruited from the community.

we included the data in a way that the only difference between
the two groups was probiotics. For the study by Dutta et al.

The intervention. Thirteen studies used a single strain of probiotics (Cui

(2015), we combined all the groups that compared different doses

et al., 2019; Demirel et al., 2013; Dongol Singh et al., 2017; Hernández‐

and compared them with the placebo to avoid double‐counting of

Enríquez et al., 2016; Hussain et al., 2016; Kaban et al., 2019; Oncel

the placebo group data.

et al., 2014; Rojas et al., 2012; Roy et al., 2014; Serce et al., 2013;
Shadkam et al., 2015; Tewari et al., 2015; Xu et al., 2016), and 13 studies

One study included neonates with and without exposure to hu-

used a preparation that contained multiple strains of probiotics (Amini

man immunodeficiency virus (HIV; based on maternal history of HIV).

et al., 2017; Braga et al., 2011; Chowdhury et al., 2016; Dashti

We included the data for these groups separately in the meta‐

et al., 2014; Dutta et al., 2015; Fernández‐Carrocera et al., 2013;
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PRISMA flow diagram

Hariharan et al., 2016; Niekerk et al., 2015 (HIV exposed); Roy

The probiotics were mostly given with breastmilk or formula

et al., 2014; Saengtawesin et al., 2014; Samanta et al., 2009; Shadkam

feedings and started when the baby was able to tolerate minimal

et al., 2015; Sinha et al., 2015). Five studies used a preparation that had a

enteral feeds. The duration and dose of probiotic supplementation

probiotic + prebiotic (synbiotic) (Cooper et al., 2017; Dilli et al., 2015;

varied among the studies.

Guney‐Varal et al., 2017; Nandhini et al., 2016; Panigrahi et al., 2017);
among these five studies, three studies (Cooper et al., 2017; Dilli

Comparison. Sixteen studies used a placebo (Cui et al., 2019; Dashti

et al., 2015; Panigrahi et al., 2017) used a probiotic preparation that had a

et al., 2014; Demirel et al., 2013; Dilli et al., 2015; Dongol

single strain of bacteria, and the other two studies used a preparation

Singh et al., 2017; Dutta et al., 2015; Kaban et al., 2019; Niekerk

that had multiple strains of bacteria (Guney‐Varal et al., 2017; Nandhini

et al., 2015 (HIV exposed); Oncel et al., 2014; Panigrahi

et al., 2016). One study did not report the strain of probiotic supple-

et al., 2017; Rojas et al., 2012; Roy et al., 2014; Serce et al., 2013;

mentation (Huaxian, 2013).

Shadkam et al., 2015; Sinha et al., 2015; Tewari et al., 2015); the

Ten studies used a probiotic preparation that contained Lactobacillus (Cooper et al., 2017; Cui et al., 2019; Dongol Singh et al., 2017;

rest of the studies used a control group receiving standard of
care only.

Hernández‐Enríquez et al., 2016; Kaban et al., 2019; Oncel et al., 2014;
Panigrahi et al., 2017; Rojas et al., 2012; Roy et al., 2014; Shadkam

Outcomes. All the studies reported data for at least one outcome that

et al., 2015), and two studies used a preparation that contained Bifi-

could be included in the meta‐analysis. Twenty five studies reported

dobacterium (Dilli et al., 2015; Hussain et al., 2016). Fourteen studies

data for all‐cause mortality, 29 studies reported data for NEC, and 21

used a preparation that had both Lactobacillus and Bifidobacterium

studies reported data for the incidence of neonatal sepsis. See

(Amini et al., 2017; Braga et al., 2011; Chowdhury et al., 2016; Dashti

Section 5.3 for more details.

et al., 2014; Fernández‐Carrocera et al., 2013; Guney‐Varal et al., 2017;
Hariharan et al., 2016; Nandhini et al., 2016; Niekerk et al., 2015 (HIV
exposed); Roy et al., 2014; Saengtawesin et al., 2014; Samanta

5.1.3 | Excluded studies

et al., 2009; Shashidhar et al., 2017; Sinha et al., 2015). Three studies
used Saccharomyces boulardii (Demirel et al., 2013; Serce et al., 2013; Xu

Overall, 138 studies were excluded. See the Characteristics of ex-

et al., 2016), and one study used Bacillus clausii (Tewari et al., 2015).

cluded studies for reasons for exclusion of studies.
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5.2.4 | Blinding (performance bias and
detection bias)

conducted in high‐income countries. Fifteen studies were
excluded because no relevant clinical outcomes were available

Vitamin A supplementation during neonatal period

from the abstract or full text of the studies. Fourteen studies

None of the included studies for neonatal vitamin A supplementation

were excluded for the wrong population, and 10 studies

was at increased ROB for blinding.

were excluded because of the wrong study design. Nine studies
had a wrong intervention, and four studies had a wrong
comparator.

5.2 | ROB in included studies
5.2.1 | Vitamin A supplementation during the
neonatal period
Figure 2 shows the ROB in the 16 included studies that addressed
vitamin A supplementation during the neonatal period.

5.2.2 | Probiotic supplementation during the
neonatal period
Figure 3 show the ROB in the 33 included studies that addressed
probiotic supplementation during the neonatal period.

5.2.3 | Allocation (selection bias)
Vitamin A supplementation during the neonatal period
All the studies for vitamin A supplementation were at low ROB for
sequence generation and allocation concealment.

Probiotic supplementation during the neonatal period
Two studies were judged to be at high ROB due to inadequate randomization (Guney‐Varal et al., 2017; Kaban et al.,
2019), and four studies did not provide enough information
to allow a judgment about methods of randomization; these
were labelled as having an unclear ROB (Hariharan et al., 2016;
Hernández‐Enríquez et al., 2016; Huaxian, 2013; Rehman
et al., 2018). The rest of the studies had a low ROB for sequence
generation.
Two studies were considered at high ROB due to inability to
conceal the allocation (Dongol Singh et al., 2017; Guney‐Varal
et al., 2017). Ten studies had an unclear ROB, as these studies did not
provide enough information to assess methods of allocation concealment (Amini et al., 2017; Cui et al., 2019; Hariharan et al., 2016;
Hernández‐Enríquez et al., 2016; Huaxian, 2013; Hussain et al., 2016;
Kaban et al., 2019, Rehman et al., 2018; Samanta et al., 2009;
Shadkam et al., 2015). The rest of the studies had a low ROB for
allocation concealment.

FIGURE 2

Risk of bias: neonatal vitamin A supplementation
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Probiotic supplementation during neonatal period
Ten studies had an unclear ROB due to blinding of the participants (Amini et al., 2017; Guney‐Varal et al., 2017; Hariharan
et al., 2016; Hernández‐Enríquez et al., 2016; Huaxian, 2013;
Hussain et al., 2016; Kaban et al., 2019; Nandhini et al., 2016;
Rehman et al., 2018; Samanta et al., 2009). The rest of the studies
had a low ROB due to the inability to do blinding of the
participants.
Thirteen studies had an unclear ROB for blinding of the outcome
assessors (Amini et al., 2017; Cui et al., 2019; Dongol Singh
et al., 2017; Guney‐Varal et al., 2017; Hariharan et al., 2016;
Hernández‐Enríquez et al., 2016; Huaxian, 2013; Hussain et al., 2016;
Kaban et al., 2019; Nandhini et al., 2016; Rehman et al., 2018; Serce
et al., 2013; Samanta et al., 2009). The rest of the studies had a
low ROB.

5.2.5 | Incomplete outcome data (attrition bias)
Vitamin A supplementation during the neonatal period
All studies were at low risk for attrition bias except two
studies that had an unclear ROB (Benn et al., 2010; Malaba
et al., 2005).

Probiotic supplementation during the neonatal period
Most of the studies had a minimal loss to follow‐up. One study
was at high ROB where more than 20% of the participants
were lost to follow‐up (Xu et al., 2016). Four studies had
an unclear ROB, as there was not enough information to make
an assessment in these studies (Hariharan et al., 2016;
Hernández‐Enríquez et al., 2016; Huaxian, 2013; Rehman
et al., 2018).

5.2.6 | Selective reporting (reporting bias)
Vitamin A supplementation during neonatal period
All studies were considered to have low ROB for selective outcome
reporting.

Probiotic supplementation during neonatal period
Most of the studies reported all relevant outcomes, and we did not
consider any particular study at high ROB. Three studies had unclear
ROB

for

selective

outcome

reporting

(Hernández‐Enríquez

et al., 2016; Kaban et al., 2019; Rehman et al., 2018).

5.2.7 | Other potential sources of bias
F I G U R E 3 Risk of bias: probiotic supplementation during
neonatal period

Vitamin A supplementation during neonatal period
No study was considered at high ROB due to other reasons.
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Probiotic supplementation during neonatal period

did not pool data from the hospital‐based studies with other studies, as

No other major source of ROB was noted. Five studies had unclear

the community‐based studies had participants that were very different

ROB due to limited available information (Hariharan et al., 2016;

from hospital‐based studies. We briefly describe the results of these

Hernández‐Enríquez et al., 2016; Huaxian, 2013; Kaban et al., 2019;

studies below.
A study by Basu et al. (2019) reported the primary outcome; this

Rehman et al., 2018).

was a composite incidence of all‐cause mortality and oxygen requirement for 28 days. The results showed a reduction in mortality in

5.3 | Effects of interventions

the vitamin A group compared to the control group (RR, 0.44; 95% CI,
0.23–0.84).

5.3.1 | VItamin A supplementation during neonatal
period

the Vitamin A group versus placebo (RR, 0.49; 95% CI, 0.45–5.32).

All‐cause mortality during the neonatal period

idhar et al. (2019) (RR, 2; 95% CI, 0.63–6.30).

No difference in mortality was reported by Sun et al. (2019) in
Similarly, no difference was noted in all‐cause mortality by Gir-

Five studies from community settings reported the effect of vitamin
A supplementation on all‐cause neonatal mortality. These combined

Adverse outcomes: Bulging fontanelle

results showed no significant difference between the intervention

Six studies reported on the effect of neonatal vitamin A supple-

and the control group (RR, 0.99; 95% CI, 0.90–1.08; six studies,

mentation on incidence of bulging fontanelle. The combined re-

126,548 participants, heterogeneity: τ2 = 0.00; χ2 = 3.64, (p = 0.46);

sults showed a 53% increased risk of bulging fontanelle in the

I2 = 0%). The grade rating for this outcome was “high.” Summary of

intervention group compared to control (RR, 1.53; 95% CI,

findings Table 2.

1.12–2.09;

heterogeneity:

τ2 = 0.08;

χ2 = 14.20,

(p = 0.01);

2

I = 65%). We have high certainty in this evidence. Summary of
Sensitivity analysis: Fixed effect model. Use of a fixed effect model did

findings Table 2.

not change the summary estimate for neonatal mortality (RR, 0.99;
95% CI, 0.90–1.08).

Adverse outcomes: Vomiting
The combined results from six studies showed that neonatal

All‐cause mortality at 6 months

vitamin A supplementation did not increase the risk of vomiting

Twelve studies from community settings reported the data for the

(RR, 1.00; 95% CI, 0.93–1.07; heterogeneity: τ2 = 0.00; χ2 = 3.90,

effect of neonatal vitamin A supplementation on all‐cause mortality

(p = 0.42); I2 = 0%).

at 6 months. The combined results showed no difference between
the intervention and control group (RR, 0.98; 95% CI, 0.89–1.07; 12

Vitamin A deficiency

studies, 154,940 participants; heterogeneity: τ2 = 0.01; χ2 = 19.14,

One study from the community setting (Benn et al., 2008) reported

(p = 0.06); I = 43%). The Grade rating for this outcome was “high.”

VAD at 6 weeks and 4 months post neonatal supplementation. No

Summary of findings Table 2. A funnel plot for publication bias was

significant difference was noted between the two groups at 6 weeks

symmetrical.

(RR, 0.94; 95% CI, 0.75–1.19) or 4 months (RR, 1.02; 95% CI,

2

0.64–1.62).
Sensitivity analysis: Fixed effect model. Use of a fixed effect model led

Another study from the hospital setting (Giridhar et al., 2019)

to minimal change in the summary estimate (RR, 0.97; 95% CI,

showed a significant decrease in VAD in the intervention group

0.91–1.03).

compared to control (RR, 0.09; 95% CI, 0.024–0.38).

All‐cause mortality at 12 months

Neurodevelopment outcomes

Eight studies from community settings reporting on the impact of

Two studies reported long‐term neurodevelopmental outcomes after

neonatal vitamin A supplementation reported data for all‐cause

use of vitamin A supplementation during the neonatal period. As the

mortality at 12 months (RR, 1.04; 95% CI, 0.94–1.14; eight studies,

outcomes measured and duration of follow up were different, we did

118,376 participants; Heterogeneity: τ2 = 0.01; χ2 = 12.99, df = 7

not pool the studies.

2

(p = 0.07); I = 46%]. We rated this evidence as high certainty
Summary of findings Table 2.

Humphrey et al. (1996) reported on neurodevelopmental outcomes at 3 year follow‐up after neonatal vitamin A supplementation
by using Bayley Scales of Infant Development. The study authors

Sensitivity analysis: Fixed effect model. Use of a fixed effect model did

analysed the data for children with (n = 91) and without (n = 432)

not change the summary estimate significantly (RR, 1.02; 95% CI;

bulging fontanelle who received vitamin A versus placebo. The re-

0.96–1.08).

sults showed that neonatal vitamin A supplementation did not have

Three studies from hospital settings also reported data on mor-

any adverse effect on development in the presence or absence of

tality. The time to event for mortality was not clear in these studies. We

bulging fontanelle. Neonatal vitamin A supplementation had a posi-
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T A B L E 2 Vitamin A compared to placebo
for neonatal health
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Vitamin A compared to placebo for neonatal health
Patient or population: neonates (0‐28 days)
Setting: low and middle income countries
Intervention: vitamin A
Comparison: placebo

Outcomes

Relative effect
(95% CI)

No. of participants
(studies)

Certainty of the
evidence (GRADE)

All‐cause neonatal
mortality

RR, 0.99
(0.90–1.08)

126,548 (6 RCTs)

⊕⊕⊕⊕ HIGH

All‐cause mortality at 6
months of age

RR, 0.98
(0.89–1.07)

154,940 (12 RCTs)

⊕⊕⊕⊕ HIGH

All‐cause mortality at 12
months of age

RR, 1.04
(0.94–1.14)

118,376 (8 RCTs)

⊕⊕⊕⊕ HIGH

Adverse Events: Bulging
Fontanelle 48–72 h

RR, 1.53
(1.12–2.09)

100,562 (6 RCTs)

⊕⊕⊕⊕ HIGH

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in
the comparison group and the relative effect of the intervention (and its 95% CI).
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the
effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to
be close to the estimate of the effect, but there is a possibility that it is substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially
different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to
be substantially different from the estimate of effect
Abbreviations: CI, confidence interval; OR, odds ratio; RR, risk ratio.

tive effect on all developmental scores. The reported developmental

probiotic supplementation on all‐cause mortality. Our meta‐analysis

scores

found a reduction of 20% in all‐cause mortality in the probiotic group

addressed

developmental

areas

such

as

orientation‐

compared to control (RR, 0.80; 95% CI, 0.66–0.96; heterogeneity:

engagement, emotional regulation, and motor quality.
Klemm et al. (2008) reported data on neurodevelopmental outcomes

τ2 = 0.00; (p = 0.55); I2 = 0%) (Figure 4). The number needed to treat

8 years after vitamin A supplementation. The authors followed a cohort

was 100. The GRADE rating for this outcome was “high.” Summary of

of participants (n = 1613) who either directly received neonatal vitamin A

findings Table 3.

or whose mother received vitamin A during pregnancy. The results
showed no significant difference in intelligence, memory, and motor

Publication bias. A funnel plot for publication bias looked symmetrical

function; however, when the neonates and their mothers were supple-

(Figure 5).

mented

with

vitamin

A

versus

placebo,

it

increased

their

performance in reading, spelling, and math computation.

Subgroup analyses. Table 1 gives the summary of data for subgroup
analyses. For the outcome of all‐cause mortality, data were
available to perform subgroup analyses based on settings

5.3.2 | Probiotic supplementation during the
neonatal period

(hospital vs. community‐based studies), type of probiotics
(single strains vs. multiple strain vs. synbiotic), type of participants (term vs. preterm/low birth weight), type of feeding

Data were available for the effect of probiotic supplementation for

(breastfeeding vs. formula feeding vs. mixed feeding), and

all‐cause mortality, NEC, sepsis, and sepsis‐specific mortality.

probiotic preparation (preparation containing Lactobacillus vs.
Bifidobacterium vs. both Lactobacillus and Bifidobacterium vs.

All‐cause mortality at longest follow‐up

S. boulardii). No significant difference was noted among the

Twenty‐five studies that included 10,998 subjects (probiotics 5548,

subgroups; however, the number of studies varied for each group

control 5450) reported data for all‐cause mortality for the effect of

within the subgroup analysis.
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(Analysis 2.1) Forest plot of comparison: 2 probiotics versus control, outcome: 2.1 all‐cause mortality

Sensitivity analysis.
Random versus fixed effect models. Use of a fixed‐effect model did not

analyses: type of probiotics (single strain vs. multiple strain vs.

change the summary estimate for the effect of probiotics on all‐cause

synbiotic), type of feeding (breastfeeding vs. formula feeding vs.

mortality (RR, 0.80; 95% CI, 0.66–0.96; heterogeneity: χ2 = 22.55,

mixed feeding), and probiotic preparation (preparation containing

2

Lactobacillus vs. Bifidobacterium vs. both Lactobacillus and Bifido-

(p = 0.55); I = 0%) Analysis 2.7.

bacterium vs. S. boulardii). No significant difference was noted
Risk of bias. Exclusion of three studies (Dongol Singh et al., 2017;

among the subgroup analyses except the one based on probiotics

Fernández‐Carrocera et al., 2013; Kaban et al., 2019) that were at

preparation (p value for subgroup difference 0.05). The probiotics

high ROB for randomizations/allocation concealment did not change

preparation that has Lactobacillus in it, either as a single strain

the summary estimate to a great extent, and results remained

(RR, 0.39; 95% CI, 0.25–0.61; 13 studies) or in combination with

statistically significant Analysis 2.8.

Bifidobacterium (RR, 0.44; 95% CI, 0.36–0.68; 13 studies), had a
significant effect compared to Bifidobacterim alone (RR, 0.20;
95% CI, 0.09, −0.47) or S. boulardii alone (RR, 0.94; 95% CI,

Incidence of NEC

0.45–1.95; two studies). This subgroup analysis should be inter-

This outcome was reported by twenty‐nine studies that included a

preted carefully, as the number of studies was not uniformly

total of 5574 (probiotics, 2843; control, 2731) participants.

distributed among all the subgroups, and the statistical difference

The combined results showed that the probiotics group had a

might be due to the small number of studies in two of the

relative reduction in NEC prevalence of 54% compared to control

subgroups.

group (RR, 0.46; 95% CI, 0.35–0.59; heterogeneity: τ = 0.11;
2

(p = 0.12); I 2 = 24%) (Figure 6). The number needed to treat was

Sensitivity analyses.

17. We have high certainty in this evidence. Summary of findings

Random versus fixed effect models. The use of a fixed effect model did

Table 3.

not change the summary estimate for the effect of probiotics on NEC
(RR, 0.45; 95% CI, 0.37–0.56; heterogeneity: χ2 = 37.92, df = 29

Publication bias. A funnel plot for publication bias looked symmetrical.

(p = 0.12); I2 = 24%).

Subgroup analyses. Table 1 shows the results of subgroup analyses.

Risk of bias. The exclusion of three studies (Dongol Singh et al., 2017;

For NEC, data were available to perform the following 3 subgroup

Fernández‐Carrocera et al., 2013; Kaban et al., 2019) with a high
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T A B L E 3 Probiotics supplementation during neonatal period
Probiotics supplementation compared to control during neonatal period
Patient or population: neonates (Mmost of the included studies had preterm and low birth weight neonates)
Setting: low and middle income countries
Intervention: probiotics/synbiotics
Comparison: control
Anticipated absolute effects* (95% CI)
Outcomes

No. of participants
(studies) Follow up

Certainty of the
evidence (GRADE)

Relative effect
(95% CI)

Risk with
control

All‐cause mortality

10904 (25 RCTs)

⊕⊕⊕⊕ HIGHa,b,c,d

RR, 0.80
(0.66–0.96)

Study population

RR, 0.78
(0.70–0.86)

Study population

RR, 0.46
(0.35–0.61)

Study population

Neonatal sepsis

Necrotizing
enterocolitis

8918 (21 RCTs)

55574 (29 RCTs)

⊕⊕⊕⊕ HIGHa,d,e

⊕⊕⊕⊕ HIGHa,d,f

47 per 1000

205 per 1000

101 per 1000

Risk difference with
probiotics (intervention)

9 fewer per 1000 (15 fewer to
1 fewer)

45 fewer per 1000 (62 fewer
to 29 fewer)

55 fewer per 1000 (66 fewer
to 41 fewer)

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the
intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio;
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a
possibility that it is substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
a

Even though three (Dongol Singh et al., 2017; Fernández‐Carrocera et al., 2013; Kaban et al., 2019) of the included studies in the analysis had high ROB
related to randomizations, the exclusion of these studies did not have much effect on the magnitude of the summary estimate or its statistical significance.
b 2
I was 0%.
c
All‐cause mortality is an objective outcome and there were no concerns about the indirect measurement of the outcome.
d
The confidence interval of the summary estimate did not include 1.
e 2
I was 23% and the p. value for heterogeneity was 0.16.
f
The I2 was 24%.

F I G U R E 5 (Analysis 2.1) Funnel plot of
comparison: 2 probiotics versus Control,
outcome: 2.1 All‐cause mortality
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(Analysis 2.9) Forest plot of comparison: 2 probiotics versus control, outcome: 2.9 necrotizing enterocolitis (any type)

ROB due to randomization/allocation concealment did not change

sepsis when the supplementation was given to babies who re-

the summary estimate significantly.

ceived breastmilk only (RR, 0.76; 95% CI, 0.61–0.83; 8 studies) or
breastmilk in combination with formula milk (RR, 0.76; 95% CI,

Incidence of neonatal sepsis

0.64–0.90; seven studies), p value for subgroups difference

The effect of probiotics on the incidence of neonatal sepsis was re-

was 0.04.

ported by 21 studies that included 9105 (probiotics, 4606; control,
4499) participants. The combined results showed a statistically sig-

Sensitivity analysis.

nificant reduction in incidence of sepsis of 22% in the intervention

Random versus fixed effect models. Use of a fixed effect model had a

group compared to control (RR, 0.78; 95% CI, 0.70–0.86; hetero-

minimal effect on summary estimates for the effect of probiotics on

geneity: τ2 = 0.01; (p = 0.16); I2 = 23%). The number needed to treat

the incidence of neonatal sepsis (RR, 0.79; 95% CI, 0.73–0.85; het-

was 14. The grade rating for this outcome was “high.” Summary of

erogeneity: χ2 = 26.06, df = 20 (p = 0.16); I2 = 23%).

findings Table 3.
Risk of bias. No significant difference was noted when two studies
Publication bias. A funnel plot for publication bias looked symmetrical.

(Fernández‐Carrocera et al., 2013; Kaban et al., 2019) with a high
ROB were excluded from the analysis Analysis 2.21.

Subgroup analysis. Table 1 shows the results of subgroup analyses.
Subgroup analysis could be done for the incidence of neonatal
sepsis according to study setting, type of probiotic (single strain

Sepsis specific mortality

vs. multiple strain vs. synbiotic), type of feeding (breastfeeding vs.

Two studies reported the data for sepsis specific mortality. The

formula feeding vs. mixed feeding), and probiotic preparation

combined results showed a reduction of sepsis specific mortality

(preparation containing Lactobacillus vs. Bifidobacterium vs. both

of 89% in the intervention group compared to control (RR, 0.21;

Lactobacillus and Bifidobacterium vs. S. boulardii). Only the type of

95% CI, 0.04–1.01; heterogeneity: τ2 = 0.00; χ2 = 0.91, df = 1

feeding differed among subgroups, probiotic supplementation

(p = 0.34); I 2 = 0%). This is limited by a wide CI of the estimate

seemed to have a significant effect for the prevention of neonatal

including 1.
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Adverse events

150,000. Overall, most of the included studies were at low ROB

No adverse event was reported in any of the included studies.

across many of the ROB items assessed using the Cochrane ROB
scale. The statistical heterogeneity in the pooled data for mortality

Neurodevelopmental outcomes

outcomes at 6 and 12 months was noted for neonatal vitamin A

Two studies assessed neurodevelopmental outcomes after

supplementation; however, the value of I2 was <50%. Subgroup

neonatal probiotic supplementation. We did not perform a

analyses done in a recent IPD analysis could potentially explain the

meta‐analysis for these outcomes, as these studies used different

reasons for heterogeneity and are discussed in Section 6.5.

scales.

The results for the use of probiotics during the neonatal per-

Sari et al. (2011) reported the data for neurodevelopmental

iod seem very promising. Almost all the studies in this meta‐

outcomes at 18–22 months post neonatal probiotic supplementa-

analysis included preterm and/or low birth weight neonates. The

tion for extremely low birth weight infants. Their results did not

effect of probiotics on all‐cause mortality was reported in

show any difference in growth and neurodevelopmental outcomes

25 studies, and the analysis included more than 10,000 participants.

between the two groups. The growth outcomes were reported as

The forest plot showed a homogenous effect in favor of the in-

weight (probiotic group 10.5 ± 1.7 kg vs. control 10.5 ± 1.7 kg, p

tervention with I 2 of 0%. We think that this effect is biologically

value .92), length (probiotic group 79.4 ± 7.8 cm vs. control

plausible, and the most likely pathway of reduction in neonatal

81.0 ± 5.3 cm, p value .32), and head circumference (probiotic group

mortality from probiotic supplementation is via a reduction in

47.5 ± 6.5 cm vs. control 46.7 ± 1.8 cm, p value .53). The neurode-

sepsis and NEC, as shown in Analysis 2.15 and Analysis 2.9, re-

velopmental outcomes were reported as mental development index

spectively. We also think that these results are less likely due to

(probiotic group 90.7 ± 15.5 vs. control 90.4 ± 14.5, p value .88) and

bias. The studies by Guney‐Varal et al. (2017), Kaban et al.

Psychomotor Development Index (probiotic group 95.4 ± 17.2 vs.

(2019), and Dongol Singh et al. (2017) were at high ROB due to

control 93.2 ± 16.4, p value .39).

inadequate randomization methods. The exclusion of these three

Oncel et al. (2014) also followed a cohort of extremely low

studies from meta‐analysis for the effect of probiotics on all‐

birth weight infants after neonatal supplementation with

cause mortality did not change the summary estimate sig-

probiotics or placebo. There was no significant difference in the

nificantly (RR, 0.82; 95% CI, 0.68–0.99). A funnel plot for pub-

neurodevelopmental outcomes at 18–24 months of age post

lication bias was symmetrical. The use of a fixed versus random

supplementation, mental development index (probiotic 81 (median),

effect model also did not change the results significantly. In ad-

49 (min) to 124 (max) vs. placebo 82, 53–128; p value .48) or

dition to these observations, the fact that the effect of probiotics

Psychomotor Development Index (probiotic 80, 49–112 vs. placebo

on the reduction of neonatal sepsis and NEC was mostly homo-

79, 49–107; p value .67).

genous (I2 of 23% and 24%, respectively) indicates that the use of
probiotics could be beneficial for babies with low birth weight
and preterm birth. We notice, however, that there was significant

6 | D I S C U S SI O N

clinical heterogeneity in the dose, duration, and strains of probiotics used; this indicates that more research is needed to de-

6.1 | Summary of main results

termine the appropriate dose and duration of probiotic
supplementation in neonates.

This review evaluated three neonatal nutritional interventions.

The use of probiotics for the prevention of NEC, sepsis, and

Vitamin A supplementation during the neonatal period in the com-

mortality in preterm and/or low birth weight babies has been

munity setting did not have any significant effect on all‐cause mor-

debated in the past. The use of probiotics was advocated after the

tality at 1, 6, or 12 months. We did not identify any studies from

publication of a Cochrane review in 2011 (Alfaleh et al., 2011,

LMICs that assessed the use of dextrose gel for the treatment or

later updated in 2014, AlFaleh & Anabrees, 2014) that showed

prevention of neonatal hypoglycaemia. Probiotic supplementation

that probiotics reduced NEC (stage II or more) (RR, 0.35; 95% CI,

during the neonatal period mainly given to low birth weight and

0.24–0.52) and mortality (RR, 0.40; 95% CI, 0.27–0.60) in preterm/

preterm babies was shown to reduce all‐cause mortality, NEC, and

low birth weight neonates (Ofek Shlomai et al., 2014; Robinson,

neonatal sepsis.

2014). Others challenged the appropriateness of the meta‐analysis
in the setting of clinical heterogeneity (Mihatsch et al., 2012;
Mihatsch, 2011) and called for large trials before this intervention

6.2 | Overall completeness and applicability of
evidence

could be recommended in clinical practice (Mihatsch, 2011). This

The evidence of neonatal vitamin A supplementation included 16

conducted in the United Kingdom (Costeloe et al., 2016). The

studies, and the number of participants in these studies exceeded

ProPrem trial used a mixture of probiotics (Bifidobacterium infantis,

led to two large clinical trials, the ProPrems trial conducted in
Australia and New Zealand (Jacob et al., 2013) and the PiPS trial
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Streptococcus thermophilus, and Bifidobacterium lactis) and included

compared to control (RR, 0.60; 95% CI, 0.48–0.74), culture‐positive

1099 preterm (<32 weeks) and very low birth weight (<1500 g)

and culture‐negative sepsis, and lower respiratory tract infections

neonates. The results of the ProPrems trial showed that the use of

(Panigrahi et al., 2017). More such community‐based studies are

probiotics did not reduce the incidence of sepsis and mortality, but

needed from other countries examining term, preterm, and low birth

did reduce the incidence of NEC (RR, 0.46; 95% CI, 0.23–0.93)

weight infants.

(Jacob et al., 2013). The PiPS trial included 1315 neonates

Are probiotics safe for use during the neonatal period? We did

between the gestational age of 23–30 weeks who were rando-

not find any substantial evidence of adverse events with the use of

mised within 24–48 h to a single probiotic (Bifidobacterium breve

probiotics in neonatal age group. It is important, however, to consider

BBG‐001) or placebo. The results of the PiPS trial showed no

the safety considerations of probiotic supplementation in this vul-

difference between the intervention and the control group for the

nerable population. Probiotics are not regulated as a medication and

outcomes of NEC (RR, 0.93; 95% CI, 0.68–1.27), sepsis (RR, 0.97;

are thus susceptible to variations in quality within and between

95% CI, 0.73–1.29), or death (RR, 0.93; 95% CI, 0.67–1.30)

countries. If not carefully produced and handled, probiotics may also

(Costeloe et al., 2016). The results of these trials were surprising in

contain pathogenic contaminants that may then lead to neonatal

the setting of known evidence from meta‐analyses of the available

sepsis. Probiotic supplementation has been linked to both bacterial

studies. A closer look at the results of the PiPS trial showed that

(Dani et al., 2016) as well as fungal sepsis (Vallabhaneni et al., 2014).

there was significant contamination of the control group, as about

Despite their rare occurrence, neonates receiving probiotics should

49% of the neonates from the control group had the same type of

be followed in a registry to ensure any reporting and observation of

probiotic bacteria in their stool as those who were in the inter-

the potential risk of sepsis in a large sample size in the real world

vention group. This decreased the power of the study, and it was

setting.

argued that a potential lack of effect might be explained by the
cross‐contamination of the control group (Deshpande et al., 2016;
McKinlay et al., 2016). The debate of appropriateness of probiotic

6.3 | Quality of the evidence

supplementation in the neonatal period has continued, and a recent network meta‐analysis concluded that there is not enough

The GRADE quality of evidence was considered high for most of the

evidence in favor of either a single or a mixture of strains of

outcomes for neonatal vitamin A and probiotic supplementation. The

probiotics that could be suggested for routine clinical use for the

GRADE method of assessment of overall evidence considers the type

prevention of NEC, sepsis, and/or mortality in preterm/low birth

of study, ROB, statistical heterogeneity, indirectness, and imprecision

weight babies (van den Akker et al., 2018).

of the summary estimates as well as the risk of publication bias

Our review focused on studies from LMIC. The effect of pro-

(Guyatt et al., 2011).

biotic supplementation on mortality, sepsis, and NEC was significant

All the included studies for neonatal vitamin A supplementation

when we pooled studies from these countries only. We noticed

were randomized and had minimal ROB. The statistical heterogeneity

clinical heterogeneity in the use of probiotics in terms of type of

for pooled studies for neonatal vitamin A supplementation was no-

probiotics, single versus multiple strains used, and baseline inter-

ticeable but was not significant enough to decrease our confidence in

ventions such as the use of breastmilk. We think that the use of a

the summary estimate. Similarly, the CIs around the summary esti-

meta‐analysis is appropriate to pool these studies, as the primary

mate were narrow, and there was no increased risk of publication

target of all the studies was the same, that is, correction of dysbiosis.

bias for studies that assessed neonatal vitamin A supplementation.

We further demonstrated that subgroup analysis based on certain

All the included studies for neonatal probiotic supplementation

clinical factors reveals no significant difference in results. We notice,

were also randomized. High ROB was noted for three of the included

however, the relative lack of studies from the community setting.

studies (Dongol Singh et al., 2017; Fernández‐Carrocera et al., 2013;

This is likely due to the increased rate of community over hospital‐

Kaban et al., 2019), but exclusion of these studies did not change the

based births in LMIC. For this reason, we read the results of a

results of any of the outcomes, including all‐cause mortality, NEC,

community‐based study by Panigrahi et al. (2017) with great interest.

and neonatal sepsis. The pooled results were mostly homogenous,

This study was the largest study conducted on the use of probiotics

and the summary estimates were precise with narrow CIs. The funnel

(synbiotics) and had a sample size of 4556; this is three times larger

plots for publication bias were symmetrical for the outcomes of all‐

than the sample size of the PiPS trial. Panigrahi et al. (2017) used a

cause mortality, NEC, and neonatal sepsis.

synbiotic which was a mixture of the probiotic Lactobacillus plantarum
ATCC‐202195 and the prebiotic fructooligosaccharide. This study
recruited neonates who were at least 35 weeks of gestation and

6.4 | Potential biases in the review process

weighed at least 2000 g from rural settings from India. The results of
the study showed a significant reduction in the primary outcome

We used standard methods of Campbell and Cochrane collabora-

(combination of sepsis and death) in the intervention group

tions to conduct the review. Two review authors screened the titles
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and abstracted the data from the included studies. Our inclusion/

for 28 days (RR, 0.44; 95% CI, 0.229–0.844)] from vitamin A

exclusion criteria were decided a priori, and a peer reviewed pro-

supplementation in very low birth weight infants (Basu et al.,

tocol was published giving details of methods of conduct of this

2019). The new study for neonatal vitamin A supplementation

review.

from the community was small and included 306 participants. The

We performed two posthoc subgroup analyses for the effect of

addition of this study did not change the results significantly

probiotic supplementation during the neonatal period. This ana-

compared to those published in the 2017 Cochrane review

lysis was based on the type of feeding, as our team thought it was

(Haider et al., 2017).

essential to establish any differential effect of probiotics when the

An individual participant meta‐analysis of neonatal vitamin A

intervention was delivered with breastmilk or formula or both. The

studies conducted in the community setting was published during

results for this analysis were similar among the subgroups for

the preparation of this review (West et al., 2019). This review ad-

outcomes of all‐cause mortality and NEC; however, there was

dressed multiple subgroup analyses both at the study‐ and

significant heterogeneity among subgroups for the outcome of

individual‐level characteristics and used the original data from in-

neonatal sepsis Analysis 2.18. A close examination of the data

dividual trials to pool the studies. The overall results were similar to

showed that the difference among subgroups was due to the group

our results for all‐cause mortality at 6 and 12 months (West

where the status of the feeding was “unclear.” Exclusion of this

et al., 2019). The subgroup analysis based on study‐level char-

subgroup showed a homogenous protective effect in the case of

acteristics showed that neonatal vitamin A supplementation sig-

breastmilk or formula milk‐fed babies against neonatal sepsis (data

nificantly reduced 6‐month mortality among the trials conducted in

not shown). So, we think that probiotics may have a significant

South Asia (RR, 0.87; 95% CI, 0.77–0.98) but not in Africa; they also

protective effect against neonatal sepsis, NEC, and mortality ir-

showed a potential for increased risk of mortality in African coun-

respective of the type of food offered. The second posthoc sub-

tries (RR, 1.07; 95% CI, 1.00–1.15). Further subgroup analyses

group analysis was based on study setting. We were interested in

showed that neonatal vitamin A supplementation reduced all‐cause

knowing if the probiotics had a similar effect on infants born in the

mortality in the context of moderate or severe maternal VAD (de-

hospital setting compared to those in the community setting. We

fined as 10% or higher proportion of women with serum retinol

were interested in this analysis because a significant number of

<0.7 μmol/L or 5% or more women with night blindness) (RR, 0.87;

births happen at home in LMIC. There were a limited number of

95% CI, 0.80–0.94), in settings where baseline (control group) early

studies conducted in the community setting that addressed the

infant mortality was 30 or more per 1000 live births (RR, 0.91; 95%

effect of probiotics; therefore, no solid conclusion could be drawn

CI, 0.85–0.98), and in the context of lack of maternal education

at this time for any of the outcomes.

(>32% mothers had no schooling) (RR, 0.88; 95% CI, 0.80–0.96). The
subgroup analyses conducted based on individual‐level characteristics such as sex, birth weight, gestational age and size, age at

6.5 | Agreements and disagreements with other
studies or reviews

dosing, parity, time of breastfeeding initiation, maternal education,
and maternal vitamin A supplementation did not show any significant differential effect of neonatal vitamin A supplementation

The effects of neonatal vitamin A supplementation have been

compared to placebo for these groups. As most of the subgroup

reviewed in two Cochrane reviews (Darlow et al., 2016; Haider

analyses that we prespecified in our review were addressed in this

et al., 2017). The Cochrane review by Haider et al. (2017) focused

study (West et al., 2019), we did not repeat these analysis in our

on randomized studies from the community setting only. We

current study.

considered studies from both community and hospital settings.

Oral dextrose as a treatment of hypoglycaemia and prevention

We updated the literature search and found one additional study

of hypoglycaemia in high‐risk neonates has been evaluated in two

from the community setting (Ahmad et al., 2019) and added three

Cochrane reviews (Hegarty et al., 2017; Weston et al., 2016). The

studies from the hospital setting (Basu et al., 2019; Giridhar

review by Weston et al. (2016) addressed treatment of neonatal

et al., 2019; Sun et al., 2019). The studies from hospital settings

hypoglycaemia and included two studies, one from New Zealand and

were done in the neonatal intensive care setting for very low

another from Ireland. They did not show any major difference in

birth weight babies. We did not pool the results of these studies

episodes of hypoglycaemia between the two study groups. The re-

with those of the community‐based studies. The Cochrane review

view by Hegarty et al. (2017) addressed the prevention of hypogly-

on neonatal vitamin A supplementation for very low birth weight

caemia in high‐risk neonates and included one study from New

infants included 11 trials and reported a reduction in risk of

Zealand. The included study showed a significant reduction in hy-

death or oxygen requirement at 1 month of age (RR, 0.93; 95% CI,

poglycaemia episodes in the intervention group compared to control

0.88–0.99). Of the three studies we included in our review from

(RR, 0.76; 95% CI, 0.62–0.94). No randomized study was available

LMIC, only one study showed a reduction in composite outcome

from LMIC in either of the two reviews mentioned above. We up-

of incidence of all‐cause mortality and oxygen requirement

dated the searches and did not find any study from LMIC.
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Other reviews have been published that assess the effect of

preterm/low birth weight babies in the neonatal intensive care

probiotic supplementation during the neonatal period. A Cochrane

unit. It is not clear if the similar protective effects would be seen

review was published in 2011 (Alfaleh et al., 2011) with an update

when probiotics are given in the community setting or to term

in 2014 (AlFaleh & Anabrees, 2014). This has not since been

babies. It is also unclear if the supplementation of prebiotics and

updated. The Cochrane review included studies from LMIC and

probiotics together (synbiotics) is more effective than probiotics

high‐income countries and concluded that probiotic supple-

alone. More studies are needed to answer these questions and to

mentation reduced NEC (stage II or more) (RR, 0.43; 95% CI,

assess the effect of dextrose supplementation for the prevention

0.33–0.56) and mortality (RR, 0.65; 95% CI, 0.52–0.81) but showed

and treatment of neonatal hypoglycaemia in LMIC.

no effect for nosocomial sepsis (RR, 0.91; 95% CI, 0.80–1.03).
More studies have been published since the publication of the

AC KNO WL EDG EM E NT S

2014 Cochrane review update. Deshpande et al. (2017) reviewed

We would like to thank Connor Appelman for his help with the

studies from LMIC that addressed probiotic supplementation

screening of titles for dextrose supplementation.

during the neonatal period. This review included twenty‐three
studies and concluded that probiotic supplementation reduced all‐

CON TRI BU TI ONS O F A U TH ORS

cause mortality (RR, 0.73; 95% CI, 0.59–0.90), NEC (RR, 0.46, 95%

Aamer Imdad, Deepika Ranjit wrote the first draft of the protocol.

CI, 0.34–0.61), and neonatal sepsis (RR, 0.80; 95% CI, 0.71–0.91).

Gamael S. S. Surin participated in the design of the search

We included thirty‐three studies and updated the meta‐analyses.

strategy and writing of the protocol. Abigail Smith and Sarah

With this new data, the magnitude and the statistical significance

Lawler designed the search strategy. Aamer Imdad wrote the

remained the same, but the summary estimates became more

manuscript for the final review. Aamer Imdad, Faseeha Rehman,

precise for the outcomes of all‐cause mortality, NEC, and sepsis.

Evans Davis, Gamael S. S. Surin, Deepika Ranjit, and Suzanna L.

We also conducted additional subgroup analyses that were not

Attia helped with data extraction and analysis. Suzanna L. Attia

previously performed.

and Aamer Imdad edited the manuscript. Zulfiqar A. Bhutta supervised and gave feedback for the design of the protocol and the
main review.

7 | A UT H O RS ' CO N CL US I O NS
D E C L A R A T I O N S O F I N T E R ES T

7.1 | Implications for practice

Zulfiqar A. Bhutta was principle investigator of study (Soofi

Neonatal vitamin A supplementation in the community setting does

this review and also did not participate in the data extraction from

not appear to reduce infant mortality at 1, 6, or 12 months of age.

this study. All other authors declare that they do not have any

Vitamin A supplementation during neonatal period increases the risk

conflict of interest.

et al., 2017). He was not involved in the selection of the study for

of bulging fontanelle. No data were available for dextrose gel supplementation for the prevention or treatment of neonatal hypogly-

DIFFER ENC ES B ETWE EN P RO TO CO L A ND REVIE W

caemia in LMIC.
Probiotic supplementation is a promising intervention and

– The planned subgroup analyses for vitamin A were not conducted,

can reduce all‐cause mortality, neonatal sepsis, and NEC in low

as the same analyses were available from a recent IPD analysis

birth weight and/or preterm babies in LMIC in the hospital set-

(West et al., 2019).

ting. Though we observed no adverse effects, infants receiving

– We did not use EPOC methodology for the ROB assessment, as all

probiotics should be entered into a registry in order to observe

the included studies were RCTs and the Cochrane ROB assess-

any concerns for safety in large sample sizes in the real world

ment tool was used for the same.

setting.

– We did two posthoc subgroup analyses for probiotic supplementation during the neonatal period. These included type of
feeding and study setting.

7.2 | Implications for research

– We did the sensitivity analysis for ROB based on sequence generation and allocation concealment.

There was significant clinical heterogeneity in terms of strains and
dose of probiotics used in the included studies. More studies are

PU BL IS HE D N OT ES

needed to decide upon the right strain and optimal dose and
duration of probiotics supplementation. Most of the included

CHARACTERISTICS OF STUDIES

studies for probiotics supplementation were conducted in

CHARACTERISTICS OF INCLUDED STUDIES
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Ahmad et al. (2019)

Methods

A block‐randomized, double‐masked, placebo‐controlled intervention trial conducted in Bangladesh

Participants

Inclusion criteria: "consent of the mother and willingness to have their infant participate; singleton birth at MCHTI clinic and
eligible for vaccination according to the national and MCHTI clinic policy".
Exclusion criteria: "planned at home delivery because of the low likelihood of vaccination at MCHTI within 48 h of birth, (2)
congenital disease or a serious infection showing that the infant was not healthy; infant with birth weight <1500 g and
inability to enrol within 48 h of birth due to lack of timely notification or other exceptional circumstances".

Interventions

Intervention group: 50,000 IU vitamin A (retinyl palmitate)
Comparison: Placebo (unfortified soya based oil)
The intervention was delivered within 48 h of birth

Outcomes

Neonatal mortality, adverse events, microbiome changes, thymus size

Notes

Data on mortality and bulging fontanelle were taken from publication (J Nutr 2019;00:1–8). Data on mortality was reported
at 15 weeks. We included the data with “all‐cause mortality at 6 months".

Risk of bias table

Authors'
judgement

Bias

Support for judgement

Random sequence generation
(selection bias)

Low risk

Quote: "The randomization lists of vitamin A and placebo within each group were
generated by WHO, using Stata, v11"

Allocation concealment
(selection bias)

Low risk

Quote: "Preplanned statistical analyses using arbitrary group identifiers…"
Comment: Most likely done

Blinding of participants and
personnel (performance bias)

Low risk

Quote: "dose of VA in oil or an identical placebo (PL) within 48…"
Comment: Most likely done

Blinding of outcome assessment
(detection bias)

Low risk

Quote: "Preplanned statistical analyses using arbitrary group identifiers (group 1, group 2)
were completed on 4 April 2014 before unblinding…"

Incomplete outcome data
(attrition bias)

Low risk

Attrition rate: 5.2%

Selective reporting (reporting bias)

Low risk

Author prespecified the outcomes. Trial was registered as ClinicalTrials.gov:
NCT01583972.

Other bias

Low risk

No other risk of bias was noted

Amini et al. (2017)

Methods

Prospective randomized control trial conducted in Iran

Participants

Inclusion Criteria: "All premature newborns (n = 115) weighting 750–1500 g or <32 weeks' gestation who received
antibiotics and total parenteral nutrition in NICU of Vali Asr Hospital were included"
Exclusion Criteria: "Premature babies <750 and more than 1500 g and neonates with congenital heart disease, congenital
malformations, and immune system deficiency, even in their family members, were excluded from the study."
Intervention: Multistrain powder probiotic infant formula containing Streptococcus thermophilus, Lactobacillus rhamnosus,
Lactobacillus acidophilus, Lactobacillus bulgaricus, Bifidobacterium infantis, Lactobacillus casei. The dose was 0.8–1 g per day
in 8–10 doses given for 13 days
Comparison: Enteral feed without probiotic

Interventions

Outcomes

NEC

Notes

Data were taken from table 3
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Risk of bias table

Authors'
judgement

Bias

Support for judgement

Random sequence generation
(selection bias)

Low risk

Quote: "In this double blind randomized clinical trial (RCT), block randomization
was used and 60 cases were randomly divided into 2 groups."

Allocation concealment (selection bias)

Unclear risk

No clear information was available about allocation concealment

Blinding of participants and personnel
(performance bias)

Unclear risk

No clear information available

Blinding of outcome assessment
(detection bias)

Unclear risk

No clear information available

Incomplete outcome data (attrition bias)

Low risk

Minimal loss to follow up

Selective reporting (reporting bias)

Low risk

Authors seem to report all the outcomes irrespective of their statistical
significance

Other bias

Low risk

No other risk of bias was noted

Basu et al. (2019)

Methods

A randomized double‐blind placebo‐controlled trial India

Participants

Inclusion Criteria: Inborn, VLBW (birth weight (BW) < 1500 g) neonates admitted in NICU and requiring respiratory support
in the form of oxygen inhalation through nasal prongs or head box, continuous positive airway pressure (CPAP), high flow
nasal cannula (HFNC), or mechanical ventilation (MV) at the age of 24 h, were included.
Exclusion Criteria: Neonates with major congenital malformation, any life‐threatening condition such as reversal of umbilical
artery end‐diastolic blood flow on antenatal Doppler, perinatal asphyxia with moderate to severe hypoxic ischemic
encephalopathy, shock with escalating doses of vasopressors, recurrent seizures, and suspected inborn errors of
metabolism

Interventions

Intervention: 10,000 IU of retinol/dose, alternate days, 28 days or until discharge
Compairson: Placebo

Outcomes

All‐cause mortality, sepsis, NEC

Notes

Study conducted in very low birth weight babies

Risk of bias table

Bias

Authors'
judgement

Support for judgement

Random sequence generation
(selection bias)

Low risk

Quote: "Randomization into vitamin A or placebo group was done using random permuted
blocks of 4, 6, and 8, prepared by an independent statistician not involved in the study."

Allocation concealment
(selection bias)

Low risk

Quote: "Allocation into vitamin A or placebo group was done using serially numbered opaque
and sealed envelopes by on‐duty residents who were appropriately trained for the
process beforehand. Allocation concealment was maintained throughout the study."

Blinding of participants and
personnel (performance bias)

Low risk

Quote: "Vitamin A and placebo oral solutions were supplied in identical bottles of 20 mL with
dropper marked at 1 mL…."

Blinding of outcome assessment
(detection bias)

Low risk

Quote: "Treating physicians, nursing staffs, and the parents were unaware about the
composition of the bottles."

Incomplete outcome data
(attrition bias)

Low risk

Three patients from the intervention and two patients from the placebo group left against
medical advice

Selective reporting
(reporting bias)

Low risk

Authors seem to report all the relevant outcomes

Other bias

Low risk

No other risk of bias was noted
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Benn et al. (2008)

Methods

Randomized placebo controlled trial conducted in Guinea‐Bissau

Participants

Inclusion Criteria: Weight at least 2500 g at presentation and no signs of overt illness or malformations
Exclusion Criteria: Weight <2500 g at presentation and/or signs of overt illness and/or malformations. Also, infants who died
in the maternity ward before the vaccination team could arrive
Total number randomized to the intervention group: 2145
Total number randomized to the control group: 2200

Interventions

Intervention: 50,000 IU vitamin A intradermally
Control: 0.5 ml vegetable oil intradermally
Common intervention given to all groups: 10 IU vitamin E intradermally

Outcomes

Primary outcomes: Overall mortality
Other outcomes: Bulging fontanelles, vomiting, irritability, infections, fever, skin problems, and healthcare contacts

Notes

Vitamin A supplementation appeared to benefit boys but was harmful to girls

Risk of bias table

Authors'
judgement

Bias

Support for judgement

Random sequence generation
(selection bias)

Low risk

Quote: "The mother drew a lot from an envelope prepared by the study supervisor. Each
envelope contained 100 lots—50 marked “1” and 50 marked “2”—indicating from which
of two numbered bottles, “1” or “2,” the child should receive the supplement"
Comment: Most likely done

Allocation concealment
(selection bias)

Low risk

Quote: "The lots were folded, making it impossible to tell what was written on them before
they were opened"
Comment: Most likely done

Blinding of participants and
personnel (performance bias)

Low risk

Quote: "When asked, none of the three assistants who were responsible for the
randomisation procedures at the hospital and at the heath centres had any idea which
bottles contained vitamin A and which placebo. We concluded that the blinding of
mothers and assistants was successful"
Comment: Most likely done

Blinding of outcome assessment
(detection bias)

Unclear risk

Quote: "Accumulating evidence for sex differential effects of vitamin A supplementation
during the trial made us hypothesise before we started the analyses that
supplementation would be particularly beneficial for boys"
Comment: Most likely done

Incomplete outcome data
(attrition bias)

Low risk

Total number of loss to follow up: 70 (1.6%)
The loss to follow up was not balanced

Selective reporting (reporting bias)

Low risk

Authors seem to report all the outcomes irrespective of their statistical significance

Other bias

Low risk

No other risk of bias was noted

Benn et al. (2010)
Methods

Randomized placebo controlled two by two factorial trial conducted in Guinea‐Bissau

Participants

Inclusion criteria: Weight <2500 g at presentation
Exclusion criteria: Weight >2500 g at presentation
Total number randomized to the intervention group: 864
Total number randomized to the control group: 872

Interventions

Intervention: 25,000 IU vitamin A intradermally
Control: 0.5 ml vegetable oil intradermally
Common intervention given to all groups: 10 IU vitamin E intradermally

Outcomes

Primary outcomes: Infant mortality
Other outcomes: Fever, septicaemia, malaria, malnutrition, and respiratory infections

Notes
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Risk of bias table

Bias

Authors'
judgement

Support for judgement

Random sequence generation
(selection bias)

Low risk

Quote: "Once consent was provided, the mother drew an envelope from a bag. Each bag was
prepared by the study supervisor and contained 48 envelopes; each envelope contained a
lot name. Within each bag were 12 envelopes with lots marked “BCG 6,” 12 marked “BCG
7,” 12 marked “no BCG 6,” and 12 marked “no BCG 7.” The numbers “6” and “7” indicated
from which of two numbered bottles, “6” or “7,” the child should receive treatment (that is,
either 25,000 IU vitamin A or placebo)"
Comment: Most likely done

Allocation concealment
(selection bias)

Low risk

Quote: "The envelopes were closed and non‐transparent, making it impossible to identify the
allocation before the envelopes were opened"
Comment: Most likely done

Blinding of participants
and personnel
(performance bias)

Unclear risk

Quote: "Once consent was provided, the mother drew an envelope from a bag"
"Each bag was prepared by the study supervisor and contained 48 envelopes; each envelope
contained a lot name"
Comment: Most likely done

Blinding of outcome
assessment
(detection bias)

Low risk

Quote: "Follow‐up was performed by assistants who were unaware of the allocated treatment"

Incomplete outcome data
(attrition bias)

Unclear risk

Total number of loss to follow up: 145 (8.4%)
The loss to follow up was not balanced

Selective reporting
(reporting bias)

Low risk

Authors seem to report all the outcomes irrespective of their statistical significance

Other bias

Low risk

No other risk of bias was noted

Comment: Most likely done

Benn et al. (2014)

Methods

Double‐blind, placebo‐controlled randomized trial conducted in Guinea‐Bissau

Participants

Inclusion criteria: Normal birth‐weight neonates who were healthy and due for BCG vaccination
Exclusion criteria: Birth weight <2500 g at presentation or overt illness and/or malformations
Total number randomized to the intervention group 1 (50,000 IU vitamin A): 2015
Total number randomized to the intervention group 25 (25,000 IU vitamin A): 2011
Total number randomized to the control group: 2022

Interventions

Intervention: 50,000 IU vitamin A intradermally or 25,000 IU vitamin A intradermally
Control: 0.5 ml Vegetable oil intradermally
Common intervention given to all groups: 10 IU vitamin E intradermally

Outcomes

Primary outcome: Infant mortality
Other outcomes: None measured

Notes

Risk of bias table

Bias

Authors'
judgement

Support for judgement

Random sequence generation
(selection bias)

Low risk

Quote. "Each envelope was prepared by the data manager, who did not take part in
the enrolment procedures, and contained 48 folded lots indicating from which
of 3 numbered bottles—“3,” “4,” or “5”—the child should receive his or her
supplement"
Comment: Most likely done

Allocation concealment
(selection bias)

Low risk

Quote. "…48 folded lots indicating from which of 3 numbered bottles—“3,” “4,” or
“5”—the child should receive his or her supplement"
Comment: Most likely done

Blinding of participants and personnel
(performance bias)

Low risk

Quote. "At each inclusion site, the randomization procedure was carried out by 1
carefully trained assistant every day except during short vacations. After
providing consent, the mother drew a lot from an envelope. Each envelope was
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prepared by the data manager, who did not take part in the enrolment
procedures…"
Comment: Most likely done
Blinding of outcome assessment
(detection bias)

Low risk

Quote. "The registration system assistants and the special team were unaware of
the allocated treatment, because they were not present during enrolment, and
the information was not transferred to the children's vaccination card or
follow‐up forms"
Comment: Most likely done

Incomplete outcome data
(attrition bias)

Unclear risk

Quote: “Of 6053 children invited to participate, 6048 were randomly allocated to
each of the 3 groups (50,000 IU vitamin A, 25,000 IU vitamin A, or placebo)
(Figure 1). The 3 randomly assigned groups were similar in terms of their
background characteristics (Table 1). A total of 176 deaths occurred; 2 of these
were due to accidents and were censored. Fourteen deaths occurred after the
child had been eligible for a national vitamin A campaign. Hence, censoring for
accidents and subsequent VAS, the cohort had 160 deaths during 4125 person‐
years of risk, corresponding to an MR of 39 per 1000 person‐years”

Selective reporting (reporting bias)

Low risk

Authors seem to report all the outcomes irrespective of their statistical
significance

Other bias

Low risk

No other risk of bias was noted

Braga et al. (2011)

Methods

Randomized, double blind control study conducted in Brazil

Participants

Inclusion criteria: All infants included in this study were born locally and admitted to the Neonatal Intensive Care Unit
(NICU) with a birth weight from 750 to 1499 g, and had no major congenital malformations, life threatening
chromosomal alterations, or congenital infections

Interventions

Intervention: Probiotic supplementation: Bifidobacterium breve and Lactobacillus casei: The intervention was started on
the second day of life and was maintained until 30 d of life, a diagnosis of NEC, discharge from the hospital, or death,
whichever occurred first. The dose was 3 ml human milk from the bank milk to which L. casei and B. breve had been
added providing 3.5 × 107 to 3.5 × 109 CFU
Comparison: The control group received the same volume of human milk without probiotics

Outcomes

Mortality, NEC and sepsis

Notes

Authors did not do intention to treat analysis. We created the intention to treat analysis by taking the number
randomized as denominators. The data on outcomes was taken from table 2 of the main manuscript

Risk of bias table

Bias

Authors'
judgement

Support for judgement

Random sequence generation
(selection bias)

Low risk

Randomization was carried out in blocks of 10, and the list of random numbers was
generated by the subprogram Epitable from Epi‐Info 6.04

Allocation concealment
(selection bias)

Low risk

A sealed envelope with the identification number in ascending order, containing information
about which group they belonged to, was provided for each infant and sent to the
hospital's nutritional centre

Blinding of participants and
personnel (performance bias)

Low risk

Neither the medical and nursing staff responsible for monitoring the infants nor the
researchers were aware of which group the infants were allocated to

Blinding of outcome assessment
(detection bias)

Low risk

Neither the medical and nursing staff responsible for monitoring the infants nor the
researchers were aware of which group the infants were allocated to

Incomplete outcome data
(attrition bias)

Low risk

Attrition in intervention group was 2% and 7% in the control group

Selective reporting (reporting bias)

Low risk

Most of the outcomes were reported

Other bias

Low risk

No other bias was noted
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Chowdhury et al. (2016)

Methods

A randomized controlled trial conducted in Bangladesh

Participants

Inclusion crietria: Preterm (<33 woks), VLBW (<1500 g) infants who are able to tolerate oral feeds and survive
beyond 48 h
Exclusion criteria: Babies with suspicion of clinical sepsis, presence of prenatal asphyxia, major congenital anomaly and
babies who expired due to other neonatal illness were excluded
Intervention: Probiotic supplementation: Bifidobacterium breve and Lactobacillus casei: The dose was 3 ml once daily of
solution containing Bifidobacterium breve and Lactobacillus casei 106 CFU. The intervention was continued for at least
10 days
Comparison: No probiotics

Interventions

Outcomes

NEC, all‐cause mortality

Notes

Authors did not perform intention to treat analysis, however, we created the intention to treat analysis from Figure 1. The
data for mortality was taken from Figure 1 and the data for NEC was taken from table 2

Risk of bias table

Authors'
judgement

Bias

Support for judgement

Random sequence generation
(selection bias)

Low risk

Coding to group 1 and 2 was done by a faculty of another department not related to this
study. First case was selected to 1 group by lottery method and subsequent group was
continued accordingly

Allocation concealment
(selection bias)

Low risk

Participants and investigators did not know group allocation

Blinding of participants and
personnel (performance bias)

Low risk

Probiotics were added to breast milk by registrar or assistant registrar of the corresponding
unit before feeding

Blinding of outcome assessment
(detection bias)

Low risk

Participants and investigators did not know group allocation

Incomplete outcome data
(attrition bias)

Low risk

15% attrition. Reasons for loss to follow up reported.

Selective reporting (reporting bias)

Low risk

All expected outcomes were reported

Other bias

Low risk

No concerns for other risk of bias

Cooper et al. (2017)

Methods

A randomized double‐blind controlled trial conducted in South Africa in community settings

Participants

Inclusion criteria: "healthy", full term (37–42 weeks), born to HIV + formula feeding mothers, ≤3 days old, 2500–4500 g,
singleton birth
Exclusion criteria: Congenital illness or malformation affecting growth; significant perinatal disease, antibiotics in 1st 3 days
of life, caregivers could not comply, or in another trial
Intervention: Probiotics: Formula containing prebiotic (bovine milk‐derived oligosaccharides) and probiotic ((B. lactis strain
CNCM‐I‐3446 with 1 × 107 cfu/g. of powder formula). The duration of intervention was 6 months
Comparison: Formula without prebiotic and probiotic

Interventions

Outcomes
Notes

All‐cause mortality
The data was taken from the last paragraph of the result section. We note that the intervention group received both
prebiotics and probiotics and the control group did not receive any prebiotics or probiotics. Some of the study participants
were HIV positive
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Risk of bias table

Authors'
judgement

Bias

Support for judgement

Random sequence generation
(selection bias)

Low risk

Quote: "The randomization was performed using the in‐house TrialSys
software".

Allocation concealment (selection bias)

Low risk

Formulas labelled similarly

Blinding of participants and personnel
(performance bias)

Low risk

Parents (caregivers), investigators, study support staff, and the clinical
project managers were blinded to the identity of the products.

Blinding of outcome assessment
(detection bias)

Low risk

Likely same care‐team

Incomplete outcome data (attrition bias)

Low risk

Total loss to follow up was 1%

Selective reporting (reporting bias)

Low risk

Authors do not seem to selectively report outcomes

Other bias

Low risk

No other risk of bias was noted.

Cui et al. (2019)

Methods

A prospective, double‐blinded randomized study conducted in China

Participants

Inclusion criteria: Formula‐fed preterm infants, gestational age ≥30 and <37 weeks; birthweight ≥1500 g and ≤ 2000 g with
vital sign and hemodynamic parameters stable
Exclusion criteria: Congenital diseases, expected hospitalisations <2 weeks and maternal or neonatal antibiotics or other
probiotics before admission
Intervention: Lactobacillus reuteri DSM 17938, five drops daily for minim of 7 days. Each drop had 1×108 colony‐forming units
Comparison: Placebo

Interventions
Outcomes

Sepsis, NEC, growth

Notes

Data were taken from table 2

Risk of bias table

Bias

Authors'
judgement

Support for judgement

Random sequence generation
(selection bias)

Low risk

Quote: "Randomization was conducted according to a random computer‐
determined allocation order considering gestational age"
Comment: Most likely done

Allocation concealment (selection bias)
Blinding of participants and personnel
(performance bias)

Unclear risk
Low risk

No clear information available for allocation concealment
Quote: "Blinding was possible because the nurses who administered L.
reuteri to the infants were not involved in the daily care and the
attending neonatal team was unaware of the randomization
assignments"

Blinding of outcome assessment
(detection bias)

Unclear risk

It was not clear if the families of the participating neonates were aware of
the treatment assignments

Incomplete outcome data (attrition bias)

Low risk

About 18% attrition reported that was balanced in two groups

Selective reporting (reporting bias)

Low risk

Authors seem to report all the relevant outcomes

Other bias

Low risk

No other risk of bias was noted
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Dashti et al. (2014)

Methods

Prospective triple‐blinded, interventional, randomized clinical trial

Participants

Inclusion criteria: Birth weight of 700‐1800 g, stable hemodynamic, be able to have enteral feeding, and written parental
consent.
Exclusion criteria: Evidence or suspicion of congenital intestinal obstruction or perforation, prenatal or postnatal diagnosis of
gastroschisis, large omphalocele, or congenital diaphragmatic hernia, and major congenital anomalies."

Interventions

Intervention: Protexin (probiotics). Protexin (Restore): 1 × 109 CFU (colony forming unit), 1 g (one sachet) contains:
Lactobacillus acidophilus, Lactobacillus rhamnosus, Bifidobacterium longum, Lactobacillus bulgaricus, Lactobacillus casei,
Streptococcus thermophilus, Bifidobacterium breve, and Bifidobacterium
The dose was as follows
– Neonates weighing <1000 g were fed with a half of sachet once daily (5×108 CFU of probiotics),
– Neonates weighing 1001–1500 g were fed with 3/4 of a sachet once daily (7.5×108 CFU of probiotics)
– Neonates weighing more than 1500 g were fed with a full sachet once daily (1×109 CFU of probiotics).
Control: "placebo that was physically indistinguishable from the probiotic powder"

Outcomes

NEC, mortality and sepsis

Notes

The data for NEC, mortality and sepsis was taken from table 2. We assumed that group A was the intervention group and
group B was the control. Authors did not mention clearly in the paper which group is the intervention group and which one
is the control group.The duration of intervention was not clearly stated

Risk of bias table

Authors'
judgement

Bias

Support for judgement

Random sequence generation
(selection bias)

Low risk

No clear data is available to support the assessment however the two groups were
comparable after randomizations and allocation seems to be concealed. So less likely that
randomizations was not done properly

Allocation concealment
(selection bias)

Low risk

Quote: "To blind the trial the probiotic and placebo sachets were set in similar
indistinguishable packages"

Blinding of participants and
personnel (performance bias)

Low risk

Quote: "The control group was fed with milk and a placebo that was physically
indistinguishable from the probiotic powder"

Blinding of outcome assessment
(detection bias)

Low risk

Quote: "After starting the feeding, infants were observed continuously by a chart containing
basic information like daily weight, feeding volume, abdominal girth, appearance of
erythema of abdominal wall, loose stools with blood, vomiting, and orogastric tube
suction volume. The amount of feeding was advanced slowly, if tolerated, with no more
than a 20 ml/kg/d"

Incomplete outcome data
(attrition bias)

Low risk

Quote: "Feeding was discontinued if there was any sign of feeding intolerance (defined as the
presence of gastric aspirate in the amount that was more than a half of the previous
feeding or abdominal distension)"

Selective reporting (reporting bias)

Low risk

Authors seem to report all the relevant outcomes

Other bias

Low risk

No other risk of bias was noted

Demirel et al. (2013)

Methods

Prospective, blinded, randomized control trial conducted in Turkey

Participants

Inclusion criteria: Neonates born ≤32 weeks and birthweight ≤1500 g who survived to start enteral feedings.
Exclusion criteria: Major congenital anomalies, lack of parental consent, death in first seven days after study start

Interventions

Intervention: Probiotic supplementation: S. boulardii: Dose was 250 mg (5 billion cfu), added to breastmilk or formula,
frequency was once daily and supplementation continued till discharge
Comparison: Placebo

Outcomes

NEC, sepsis, mortality

Notes

Data was not analysed as intention to treat analysis. We created the intention to treat analysis by using the number
randomized and the outcome numbers given in table 3
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Risk of bias table

Authors'
judgement

Bias

Support for judgement

Random sequence generation
(selection bias)

Low risk

Quote, "Randomisation was simple and unadjusted and was performed using
sequential numbers generated at the computer centre of the NICU"

Allocation concealment
(selection bias)

Low risk

Quote, "The allocations were sealed in opaque, sequentially numbered envelopes"

Blinding of participants and
personnel
(performance bias)

Low risk

Quote, "The supplements were prepared by personnel on the breast milk team
following the instructions in the sealed envelope. These individuals were the only
personnel who were aware of the group assignments, and they were not involved
in the care of the infants"

Blinding of outcome assessment
(detection bias)

Low risk

Quote, "The supplements were prepared by personnel on the breast milk team
following the instructions in the sealed envelope. These individuals were the only
personnel who were aware of the group assignments, and they were not involved
in the care of the infants"

Incomplete outcome data
(attrition bias)

Low risk

7/278 dropped out. The intervention and the control group were fairly similar

Selective reporting
(reporting bias)

Low risk

Authors seems to report all the outcomes mentioned in the analysis plan

Other bias

Low risk

No other bias was noted

Dilli et al. (2015)

Methods

Prospective, randomized, controlled trial conducted in TurkeyQuote

Participants

Inclsuin criteria:: "VLBW infants with a gestational age of <32 weeks and a birth weight of <1500 g, born at or transferred to
the NICU within the 1st week of life and fed enterally before inclusion, were eligible
Exclusion criteria: Infants with any disease other than those linked to prematurity or congenital anomalies of the intestinal
tract, not fed enterally or who died before the seventh day after birth, whose mothers had taken nondietary probiotic
supplements, and whose parents refused to participate were excluded"

Interventions

Intervention: Probitics/Prebiotics
Multiple Arm trial
1) Probiotic (Bifiidobacterium lactis, 5×109 colony‐forming units)
2) Prebiotic (inulin, 900 mg)
3) Synbiotic (Bifidobacterium lactis, 5×109 colony‐forming units, 30 mg plus inulin, 900 mg
4) The control group: maltodextrin powder as a placebo
The dose was 1 sachet per day of pre/probiotics with breast milk or formula until discharge or death, for a maximum of 8
weeks, whichever comes first

Outcomes

NEC, sepsis and mortality

Notes

The data were taken from table 3. We included data as probiotics+synbiotics vs. prebiotics+placebo

Risk of bias table

Bias

Authors'
judgement

Support for judgement

Random sequence generation
(selection bias)

Low risk

Quote: "Infants were randomized by balanced blocks using sealed
envelopes"

Allocation concealment (selection bias)

Low risk

Quote: "Infants were randomized by balanced blocks using sealed
envelopes"

Blinding of participants and personnel
(performance bias)

Low risk

Quote: " In feeding units, sachets were opened and mixed with 1 ml of
sterile water or breastmilk immediately before administration to infants
who were receiving enteral feeding on the day of the supplementation.
The feeding team was not involved in the care of the infant and
followed directions on the sealed envelopes"
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Blinding of outcome assessment
(detection bias)

Low risk

Quote: "The only personnel who knew of the infants group assignments
were the investigators". As the outcomes were mostly objective, it is
less likely that study had significant detection bias

Incomplete outcome data (attrition bias)

Low risk

Minimal loss to follow up reasons reported

Selective reporting (reporting bias)

Low risk

Authors seem to report all the relevant outcomes

Other bias

Low risk

No other sources of bias were noted

Dutta et al. (2015)

Methods

A randomized, placebo‐controlled trial conducted in India

Participants

Inclusion criteria:
(1) Neonates born at 27–33 weeks gestation in our hospital
(2) aged <96 h of life
(3) who were likely to either remain admitted in hospital or reside within 30 km of the hospital for the next 28 days
(4) who were tolerating at least 15 ml/kg/day of milk feeds
Exclusion criteria:
(1) a gastro‐intestinal malformation
(2) prior NEC or sepsis
(3) any life‐threatening malformation that limited estimated life expectancy to less than a month

Interventions

Intervention group: Probiotic Lactobacillus acidophilus (662.5 million), Lactobacillus rhamnosus (362.5 million), Bifidobacterium
longum (87.5 million), and Saccharomyces boulardii (137.5 million)
Four groups
A. High‐dose long course 1010 cells 12 hourly for 21 days
B. High‐dose short course 1010 cells 12 hourly for days 1–14; followed by placebo from days 15–21
C. Low‐dose long course 109 cells 12 hourly for 21 days
D. Control group: Placebo for 21 days

Outcomes

NEC, mortality and sepsis

Notes

We combined all the probiotics groups (group A + B + C) to avoid the double counting of the placebo.

Risk of bias table

Authors'
judgement

Bias

Support for judgement

Random sequence generation
(selection bias)

Low risk

Quote: "A block randomized sequence was generated online by an investigator who was
not involved in the recruitment of subjects"

Allocation concealment
(selection bias)

Low risk

Quote: "A block randomized sequence was generated online by an investigator who was
not involved in the recruitment of subjects"

Blinding of participants and personnel
(performance bias)

Low risk

Quote: "The external appearance and the contents of the sachets of high dose, low dose,
and placebo were identical looking.

Blinding of outcome assessment
(detection bias)

Low risk

As the intervention was concealed properly, less likely that outcomes assessors were
aware of the allocation

Incomplete outcome data
(attrition bias)

Low risk

Minimal loss to follow up

Selective reporting (reporting bias)

Low risk

Authors seems to report all the relevant outcomes

Other bias

Low risk

No other risk of bias was noted

Edmond et al. (2015)

Methods

Randomized, double‐blind, placebo‐controlled trial conducted in Ghana

Participants

Recruited from the community, at least 2 h old, able to tolerate oral feeds and the family was likely to stay in the area.
Parental consent was needed for inclusion to study.

Interventions

Intervention: Vitamin A: single dose: each dose was 50,000 IU
Control: Placebo
Common intervention given to all groups: Vitamin E
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Outcomes

Primary outcome: All‐cause mortality
Other outcomes: Diarrhea, vomiting, bulging fontanelle, irritability, fever

Notes

Some of the participants were HIV positive
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Risk of bias table

Authors'
judgement

Bias

Support for judgement

Random sequence generation
(selection bias)

Low risk

Quote: “The computerised block randomisation scheme was done with a block size of 20, so
that in each block ten infants received vitamin A and ten received placebo”
Comment: Most likely done

Allocation concealment
(selection bias)

Low risk

Quote: “An independent statistician who was not part of the trial prepared the
randomisation code at the WHO offices in Geneva, Switzerland. The code was available
only to the Data Safety and Monitoring Board (DSMB) and their statistician”
Comment: Most likely done

Blinding of participants and
personnel (performance bias)

Low risk

Quote: “The research team and parents were fully unaware of the content of the capsules,
which were only labelled with the infant number. Amanufacturer (StridesArcolab
Limited, Bangalore, India) supplied the capsules. Separate staff, who were not part of the
trial, labelled all capsules”
Comment: Most likely done

Blinding of outcome assessment
(detection bias)

Unclear risk

Quote: "…"
Comment: Most likely done

Incomplete outcome data
(attrition bias)

Low risk

Quote: “Our loss to follow‐up was only 1.1% at the time of ascertainment of our primary
outcome at 6 months and only 2.9% at 12 months”

Selective reporting (reporting bias)

Low risk

Authors seem to report all the relevant outcomes

Other bias

Low risk

No other risk of bias was noted

Fernández‐Carrocera et al. (2013)

Methods

Propsective, double‐blind, randomized clinical trial conducted in Mexico

Participants

Inclusion criteria: Preterm newborns who weighed <1500 g admitted at the intensive and intermediate care units
Exclusion criteria: Preterm newborns weighing <1500 g with a low Apgar score (<6 at 5 min), gastrointestinal malformations,
genetic syndromes, asphyxia and IA–IB NEC stages according to Bell's

Interventions

Intervention: Probiotic supplementation: "Lacidophilus 1.0×109 colony forming units (CFU) CFU/g, Lactobacillus rhamnosus
4.4×108 CFU/g, Lactobacillus casei 1.0×109 CFU/g, Lactobacillus plantarum 1.76×108 CFU/g, Bifidobacteruim infantis
2.76×107 CFU/g, Streptococcus theremophillus 6.6×105 CFU/g, each pack (Laboratorio Italmex SA)"
Control: "The control group received their regular feeds from their mother's own milk when available with nothing added, or
a premature infant formula"

Outcomes

All‐cause mortality, NEC

Notes

Data were taken from table 3

Risk of bias table

Bias

Authors'
judgement

Support for judgement

Random sequence generation
(selection bias)

Low risk

Infants were prospectively and randomly assigned to one of two groups using a random digit
table

Allocation concealment
(selection bias)

Low risk

"which was handled by the Human Milk Bank staff that was not involved in the care of the
patients and adhered to proper trial procedures."

Blinding of participants and
personnel (performance bias)

Low risk

"As allocation concealment measure, the study group received a suspension that matched
the physical appearance of milk and the bottles were labelled only with the patient's
name and identification number as usual."

Blinding of outcome assessment
(detection bias)

Low risk

Attending physicians and nurses caring for the infants were blinded to the group
assignments.
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Incomplete outcome data
(attrition bias)

Low risk

Minimal loss to follow up

Selective reporting (reporting bias)

Low risk

Authors seem to report all the relevant outcomes

Other bias

Low risk

No other risk of bias was noted

ET AL.

Giridhar et al. (2019)

Methods

Randomized, parallel group, placebo controlled trial

Participants

Inclusion criteria: All infants admitted to the neonatal intensive care unit with birth weight between 750 and 1250 g and
between 24 to 96 h of life
Exclusion criteria: Lethal congenital malformations, terminal illness characterized by shock or bradycardia for more than 2 h,
refusal of consent

Interventions

Intervention 1: Vitamin A: 5000 IU (0.125 ml) IM on alternate days till establishment of adequate enteral feeds followed by
oral vitamin A 10,000 IU (1 ml) once daily for a total duration of 28 days
Control intervention 1: Placebo: 0.125 ml 0.9% normal saline IM alternate days till establishment of adequate enteral feeds
followed by 1 ml oral dose of inert pharmacy made substance once daily for a total duration of 28 days

Outcomes

Proportion of infants with vitamin A deficiency (plasma retinol <200 mcg/L), mortality, sepsis

Notes

Risk of bias table

Authors'
judgement

Bias

Support for judgement

Random sequence generation
(selection bias)

Low risk

Quote: "The random sequence was generated online from the web site www.
randomizer. org"

Allocation concealment (selection bias)

Low risk

Quote: "Each stratum had permuted, even‐numbered, randomly varying block sizes"

Blinding of participants and personnel
(performance bias)

Low risk

Quote: "The investigators, supervisors, caregivers, laboratory personnel, and
statistician were blinded to the intervention"

Blinding of outcome assessment
(detection bias)

Low risk

Quote: "The investigators, supervisors, caregivers, laboratory personnel, and
statistician were blinded to the intervention"

Incomplete outcome data (attrition bias)

Low risk

Minimal loss to follow up

Selective reporting (reporting bias)

Low risk

Authors seem to report all the relevant outcomes

Other bias

Low risk

No other risk of bias was noted

Guney‐Varal et al. (2017)

Methods

Prospective, randomized controlled trial conducted in Turkey

Participants

Inclusion Criteria: preterm infants with a gestational age ≤32 week and a birth weight ≤ 1500 g
Exclusion Crietria: "detected chromosomal abnormalities, previous gastrointestinal system surgery, a diagnosis of metabolic
disease, babies lost in the first postnatal week and babies with severe sepsis episode were excluded from the study"

Interventions

Intervention: Probiotic supplementation: Lactobacillus rhamnosus (4.1×108 cfu) + Lactobacillus casei (8.2×108 cfu) +
Lactobacillus plantorum (4.1×108 cfu) + Bifidobacterium animalis (4.1×108 cfu)
Comparison: No probiotics

Outcomes

Mortality, NEC, sepsis

Notes

Data were taken from table 2
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Risk of bias table

Bias

Authors'
judgement

Random sequence generation (selection bias)

High risk

"Alternate randomization was used to enrol the infants to the
study arms"
This method of randomization is not adequate

Allocation concealment (selection bias)

High risk

Less likely to be done as the sequence generation was done on
alternate basis

Blinding of participants and personnel
(performance bias)

Unclear risk

No details are provided about blinding

Blinding of outcome assessment (detection bias)

Unclear risk

No details are provided about blinding

Incomplete outcome data (attrition bias)

Low risk

Minimal loss to follow up

Selective reporting (reporting bias)

Low risk

Authors seem to report all the relevant outcomes

Other bias

Low risk

No other risk of bias was noted

Support for judgement

Hariharan et al. (2016)

Methods

Prospective, randomized control trial conducted in India

Participants

Inclusion criteria: "Infants with birth weight <1250 g, gestation <32 weeks"

Interventions

Intervention: Lactobacillus acidophilus, Bifidobacterium bifidum, Saccharomyces boulardii 2.5 ×109 UFC of each twice a day, from the
3rd day of life, for 6 week courses
Comparison: No probiotic

Outcomes

Mortality, NEC, sepsis

Notes

Only abstract available

Risk of bias table

Bias

Authors'
judgement

Support for judgement

Random sequence generation (selection bias)

Unclear risk

No details were available as only the abstract was available

Allocation concealment (selection bias)

Unclear risk

No details were available as only the abstract was available

Blinding of participants and personnel (performance bias)

Unclear risk

No details were available as only the abstract was available

Blinding of outcome assessment (detection bias)

Unclear risk

No details were available as only the abstract was available

Incomplete outcome data (attrition bias)

Unclear risk

No details were available as only the abstract was available

Selective reporting (reporting bias)

Low risk

Minimal loss to follow up

Other bias

Unclear risk

No details were available as only the abstract was available

Hernández‐Enríquez et al. (2016)

Methods

Prospective randomized controlled trial conducted in Mexico

Participants

Inclusion criteria: Infants with very low birth weight

Interventions

Intervention: Lactobacillus reuteri 5 drops, equivalent to 100 million colony forming units (1 × 108 CFU) daily, whether they
were newborns with weight >1000 to 1500 g. In the case of newborns with weight <1000 g them 3 drops were
administered Lactobacillus reuteri (60 million CFU) daily
The duration of supplementation was 20 days
Compasrion: Group B (control group) received no probiotic.

Outcomes

NEC, sepsis

Notes

Study published in Spanish. Data extracted from the abstract
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Risk of bias table

Bias

Authors'
judgement

Support for judgement

Random sequence generation (selection bias)

Unclear risk

Study published in Spanish. Details not available

Allocation concealment (selection bias)

Unclear risk

Study published in Spanish. Details not available

Blinding of participants and personnel (performance bias)

Unclear risk

Study published in Spanish. Details not available

Blinding of outcome assessment (detection bias)

Unclear risk

Study published in Spanish. Details not available

Incomplete outcome data (attrition bias)

Unclear risk

Study published in Spanish. Details not available

Selective reporting (reporting bias)

Unclear risk

Study published in Spanish. Details not available

Other bias

Unclear risk

Study published in Spanish. Details not available

Huaxian, 2013

Methods

Randomized controlled trial conducted in China

Participants

Inclusuion criteria: Preterm babies admitted to NICU

Interventions

Intervention: Probiotics and early minimal feeding
Control: Early minimal feedings

Outcomes

NEC

Notes

Only abstract was available

Risk of bias table

Bias

Authors'
judgement

Support for judgement

Random sequence generation (selection bias)

Unclear risk

No details were available as only the abstract was available

Allocation concealment (selection bias)

Unclear risk

No details were available as only the abstract was available

Blinding of participants and personnel (performance bias)

Unclear risk

No details were available as only the abstract was available

Blinding of outcome assessment (detection bias)

Unclear risk

No details were available as only the abstract was available

Incomplete outcome data (attrition bias)

Unclear risk

No details were available as only the abstract was available

Selective reporting (reporting bias)

Low risk

Minimal loss to follow up

Other bias

Unclear risk

No details were available as only the abstract was available

Humphrey et al. (1996)

Methods

A placebo‐controlled trial conducted in Indonesia

Participants

Inclusion criteria: All infants born at Hasan Sadikin Hospital in Bandung, Indonesia from June 18, 1992, to June 3, 1993
Exclusion criteria: Infants that were considered very low birthweight (<1500 g) and infants with life‐threatening conditions
Total number randomized in the intervention group: 1034
Total number randomized in the control group: 1033

Interventions

Intervention: 1 dose of 52 μmol of vitamin A (as retinyl palmitate) orally
Control: Placebo (<0.10 μmol of vitamin A) orally
Common intervention given to all groups: 23 μmol vitamin E (as dl‐α‐tocopherol) orally

Outcomes

Primary outcome: Infant Morbidity & Mortality
Other outcomes: Diarrhea, fever, cough, rapid breathing, wheezing, otitis media, pneumonia, sepsis

Notes
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Risk of bias table

Authors'
judgement

Bias

Support for judgement

Random sequence generation
(selection bias)

Low risk

Quote: "The randomization scheme and coded supplement packets were prepared by a
team in Baltimore, none of whom was involved in recruitment or follow‐up of infants in
Indonesia"
Comment: Most likely done

Allocation concealment
(selection bias)

Low risk

Quote: "Supplements were individually coded, odorless, and identical in appearance"
Comment: Most likely done

Blinding of participants and
personnel (performance bias)

Low risk

Quote: "The randomization scheme and coded supplement packets were prepared by a
team in Baltimore, none of whom was involved in recruitment or follow‐up of infants in
Indonesia
Comment: Most likely done

Blinding of outcome assessment
(detection bias)

Low risk

Quote:: "Two study pediatricians, masked to the treatment group of the case, independently
reviewed each verbal autopsy and assigned as a probable cause of death all diagnoses
for which the criteria of the algorithm were met"
Comment: Most likely done

Incomplete outcome data
(attrition bias)

Unclear risk

Total number of loss to follow up: n (%)
The loss to follow up was balanced

Selective reporting (reporting bias)

Low risk

Authors seem to report all the relevant outcomes

Other bias

Low risk

No other risk of bias was noted

Hussain et al. (2016)

Methods

Propsective, randomized controlled trial conducted in Pakistan

Participants

Inclusion criteria:
1. Pre‐term neonates <36 weeks gestation
2. Low birth weight neonates <2.5 Kg
3. Both genders
4. Both NG feed and bottle feed neonates
5. All neonates that were admitted at day 1 of life
Exclusion criteria:
1. Neonates <30 weeks low birth weight neonates, <1.5 Kg
2. Neonate on mechanical ventilatory support
3. IUGR (gestational age>36 weeks and weight <2.5 kg
4. Patients with congenital cyanotic heart diseases or has birth asphyxia and persistent cyanosis and need of oxygen
inhalation.

Interventions

Intervention: Probiotic supplementation: Bifidobacteria.
Comparison: No probiotics

Outcomes

NEC

Notes

The strain of the probiotic was not clearly stated. The dose and duration of the intervention was not given

Risk of bias table

Bias

Authors'
judgement

Random sequence generation (selection bias)

Low risk

Quote: "neonates were divided in two groups by using random
number tables"

Allocation concealment (selection bias)

Unclear risk

Seems unlikely, but no clear statement is made regarding this
matter

Blinding of participants and personnel (performance bias)

Unclear risk

No supporting statement is age in this regard

Blinding of outcome assessment (detection bias)

Unclear risk

No clear statement is made in this regard

Support for judgement
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Incomplete outcome data (attrition bias)

Low risk

Minimal loss to follow up

Selective reporting (reporting bias)

Low risk

Authors seem to report the relevant outcomes

Other bias

Low risk

No other source of bias was noted

ET AL.

Kaban et al. (2019)

Methods

A double‐blind randomized controlled clinical trial conducted in Indonesia

Participants

Inclusion criteria: Gestational age of 28–34 weeks, birth weight of 1000–1800 g in a stable condition
Exclusion criteria: Lower gastrointestinal tract obstruction, massive gastrointestinal tract bleeding, NEC, sepsis and shock,
and refusal of the infants' parents to participate in the study

Interventions

Intervention: Lactobacillus reuteri DSM 17938, duration of at least 7 days or until the subject was discharged, experienced
NEC, or died, five drops per day, 108 colony‐forming units/day
Comparison: Placebo: The placebo contains a mixture of pharmaceutical‐grade medium‐chain triglycerides and sunflower oil
together with pharmaceutical‐grade silicon

Outcomes

Mortality, sepsis and death

Notes

Data were taken from table 4

Risk of bias table

Authors'
judgement

Bias

Support for judgement

Random sequence generation
(selection bias)

High risk

Quote: "Subjects were allocated to the groups by a third party using a simple
alternating randomization technique"
Comment: Alternation allocation of patients is not random

Allocation concealment (selection bias)

Unclear risk

Quote: "Subjects were allocated to the groups by a third party using a simple
alternating randomization technique"
Comment: It is not clear if the allocation was revealed before the patient were
allocated to intervention or placebo

Blinding of participants and personnel
(performance bias)

Unclear risk

Authors mentioned that it was a double blind trial but no details were provided on
how the blinding was done

Blinding of outcome assessment
(detection bias)

Unclear risk

Authors mentioned that it was a double blind trial but no details were provided on
how the blinding was done

Incomplete outcome data (attrition bias)

Low risk

No attrition was reported

Selective reporting (reporting bias)

Unclear risk

Authors seem to report all the relevant outcomes

Other bias

Unclear risk

No other risk of bias was noted

Klemm et al. (2008)

Methods

Community‐based, double‐masked, cluster‐randomized, and placebo‐controlled trial conducted in Bangladesh

Participants

Inclusion criteria: Infants born to consenting mothers who were participating in the parent trial
Exclusion criteria: Infants of consenting mothers who had died before they could be supplemented by staff, infants born
outside of the study area, and infants who could not be reached to receive a supplement during the first 30 days after
birth
Total number randomized in the intervention group: 8525
Total number randomized in the control group: 8591

Interventions

Intervention: 50,000 IU vitamin A
Control: Placebo
Common intervention given to all groups:

Outcomes

Primary outcome: All‐Cause infant mortality
Other outcomes: Bulging fontanel

Notes

–
–

"Follow‐up of the trial cohort at 3 years of age revealed no evidence of adverse effects associated with having had a
perinatal bulging fontanel in terms of cognitive, motor, and behavioral test outcomes"
This study was concluded early by direction of the Data Safety and Monitoring Board
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Risk of bias table

Authors'
judgement

Bias

Support for judgement

Random sequence generation
(selection bias)

Low risk

Quote: "Sectors were listed in geographically contiguous order and were
randomized in blocks of 4 within each of 3 previously randomized
maternal supplementation trial treatment arms…"
Comment: Most likely done

Allocation concealment (selection bias)

Unclear risk

Quote: "Community maps of the area were developed, homes were issued
numeric addresses, and married women of reproductive age were
enumerated and issued unique study identification numbers"
Comment: Most likely done

Blinding of participants and personnel
(performance bias)

Low risk

Quote: "The supplements for both groups were opaque gelatinous capsules
identical in shape, size, and color containing edible oil"
Comment: Most likely done

Blinding of outcome assessment
(detection bias)

Unclear risk

Quote: "Infant vital status was assessed weekly at home for the first 12
weeks of life by field staff and then again at 24 weeks of age"
Comment: Most likely done

Incomplete outcome data (attrition bias)

Low risk

Total number of loss to follow up: 11 (0.07%)
The loss to follow up was not balanced

Selective reporting (reporting bias)

Low risk

Authors seem to report all the relevant outcomes

Other bias

Low risk

No other risk of bias was noted

Malaba et al. (2005)

Methods

Randomized, placebo‐controlled, 2‐by‐2 factorial design trial was conducted in Zimbabwe

Participants

Inclusion criteria: Neither the mother nor the infant had an acutely life‐threatening condition, the infant was a singleton with
a birth weight of >1500 g, and the mother planned to stay in the region after delivery
Exclusion criteria: Either the mother and/or the infant had an acutely life‐threatening condition, the infant was not a
singleton or had a birth weight of <1500 g, and the mother did not plan to stay in the region after delivery
Total number randomized in the intervention group:
– Aa: 3529
– Ap: 3529
– Pa: 3530
Total number randomized in the control group: Pp: 3522

Interventions

Intervention:
– Mothers received 400,000 IU vitamin A (as retinyl palmitate) and infants received 50,000 IU vitamin A (Aa group)
– Mothers received 400,000 IU vitamin A and infants received placebo (Ap group)
– Mothers received placebo and infants received 50,000 IU vitamin A (Pa group)
Control: Both mothers and infants received placebo (Pp group)
Common intervention given to all groups: Soy oil base with vitamin E as a preservative (50 IU per maternal capsule; 10 IU per
infant capsule)

Outcomes

Primary outcome: Infant mortality
Other outcomes: None

Notes

Risk of bias table

Bias

Authors'
judgement

Random sequence generation (selection bias)

Low risk

Quote: "A separate team at Johns Hopkins University prepared the
study capsule packets. Study identification numbers were
randomly allocated to the treatment groups by computer in
blocks of 12"
Comment: Most likely done

Allocation concealment (selection bias)

Low risk

Quote: "Lists linking the study number to the treatment were kept
in sealed envelopes and encrypted computer files"
"Treatment and placebo capsules appeared identical…"
Comment: Most likely done

Support for judgement
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Blinding of participants and personnel (performance bias)

Unclear
risk

ET AL.

Quote: "Treatment and placebo capsules appeared identical…"
Comment: Most likely done

Blinding of outcome assessment (detection bias)

Low risk

Quote: "Cause of death was determined from medical records for
infants who died in a hospital or from a review of verbal autopsy
information by a study pediatrician, who was masked to
treatment group, for infants dying at home"
Comment: Most likely done

Incomplete outcome data (attrition bias)

Unclear
risk

Total number of loss to follow up: n (%)
The loss to follow up was not balanced

Selective reporting (reporting bias)

Low risk

Authors seem to report all the relevant outcomes

Other bias

Low risk

No other risk of bias was noted

Masanja et al. (2015)

Methods

A randomized, double‐blind, placebo‐controlled trial conducted in Tanzania

Participants

Inclusion criteria: Able to feed orally, parents planned to stay in the study area for at least 6 months, and informed written
consent was provided
Exclusion criteria: Infants enrolled in another trial
Total number randomized in the intervention group: 15,995
Total number randomized in the control group: 16,004

Interventions

Intervention: 50,000 IU of vitamin A (as retinol palmitate) orally
Control: Placebo (minute amounts of vitamin E (9.5–12.6 IU) in soybean oil) orally
Common intervention given to all groups: Minute amounts of vitamin E (9.5–12.6 IU) in soybean oil

Outcomes

Primary outcome: Mortality between supplementation and 6 months of age
Other outcomes: Mortality between supplementation and 28 days of age, Mortality between supplementation and 365 days
of age, and hospital admission in the first 6 months of life

Notes

Risk of bias table

Bias

Authors'
judgement

Support for judgement

Random sequence generation
(selection bias)

Low risk

Quote: "We randomly assigned infants to receive either vitamin A or a placebo. The unit of
randomisation was the individual infant. Block randomisation was done at WHO (Geneva,
Switzerland) in block sizes of 20 (ten infants received vitamin A and ten received placebo)"
Comment: Most likely done

Allocation concealment
(selection bias)

Low risk

Quote: "The vitamin A and placebo capsules were identical in taste and appearance. Capsules
were individually packed in blister packs of two capsules each; one for the dose and the
second for the backup dose. Labels for the capsules were printed at WHO with country
and infant study number in sequential order"
Comment: Most likely done

Blinding of participants and
personnel (performance bias)

Low risk

Quote: "Codes for the experimental regimens were kept with the data and safety monitoring
board and broken during the analysis after a cleaned and locked database for the study
was submitted to WHO"
Comment: Most likely done

Blinding of outcome assessment
(detection bias)

Low risk

Quote: "All reported deaths of children were investigated and trained field staff visited the
family at least 6 weeks after the date of death to do a verbal autopsy interview"
"Trained field interviewers visited enrolled infants at home (or in health facilities for cases in
which the mother and child were not discharged after delivery) 1 day and 3 days after
dosing to monitor possible adverse events after supplementation"
Comment: Most likely done

Incomplete outcome data
(attrition bias)

Unclear risk

Total number of loss to follow up: n (%)
The loss to follow up was not balanced

Selective reporting (reporting bias)

Low risk

Authors seem to report all the relevant outcomes

Other bias

Low risk

No other risk of bias was noted
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Mazumder et al. (2015)

Methods

Randomized, double‐blind, placebo‐controlled trial conducted in India

Participants

Inclusion criteria: Livebirths born in the study area
Exclusion criteria: Died before screening, serious illness, and/or were admitted into the intensive care unit
Total number randomized in the intervention group: 22,493
Total number randomized in the control group: 22,491

Interventions

Intervention: 50,000 IU vitamin A plus vitamin E 9.5–12.6 IU
Control: Placebo (vitamin E 9.5–12.6 IU)
Common intervention given to all groups: Vitamin E 9.5–12.6 IU

Outcomes

Primary outcome: Infant mortality from supplementation to 6 months
Other outcomes: Neonatal mortality, mortality between supplementation and 12 months of age, infant hospital
admission one or more times due to any illness between supplementation and 6 months of age, potential adverse
events in the 3‐day period following supplementation, and vitamin A status in a sub‐sample of infants at 2 weeks
and 3 months of age

Notes

Risk of bias table

Authors'
judgement

Bias

Support for judgement

Random sequence generation
(selection bias)

Low risk

Quote: "The unit of randomisation was the individual infant. We randomly
assigned infants using a block randomisation scheme with a block size
of 20, so that in each block ten infants received vitamin A and ten
received placebo. The randomisation list was prepared offsite at WHO
(Geneva, Switzerland) by a statistician not otherwise involved with the
trial"
Comment: Most likely done

Allocation concealment (selection bias)

Low risk

Quote: "The vitamin A and placebo capsules were identical in colour, shape,
and size. Capsules were individually packaged in identical blister packs
with two capsules, one for the dose and the other as a backup"
Comment: Most likely done

Blinding of participants and personnel
(performance bias)

Low risk

Quote: "Investigators, participants' families, and the data analysis team
were masked to treatment allocation"
Comment: Most likely done

Blinding of outcome assessment
(detection bias)

Low risk

Quote: "Research staff were trained to do surveillance, interview families,
obtain informed consent, give capsules, collect baseline and follow‐up
information, and data capture"
Comment: Most likely done

Incomplete outcome data (attrition bias)

Low risk

Total number of loss to follow up: 40 (0.09%)
The loss to follow up was not balanced

Selective reporting (reporting bias)

Low risk

Authors seem to report all the relevant outcomes

Other bias

Low risk

No other risk of bias was noted

Nandhini et al. (2016)

Methods

A prospective, double blind. controlled trail conducted in India

Participants

Inclusion criteria: Preterm infants, enterally fed, 28–34 weeks, birthweight >1000 g, admitted to the NICU
Exclusion crietria: major congenital anomalies, surgical problems of the GI tract, severe birth asphyxia, early onset sepsis

Interventions

Intervention: Synbiotic supplementation: probiotics (Lactobacillus acidophilus (700 million CFU), Bifidobacterium longum (400
million CFU), Lactobacillus rhamnosus (400 million CFU), Lactobacillus plantaris (300 million CFU), Lactobacillus casei (300
million CFU), Lactobacillus bulgaricus (300 million CFU), Bifidobacterium infantis (300 million CFU) and Bifidobacterium breve
(300 million CFU) + Prebiotic (fructo‐oligosaccharide)
The dose was given two times daily for 7 days. The Probitiotics were mixed with breastmilk
Comparison: Standard of care without synbiotics

Outcomes

Mortality, neonatal sepsis, NEC

Notes

Data were included from table 2. We created the intervention to treat analysis
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Risk of bias table

Authors'
judgement

Bias

Support for judgement

Random sequence generation
(selection bias)

Low risk

After obtaining informed consent from the parents, neonates satisfying the inclusion
criteria were randomized prior to starting enteral feeds into two groups using
computer generated random numbers kept in opaque sealed envelopes

Allocation concealment (selection bias)

Low risk

After obtaining informed consent from the parents, neonates satisfying the inclusion
criteria were randomized prior to starting enteral feeds into two groups using
computer generated random numbers kept in opaque sealed envelopes

Blinding of participants and personnel
(performance bias)

Unclear risk

No details are provided in the study

Blinding of outcome assessment
(detection bias)

Unclear risk

No details are provided in the study

Incomplete outcome data (attrition bias)

Low risk

Miminal loss to follow up

Selective reporting (reporting bias)

Low risk

Author seem to report all the outcomes

Other bias

Low risk

No other bias was noted

Niekerk et al. (2015) (HIV exposed)

Methods

A randomized, double blind, placebo‐controlled clinical trial conducted in South Africa

Participants

Inclsuion criteria: "(i) HIV‐positive or HIV‐negative mothers who gave birth to a premature and VLBW baby at TBCH and
consented to participate in the study; (ii) only breastfeeding mothers, regardless of their HIV status; and (iii) HIV‐positive
mothers that were on the prevention of mother to child transmission treatment schedule. Babies were included if they (i)
had a birth weight of 500 g and 1250 g; (ii) were either HIV‐exposed or HIV‐unexposed; and (iii) received breast milk
(either from their mothers or donor breast milk)"
Exclusion criteria: abnormalities such as gastroschisis, a large omphalocele or congenital diaphragmatic hernia

Interventions

Intervention: Probiotics: L. rhamnosus GG [0.35 ×10^9 colony‐forming units (CFU)] and B. infantis (0.35 ×109 CFU), 5 drops
daily for 28 days
Control: Placebo

Outcomes

Mortality and NEC

Notes

Data were taken from table 3. This was a multiple arm trial and we included the data for HIV exposed and HIV nonexposed
separately

Risk of bias table

Bias

Authors'
judgement

Support for judgement

Random sequence generation
(selection bias)

Low risk

Quote: "Participants were randomized into either the study or control groups
(probiotic vs. placebo supplementation) with a random‐number sequence
allocated to each participant number"

Allocation concealment (selection bias)

Low risk

Quote: "No differences in the colour and appearance of the probiotic and placebo
were noted. The probiotic and placebo were blinded with the use of a colour‐
coded label (orange or purple)"

Blinding of participants and personnel
(performance bias)

Low risk

Quote: "The attending physician, nurses, researcher, research assistant and study
participants were blinded to the group assignment"

Blinding of outcome assessment
(detection bias)

Low risk

Quote: "The attending physician, nurses, researcher, research assistant and study
participants were blinded to the group assignment"

Incomplete outcome data (attrition bias)

Low risk

Minimal loss to follow up

Selective reporting (reporting bias)

Low risk

Authors seem to report all the relevant outcomes

Other bias

Low risk

No other bias was noted
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Niekerk et al. (2015) (HIV nonexposed)

Methods

Same as above study

Participants
Interventions
Outcomes
Notes

Risk of bias table

Authors'
judgement

Bias

Support for judgement

Random sequence generation
(selection bias)

Low risk

Quote: "Participants were randomized into either the study or control groups
(probiotic vs. placebo supplementation) with a random‐number sequence
allocated to each participant number"

Allocation concealment (selection bias)

Low risk

Quote: "No differences in the colour and appearance of the probiotic and placebo
were noted. The probiotic and placebo were blinded with the use of a colour‐
coded label (orange or purple)"

Blinding of participants and personnel
(performance bias)

Low risk

Quote: "The attending physician, nurses, researcher, research assistant and study
participants were blinded to the group assignment"

Blinding of outcome assessment
(detection bias)

Low risk

Quote: "The attending physician, nurses, researcher, research assistant and study
participants were blinded to the group assignment"

Incomplete outcome data (attrition bias)

Low risk

Minimal loss to follow up

Selective reporting (reporting bias)

Low risk

Authors seem to report all the relevant outcomes

Other bias

Low risk

No other bias was noted

Oncel et al. (2014)

Methods

A prospective, double‐blinded, randomized, placebo controlled trial conducted in Turkey

Participants

Inclusion criteria: Preterm infants with a gestational age ≤32 weeks and birth weight ≤1500 g, which survived to feed
enterally, were eligible for the study.
Exclusion crietria: Major congenital malformations and lack of parental consent.

Interventions

Intervention group: Probiotic supplementation:Infants in the probiotic group received 5 drops of oil‐based suspension
containing 1×108 colony‐forming units of Lactobacillus reuteri DSM 17938". The probiotic was given once a day, until
death or discharge from the hospital
Comparison: Placebo

Outcomes

Mortality, NEC

Notes

We created the intention to treat analysis by using the numbers from fig. 1 and the table 2. We included all the patients who
were randomized to intervention or control group

Risk of bias table

Bias

Authors'
judgement

Support for judgement

Random sequence generation
(selection bias)

Low risk

Study infants were randomly assigned to probiotic or placebo by using sequential numbers
generated at the computer centre of the NICU by 1:1 allocation ratio

Allocation concealment
(selection bias)

Low risk

The allocations were contained in opaque, sequentially numbered sealed envelopes

Blinding of participants and
personnel (performance bias)

Low risk

Identical vial containing only oil base were administered following the same protocol as the
probiotic group.

Blinding of outcome assessment
(detection bias)

Low risk

Seems less likely
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Incomplete outcome data
(attrition bias)

Low risk

Minimal loss to follow up

Selective reporting (reporting bias)

Low risk

Authors seem to report all the relevant outcomes

Other bias

Low risk

No other bias was noted

ET AL.

Panigrahi et al. (2017)

Methods

A community‐based, double‐blind, placebo controlled randomized trial conducted in India

Participants

Inclusion criteria: Neonate >24 h and <96 h old, ≥2000 g at birth, breastfeeding begun by 24 h of life, ability to tolerate oral
feeds, informed consent by parent or guardian
Exclusion criteria: Evidence or suspicion of clinical sepsis before the infant was randomized, gestational age reported voluntarily by
the mother to be <35 weeks, infant >96 h old, infant did not cry immediately after birth, mother had fever (>38°C) within 2 days
of delivery, mother had foul‐smelling amniotic discharge within 2 days of delivery, mother had abdominal tenderness within 2
days of delivery, amniotic fluid was meconium‐stained, infant was on antibiotics, mother unlikely to stay in the village for 60 days,
difficulty in carrying out study (maternal sickness etc.), or presence of major congenital anomalies (defined as any malformation
that was felt to be life‐threatening or that required surgical intervention)"

Interventions

Intervention: Synbiotic supplementation: The synbiotic preparation consisted of a capsule containing ~109 Lactobacillus
plantarum ATCC strain 202195 and 150 mg of fructooligosaccharide with 100 mg maltodextrin as excipient
The synbiotic was administered orally to the newborns for 7 days beginning on day 2–4 of life
Comparison: Placebo capsules contained only 250 mg of maltodextrin

Outcomes

Mortality, sepsis

Notes

This was a community based study. Data were taken from table 2

Risk of bias table

Authors'
judgement

Bias

Support for judgement

Random sequence generation
(selection bias)

Low risk

Quote: "Each assignment was the product of a random permutation scheme
that assigned 2 intervention and 2 placebo slots to each of 38
consecutive blocks of 4 assignments for each village. This numbered list
and corresponding bar codes were created by the GCRC (General
Clinical Research Center) at the University of Maryland with assistance
from the Department of Bioinformatics"

Allocation concealment (selection bias)

Low risk

Quote: "This numbered list and corresponding bar codes were created by
the GCRC (General Clinical Research Center) at the University of
Maryland with assistance from the Department of Bioinformatics and
given to the clinical trial supplier (Laxai USA, South Plainfield, New
Jersey, USA) for labelling of the synbiotics and to prepare packages for
each village to be assigned consecutively to enrolled subjects"

Blinding of participants and personnel
(performance bias)

Low risk

Quote: "physicians had no access to randomization, distribution, or
administration of the intervention making them completely blinded to
the intervention"

Blinding of outcome assessment
(detection bias)

Low risk

Quote: "physicians had no access to randomization, distribution, or
administration of the intervention making them completely blinded to
the intervention"

Incomplete outcome data (attrition bias)

Low risk

Minimal loss to follow up

Selective reporting (reporting bias)

Low risk

Authors seem to report all the relevant outcomes

Other bias

Low risk

No other risk of bias was noted

Rahmathullah et al. (2003)

Methods

Community based, randomized, double‐blind, placebo controlled trial conducted in southern India

Participants

Inclusion criteria: Liveborn infants from all pregnancies in the participating villages
Exclusion criteria: Stillbirths, Miscarriages, Any delivery more than 20 km outside the study area, and infants who died
before the study team arrived
Total number randomized in the intervention group: 6624
Total number randomized in the control group: 6570

IMDAD

|

ET AL.

Interventions

Intervention: 24,000 IU vitamin A
Control: Placebo
Common intervention given to all groups: Edible oil solution

Outcomes

Primary outcome: Infant mortality at 6 months
Other outcomes: None
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Notes

Risk of bias table

Authors'
judgement

Bias

Support for judgement

Random sequence generation
(selection bias)

Low risk

Quote: "Randomisation was at the individual level, stratified by
geographical area in blocks of four. Because births were likely in a
variety of locations, randomisation was conducted at the time of
recruitment"
Comment: Most likely done

Allocation concealment (selection bias)

Low risk

Quote: "Treatment codes were kept in a sealed envelope in a locked filing
cabinet in Baltimore"
Comment: Most likely done

Blinding of participants and personnel
(performance bias)

Low risk

Quote: "Investigators, study staff, and mothers were masked to the
assigned treatment"
Comment: Most likely done

Blinding of outcome assessment
(detection bias)

Unclear risk

Quote: "Project staff visited the household every 2 weeks to assess the
vital status of the child and any morbidity.
"Investigators, study staff, and mothers were masked to the assigned
treatment"
Comment: Most likely done

Incomplete outcome data (attrition bias)

Unclear risk

Total number of loss to follow up: 143 (1.1%)
The loss to follow up was not balanced

Selective reporting (reporting bias)

Low risk

Authors seem to report all the relevant outcomes

Other bias

Low risk

No other risk of bias was noted

Rehman et al. (2018)

Methods

A randomized control conducted in Pakistan

Participants

Inclsuion criteria:"preterm infants having gestation of 27 to 36 + 7 weeks; they were VLBW (<1500 g) and they survived to
feed enterally"
Exclusion criteria: None available as only abstract was available for data extraction

Interventions

Authors mentioned that they supplemented the neonates with Probiotic mixtures. Exact strain was not clear

Outcomes

NEC

Notes

Study only available as abstract

Risk of bias table

Bias

Authors'
judgement

Support for judgement

Random sequence generation (selection bias)

Unclear risk

Study available as abstract

Allocation concealment (selection bias)

Unclear risk

Study available as abstract

Blinding of participants and personnel (performance bias)

Unclear risk

Study available as abstract

Blinding of outcome assessment (detection bias)

Unclear risk

Study available as abstract

Incomplete outcome data (attrition bias)

Unclear risk

Study available as abstract

Selective reporting (reporting bias)

Unclear risk

Study available as abstract

Other bias

Unclear risk

Study available as abstract
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Rojas et al. (2012)

Methods

A multicenter, double‐blinded, randomized, placebo‐controlled trial conducted in Colombia

Participants

Inclusion Cciteria: "Preterm infants admitted to NICU, birth weight ≤ 2000 g, haemodynamically stable (blood pressure not
requiring boluses or pressors), and ≤ 48 h of age"
Exclusion criteria: "Infants with evidence or suspicion of congenital intestinal obstruction or perforation, gastroschisis, large
omphalocele, congenital diaphragmatic hernia, major congenital heart defects, or anticipated transfer to a NICU not
participating in the study were excluded"

Interventions

Intervention: Probiotic administration:"Infants in the probiotic group received 5 drops of an oil‐based suspension containing
108 colony‐forming units of L reuteri DSM 17938"
Comparison: Oil based placebo

Outcomes

Mortality, NEC

Notes

Data were taken from table 2. The duration of the intervention was not clearly stated

Risk of bias table

Authors'
judgement

Bias

Support for judgement

Random sequence generation
(selection bias)

Low risk

Quote: " Study participants were randomly assigned to probiotic or placebo by the use of a
computer‐generated balanced block randomization scheme"

Allocation concealment
(selection bias)

Low risk

Quote: "Treatment assignment was performed by using sealed, sequentially numbered,
opaque envelopes, color‐coded for strata, available in each NICU pharmacy"

Blinding of participants and
personnel (performance bias)

Low risk

Quote: "Infants were administered probiotic or placebo regardless of whether enteric feeds
were started"

Blinding of outcome assessment
(detection bias)

Low risk

The authors do not report clearly if the outcome assessment was blinded, however in the
setting of adequate allocation concealment and blinding of interventions it is less likely
the outcome assessors knew the intervention vs placebo group

Incomplete outcome data
(attrition bias)

Low risk

Quote: "The study was terminated before the completion of the targeted sample because of
a substantial drop in patient recruitment among participating institutions as well as
funding restrictions that limited our ability to recruit the required additional subjects"

Selective reporting (reporting bias)

Low risk

Authors seem to report all the relevant outcomes

Other bias

Low risk

No other risk of bias was noted

Roy et al. (2014)

Methods

A prospective, randomized, double blind, placebo‐controlled trial in India

Participants

Inclusion criteria: "Admission to the NICU, a stable oral feeding within 72 h of birth and an informed parental consent;
gestational age (GA) < 37 weeks; birth weight <2500 g; adequate renal and liver function; a postnatal age <2 week; did
not have baseline fungal colonization at enrolment (with colonization defined by isolation of fungi from a culture
specimen obtained from any site during the first 3 days of life); did not receive any form of antifungal prophylaxis other
than the probiotic used"
Exclusion criteria: "presence of major congenital malformation; antenatal and perinatal risk factors for sepsis, major
congenital malformation; stigma of congenital infection; severe lesions diagnosed by cranial ultrasound (e.g.
intraventricular haemorrhage (IVH) grade 3 and 4 and major ischemic lesions); altered liver and renal function; likely to
die within 72 h of birth; and babies of mothers taking supplemental probiotics by capsule/powder"

Interventions

Intervention: "6×109 CFU Lactobacillus: half a sachet of Lactobacillus acidophilus 1.25 billion, B. longum 0.125billion, B.
bifidum 0.125billion, and B. lactis 1 billion/1 g sachet, daily for 6 weeks or NICU discharge
Control:sterile water in breastmilk

Outcomes

NEC, mortality and sepsis

Notes

Data were taken from table 2
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Risk of bias table

Authors'
judgement

Bias

Support for judgement

Random sequence generation
(selection bias)

Low risk

Quote: "The newborns were randomized into two groups by a random‐generated
(computer‐generated), predetermined number table"

Allocation concealment
(selection bias)

Low risk

Quote: "All doctors, nurses, laboratory staff, and parents are blind to the randomized
allocation"
Less likely that allocation was revealed

Blinding of participants and
personnel (performance bias)

Low risk

Quote: "All doctors, nurses, laboratory staff, and parents are blind to the randomized
allocation"

Blinding of outcome assessment
(detection bias)

Low risk

Quote: "All doctors, nurses, laboratory staff, and parents are blind to the randomized
allocation"

Incomplete outcome data
(attrition bias)

Low risk

Minimal loss to follow up

Selective reporting (reporting bias)

Low risk

Authors seem to report all the relevant outcomes

Other bias

Low risk

No other risk of bias was noted

Saengtawesin et al. (2014)

Methods

A prospective, randomized control trial conducted in Thailand

Participants

Inclusion criteria: "all preterm infants with gestational age ≤34 weeks and birth weight ≤1500 g"
Exclusion criteria: "Very low birth weight preterm infants who had severe birth asphyxia, chromosome anomalies, cyanotic
congenital heart disease, congenital intestinal obstruction, gastroschisis, omphalocele, nil per oral >3 weeks and parents
who declined consent"

Interventions

Intervention: Probiotics: "Infloran(1×10^9 Lactobacillus acidophilus and 1×109 Bifidobacterium bifida): 125 mg/kg/dose two
times daily for 6 weeks
Control: "unsupplemented breast milk or preterm formula"

Outcomes

Neonatal Sepsis, NEC

Notes

Risk of bias table

Bias
Random sequence generation
(selection bias)

Authors'
judgement

Support for judgement

Low risk

Quote: "randomized by blocks of four into two groups, study and control group"
Comment: Most likely done

Allocation concealment
(selection bias)

Low risk

Quote: "Infants in the control group were fed either breast milk or premature formula alone.
Infloran® was stored in a refrigerator at 4°C to 8°C, at the hospital pharmacy and sent
then to the neonatal unit according to prescription"
Comment: The sequence was kept at a central location

Blinding of participants and
personnel (performance bias)

Low risk

Seems less likely that participants were aware of the intervention

Blinding of outcome assessment
(detection bias)

Low risk

Quote: "Whenever an infant was suspected to have NEC, he/she was evaluated by two
attending neonatologist"
Seems less likely that outcome assessment was biased

Incomplete outcome data
(attrition bias)

Low risk

Minimal loss to follow up

Selective reporting (reporting bias)

Low risk

Authors seem to report all the relevant outcomes

Other bias

Low risk

No other risk of bias was noted
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Samanta et al. (2009)

Methods

A prospective randomized double‐blind control trial conducted in India

Participants

Inclusion criteria: "preterm (<32 weeks) VLBW (<1500 g) born between October 2007 and March 2008, started feed
enterally, survived beyond 48 h of life"
Exclusion criteria: "babies with major congenital and GI anomalies and babies who expired due to other neonatal illnesses"

Interventions

Intervention: Probitotics containing Bifidobacteria infantis, Bifidobacteria bifidum, Bifidobacteria longum, Lactobacillus
acidophilus: Dose 2.5 billion cfu each of 4 strains twice daily until NICU discharge
Control: Breastmilk without probiotics

Outcomes

Mortality, sepsis

Notes

Risk of bias table

Authors'
judgement

Bias

Support for judgement

Random sequence generation
(selection bias)

Low risk

Quote: "the infants were randomly assigned to two groups by random
number table sequence"

Allocation concealment (selection bias)

Unclear risk

No details are provided

Blinding of participants and personnel
(performance bias)

Unclear risk

No details are provided

Blinding of outcome assessment
(detection bias)

Unclear risk

No details are provided

Incomplete outcome data (attrition bias)

Low risk

Minimal loss to follow up

Selective reporting (reporting bias)

Low risk

Authors seem to report all the relevant outcomes

Other bias

Low risk

No other risk of bias was noted

Sari et al. (2011)

Methods

Prospective, randomized, controlled trial Turkey

Participants

Inclusion criteria: Infants with gestational age of <33 weeks or birth weight of 1500 g
Exclusion criteria: Major congenital malformations and lack of parental consent

Interventions

Intervention: "Lactobacillus sporogenes with a dose of 350 000 000 c.f.u. once a day until discharge"
Control: "The control group was fed with breast milk or formula without the probiotics

Outcomes

NEC, mortality, sepsis

Notes

Data were taken from table 2 of the study. We created the intention to treat analysis

Risk of bias table

Authors'
judgement

Support for judgement

Random sequence generation
(selection bias)

Low risk

Quote: "using sequential numbers generated at the computer center of…"

Allocation concealment (selection bias)

Low risk

Quote: "The allocations were contained in opaque, sequentially numbered
sealed envelopes"

Blinding of participants and personnel
(performance bias)

Low risk

Quote: "Thus, the only personnel who knew of the infants’ group
assignments were the investigators and those in the breast‐milk team
who were not involved in the care of the study infants"

Blinding of outcome assessment
(detection bias)

Low risk

Bias
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Quote: "Whenever an infant was suspected to have NEC, the infant was
evaluated by two senior‐attending neonatologists who did not know the
group assignment of the infant"
Incomplete outcome data (attrition bias)

Low risk

Minimal loss to follow up

Selective reporting (reporting bias)

Low risk

Authors seem to report all the outcomes irrespective of their statistical
significance

Other bias

Low risk

No other risk of bias was noted

Serce et al. (2013)

Methods

A prospective, double blind, placebo controlled trial conducted in Turkey

Participants

Inclusion criteria: "VLBW infants (gestational age ≤32 weeks; birth weight ≤1500 g) who survived to feed enterally were
eligible for the trial"
Exclusion criteria: "Infants who had severe asphyxia (stage III), major congenital anomalies, those who had been fasted for
more than 3 weeks, died in the first postnatal 14 days and infants who used antifungal therapy were excluded"

Interventions

Intervention: "The study group received Saccharomyces boulardii (50 mg/kg equal to 0.5×109 cell/kg per dose twice daily until
discharge
Comparison: placebo (distilled water; 1 ml per dose twice daily)

Outcomes

Mortality, NEC, sepsis

Notes

Data were taken from table 3

Risk of bias table

Authors'
judgement

Bias

Support for judgement

Random sequence generation
(selection bias)

Low risk

Quote: "Randomization was performed by using sequential numbers
generated at the computer…"

Allocation concealment (selection bias)

Low risk

Quote: "The allocations were contained in opaque, sequentially numbered
sealed envelopes"

Blinding of participants and personnel
(performance bias)

Low risk

Quote: "The allocations were contained in opaque, sequentially numbered
sealed envelopes"
Comment less likely that participants were aware

Blinding of outcome assessment
(detection bias)

Unclear risk

No information was provided on who made the assessment

Incomplete outcome data (attrition bias)

Low risk

Minimal loss to follow up

Selective reporting (reporting bias)

Low risk

Authors seem to report all the outcomes irrespective of their statistical
significance

Other bias

Low risk

No other risk of bias was noted

Shadkam et al. (2015)

Methods

A prospective, triple blind, placebo controlled trial conducted in Iran

Participants

Inclusion criteria: "premature infants admitted at the neonatal intensive care unit (NICU) during October 2012‐March 2013.
Gestational age of infants was estimated at 28–34 weeks using the Dubowitz method, and birth weight of infants was
calculated to be 1000–1800 g"
Exclusion criteria: "presence of disorders such as digestive obstruction, GI bleeding, gastroschisis, omphalocele, withdrawal
syndrome, neonatal proven or clinical sepsis, congenital heart defect and asphyxia (degree II or III)"

Interventions

Intervention: "5 ml of a mixture containing Lactobacillus reuteri DSM 17938. One drop of this product holds a minimum of 20
million live Lactobacillus reuteri protectis." The intervention was given two times daily. The intervention was given until
the child achieved full enteral feedings
Control: "placebo group received 0.5 ml of distilled water every 12 hours"

Outcomes

Mortality, sepsis, NEC

Notes

Data were taken from table 2
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Risk of bias table

Authors'
judgement

Support for judgement

Random sequence generation
(selection bias)

Low risk

Quote: "using the random allocation software"

Allocation concealment (selection bias)

Unclear risk

No details were provided on where the allocation was placed

Blinding of participants and personnel
(performance bias)

Low risk

Quote: "the intervention was implemented by nurses, and the physician was
not aware of the condition of neonates in detail"

Blinding of outcome assessment
(detection bias)

Low risk

Quote: "the intervention was implemented by nurses, and the physician was
not aware of the condition of neonates in detail"

Incomplete outcome data (attrition bias)

Low risk

Minimal loss to follow up

Selective reporting (reporting bias)

Low risk

Authors seem to report all the outcomes irrespective of their statistical
significance

Other bias

Low risk

No other risk of bias was noted

Bias

Shashidhar et al. (2017)

Methods

A double blind randomized controlled trial in India

Participants

Inclusion criteria: "All neonates with a birth weight between 750 and 1499 g admitted to the NICU"
Exclusion criteria: "Neonates with gastrointestinal anomalies, severe congenital malformation, and those not started on
enteral feeds by day 14 of life were excluded"

Interventions

Intervention: "Multicomponent probiotic formulation of Lactobacillus acidophilus, Lactobacillus rhamnosus, Bifidobacterium
longum, and Saccharomyces boulardii in the form of powdered sachets of 1 g each. The intervention was administered once
a day at a dose of 1.25×109 CFU starting within 24 h of initiation of feeds. The probiotic supplementation was continued
till discharge given once a day if the volume of feeds was 2 ml or more, and in two divided doses if the baby received
<2 ml/feed
Control: "The no probiotic group received only breast milk and served as the control"

Outcomes

Mortality, NEC

Notes

Data were taken from table 2

Risk of bias table

Bias

Authors'
judgement

Support for judgement

Random sequence generation
(selection bias)

Low risk

Quote: "The subjects were randomly allocated into two groups using
computer generated random numbers by an investigator not directly
involved in the study"

Allocation concealment (selection bias)

Low risk

Quote: "Sequentially numbered opaque sealed envelopes were used for
allocation concealment"

Blinding of participants and personnel
(performance bias)

Low risk

Quote: "The two groups were coded as A and B and the group code was kept
off site in an opaque sealed envelope and opened only after the final
analysis was done"

Blinding of outcome assessment
(detection bias)

Low risk

Quote: "The two groups were coded as A and B and the group code was kept
off site in an opaque sealed envelope and opened only after the final
analysis was done"

Incomplete outcome data (attrition bias)

Low risk

Minimal loss to follow up

Selective reporting (reporting bias)

Low risk

Authors seem to report all the outcomes irrespective of their statistical
significance

Other bias

Low risk

No other risk of bias was noted
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Dongol Singh et al. (2017)

Methods

A randomized, double blind, placebo controlled conducted in Nepal

Participants

Inclusion criteria: Preterm babies admitted to the NICU
Exclusion criteria: "Sick infants (neonates with clinical or proven sepsis), those with congenital malformation especially
(central nervous system) malformation and other such as gastrointestinal obstruction, gastrointestinal bleeding,
gastroschisis, omphalocoele, congenital heart defect and birth asphyxia (grade III). Out born babies were also excluded in
this study"

Interventions

Intervention: "probiotics Lactobacillus casei var. rhamnosis (LCR 35) 0.8 mg (half packet) dissolved in 2 ml of EBM in infant
more than 1500 g and 0.4 mg probiotics (1/4th packet) dissolved in 1 ml of EBM in infants <1500 g was given twice a day
until they reached full feeding"
Control: "placebo as expressed breast milk only"

Outcomes

NEC and mortality

Notes

Data were taken from the last two paragraphs of the result section

Risk of bias table

Bias

Authors'
judgement

Support for judgement

Random sequence generation (selection bias)

Low risk

Quote: "using random selection by lottery"

Allocation concealment (selection bias)

High risk

Quote: "Intervention was instructed by the researcher and conducted by
nursing staff of NICU"

Blinding of participants and personnel
(performance bias)

Low risk

Less likely that neonates were aware of the intervention

Blinding of outcome assessment
(detection bias)

Unclear risk

No clear information was provided on who made the assessment for clinical
outcomes

Incomplete outcome data (attrition bias)

Low risk

Minimal loss to follow up

Selective reporting (reporting bias)

Low risk

Authors seem to report all the outcomes irrespective of their statistical
significance

Other bias

Low risk

No other risk of bias was noted

Sinha et al. (2015)

Methods

Randomized, double‐blind, placebo‐controlled trial conducted in India in community settings

Participants

Inclusion criteria: infants aged 3 days, born in the hospitals weighing 1500–2500 g"
Exclusion criteria: "extremely premature infants (<34 weeks), sick infants, those with congenital malformations incompatible
with life, and those with guardians not giving consent and belonging to out of study areas"

Interventions

Intervention: "VSL#3 (a mix of eight strains: Streptococcus thermophilus, Bifidobacterium breve, Bifidobacterium longum,
Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, and Lactobacillus
delbrueckii spp bulgaricus, at a dose of 10 billion cfu for 30 days, starting on the third day of life and continued for
30 days"
Control: "A similar‐looking maltodextrin preparation in the same outer packing was administered to the control group"

Outcomes

Mortality, sepsis

Notes

Data were taken from table 2 and table 4. For sepsis, we included the numbers for suspected sepsi

Risk of bias table

Bias

Authors'
judgement

Support for judgement

Random sequence generation
(selection bias)

Low risk

Quote: "A team of scientists at INCLEN Trust, New Delhi, used a computer‐
generated table for subject allocation"

Allocation concealment (selection bias)

Low risk

Quote: "Allocation concealment was ensured by sequentially numbering
the sachet packets containing VSL#3 or placebo after block
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randomisation. Identical packaging of VSL#3 and a placebo with similar
consistency and colour was provided"
Blinding of participants and personnel
(performance bias)

Low risk

Quote: "Parents of enrolled infants, investigators and field workers were
masked to treatment allocation. Data analysis was performed in a
blinded manner"

Blinding of outcome assessment
(detection bias)

Low risk

Quote: "Parents of enrolled infants, investigators and field workers were
masked to treatment allocation. Data analysis was performed in a
blinded manner"

Incomplete outcome data (attrition bias)

Low risk

Minimal loss to follow up

Selective reporting (reporting bias)

Low risk

Authors seem to report all the outcomes irrespective of their statistical
significance

Other bias

Low risk

No other risk of bias was noted

Soofi et al. (2017)

Methods
Participants

A cluster randomized, placebo controlled trial conducted in Pakistan
Inclusion criteria: All infants born in the study village were eligible for inclusion.
Exclusion criteria: Infants with congenital anomalies were excluded

Interventions

Intervention: The intervention group received a single dose of vitamin A 50,000 IU
Comparison: the comparison group received placebo.
Both the groups received vitamin E.

Outcomes

All‐cause mortality, febrile illness, diarrhoea or pneumonia

Notes

Risk of bias table

Bias

Authors'
judgement

Support for judgement

Random sequence generation
(selection bias)

Low risk

Quote: “This was a cluster randomized, placebo‐controlled trial”; and “an
external consultant generated the computerized allocation sequence of
clusters to each study intervention to either group using Epi Info 3.5.3
with restricted randomization based on population size, expected births
and LHW presence”

Allocation concealment (selection bias)

Low risk

Quote: “An external consultant generated the computerized allocation
sequence of clusters to each study intervention to either group using Epi
Info 3.5.3 with restricted randomization based on population size,
expected births and LHW presence”

Blinding of participants and personnel
(performance bias)

Low risk

Quote: “The capsules were identical in appearance (Banner Pharmacaps,
Canada) and supplied through the courtesy of the Micronutrient
Initiative (Ottawa, Canada). The capsules were packaged in containers
labelled as A & B. The content of the capsules were masked from field
staff and supervisors, and the codes were only known to the external
consultant responsible for cluster randomizations and the chair of the
DSMB. The masking was maintained until the completion of the study”

Blinding of outcome assessment
(detection bias)

Low risk

Quote: “The capsules were identical in appearance (Banner Pharmacaps,
Canada) and supplied through the courtesy of the Micronutrient
Initiative (Ottawa, Canada). The capsules were packaged in containers
labelled as A & B. The content of the capsules were masked from field
staff and supervisors, and the codes were only known to the external
consultant responsible for cluster randomization and the chair of the
DSMB. The masking was maintained until the completion of the study”

Incomplete outcome data (attrition bias)

Low risk

Quote: “We were able to follow 10,286 (93%) infants until death or 6
months of age”

Selective reporting (reporting bias)

Low risk

Author seem to report all the relevant outcomes

Other bias

Low risk

No other risk of bias was noted

IMDAD

|

ET AL.

57 of 88

Sun et al. (2019)

Methods

A prospective, randomized study conducted in China

Participants

Inclusion criteria: Admitted to the neonatal intensive care unit at a gestational age of 28 weeks, 96 h of age
Exclusion criteria: Genetic metabolic diseases; congenital major abnormalities; congenital TORCH infections with overt signs
at birth; terminal stage of illness (pH 7.0 or hypoxia with bradycardia 2 h); or the lack of parental consent

Interventions

Intervention: Vitamin A, 1500 IU/day and continued if the infant tolerated the milk, for 28 days or until discharge
Comparison: Placebo

Outcomes

Mortality, NEC

Notes

Risk of bias table

Authors'
judgement

Bias

Support for judgement

Random sequence generation
(selection bias)

Low risk

Quote: "A blocked randomization method stratified by the neonatal
intensive care unit size was used to assign infants to either the control
or oral VA group"

Allocation concealment (selection bias)

Low risk

Quote: "solutions, which were only labelled with the study site and infant
number"

Blinding of participants and personnel
(performance bias)

Low risk

Quote: "The medical and nursing teams caring for the infants were thus
completely unaware of the content of the solutions"

Blinding of outcome assessment
(detection bias)

Low risk

Quote: "The medical and nursing teams caring for the infants were thus
completely unaware of the content of the solutions, which were only
labelled with the study site and infant number"

Incomplete outcome data (attrition bias)

Low risk

No loss to follow up was noted

Selective reporting (reporting bias)

Low risk

Authors seem to report all the relevant outcomes

Other bias

Low risk

No other risk of bias was noted

Tewari et al. (2015)

Methods

A double‐blinded, placebo‐controlled, randomized trial conducted in India

Participants

Inclusion criteria: "Preterm neonates <34 weeks admitted to the NICU"
Exclusion criteria:
"i. Extramural preterm neonates >10 day age with clinical or lab marker of sepsis
ii. Preterm babies with necrotizing enterocolitis (NEC) or an intestinal surgical anomaly
iii. Preterm babies with a lethal congenital anomaly, dysmorphism or aneuploidy"

Interventions

Intervention: "Bacillus clausii containing 2×109 spores in 5 ml minibottle in a dose of 2 ml per‐oral every 8 h mixed with the
enteral feeds through orogastric tube or oral feeds, giving them 2.4×109 spores per day. Probiotic supplementation was
continued till postnatal age of 6 weeks, or till discharge or death or occurrence of LOS, whichever was earlier for babies
in both"
Control: "Babies in the placebo group received sterile water, 2 ml per‐oral every 8 h mixed with feeds"

Outcomes

Mortality, sepsis, NEC

Notes

Data were taken from table 3 and 4. We combined the numbers for very preterm and extreme preterm babies

Risk of bias table

Bias

Authors'
judgement

Support for judgement

Random sequence generation
(selection bias)

Low risk

Quote: "Randomization was done using an online service (www.
randomization.com)"

Allocation concealment (selection bias)

Low risk

Quote: "Serially numbered opaque sealed envelopes with the allocation
were available with the in‐charge nurse of the NICU, who dispensed the
intervention in a syringe for oral administration"
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Blinding of participants and personnel
(performance bias)

Low risk

Quote: "All probiotic and sterile water mini bottles were coded and labels
concealed"

Blinding of outcome assessment
(detection bias)

Low risk

Quote: "All the investigators were blinded to the intervention"

Incomplete outcome data (attrition bias)

Low risk

Minimal loss to follow up

Selective reporting (reporting bias)

Low risk

Authors seem to report all the outcomes irrespective of their statistical
significance

Other bias

Low risk

No other risk of bias was noted

West et al. (1995)

Methods

A randomized, double‐masked trial conducted in Nepal

Participants

Inclusion criteria: Infants 5 months of age or younger
Exclusion criteria: Infants >5 months of age
Total number randomized in the intervention group: 5832
Total number randomized in the control group: 6086

Interventions

Intervention:
– 15,000 RE (50,000 IU) vitamin A administered orally in approximately 3 drops of oil for neonates (<1 month old)
– 30,000 RE (100,000 IU) vitamin A administered orally in approximately 6 drops of oil for infants ages 1–5 months old
Control:
– 75 RE (250 IU) administered orally for neonates (<1 month old)
– 150 RE (500 IU) administered orally for infants ages 1–5 months old
Common intervention given to all groups: Approximately 3.3 IU vitamin E per drop of oil

Outcomes

Primary outcome: Infant mortality, all‐cause mortality
Other outcomes: Malnutrition, ALRI, diarrhea or dysentery, whooping cough, meningitis, sudden death

Notes

All analyses were completed on an intent‐to‐treat basis

Risk of bias table
Bias

Authors'
judgement

Support for judgement

Random sequence generation
(selection bias)

Low risk

Quote: "After a random start, wards were systematically assigned, blocked
on VDAs, for infants to receive…"
Comment: Most likely done

Allocation concealment (selection bias)

Low risk

Quote: "…from gelatinous capsules of identical appearance"
Comment: Most likely done

Blinding of participants and personnel
(performance bias)

Low risk

Quote: "The protocol and procedures for the trial were reviewed and
approved by the Nepal Medical Research Council, Kathmandu, and the
Joint Committee on Clinical Investigation at the Johns Hopkins
University School of Medicine, Baltimore"
Comment: Most likely done.

Blinding of outcome assessment
(detection bias)

Unclear risk

Quote: "Verbal autopsy reports were independently reviewed by two
physicians (SKK and RA) who standardized their reviews for ‘S0 pre‐
study death reports"
Comment: Most likely done

Incomplete outcome data (attrition bias)

Unclear risk

Total number of loss to follow up: n (%)
The loss to follow up was not balanced

Selective reporting (reporting bias)

Low risk

Authors seem to report all the outcomes irrespective of their statistical
significance

Other bias

Unclear risk

No other risk of bias was noted
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Xu et al. (2016)

Methods

A prospective, randomized, case‐controlled trial conducted in China

Participants

Inclusion criteria: "hospital‐born formula‐fed infants with a gestational age of 30–37 weeks and a birth weight between
1500 and 2500 g"
Exclusion criteria: "severe neonatal pathologies, such as severe birth complications, GI malformations, chromosomal
abnormalities, known immunodeficiency, hydrops fetalis, central venous catheter, antifungal drugs, and probiotics"

Interventions

Intervention: "The intervention group received Saccharomyces boulardii CNCM I‐745, administered two times per day as
separate medication, not mixed with formula, at a dosage of 50 mg/kg. The study period ended at the 28th day after birth
or when the infant was discharged from the hospital. Minimum duration of intervention was 7 days"
Control: "Nothing was administered to the control group"

Outcomes

Neonatal sepsis

Notes

Data were taken from table 2

Risk of bias table

Bias

Authors'
judgement

Support for judgement

Random sequence generation
(selection bias)

Low risk

Quote: "Randomization was conducted according to a random computer‐
determined allocation order considering birth weight"

Allocation concealment (selection bias)

Low risk

Quote: "Blinding was possible because the nursing staff who administered
S. boulardii to the infants was not involved in the daily care and the
attending neonatal team was unaware of the randomization
assignments"
Comment: Less likely that randomization sequence was revealed

Blinding of participants and personnel
(performance bias)

Low risk

Quote: "Blinding was possible because the nursing staff who administered
S. boulardii to the infants was not involved in the daily care and the
attending neonatal team was unaware of the randomization
assignments"

Blinding of outcome assessment
(detection bias)

Low risk

Quote: "Blinding was possible because the nursing staff who administered
S. boulardii to the infants was not involved in the daily care and the
attending neonatal team was unaware of the randomization
assignments"

Incomplete outcome data (attrition bias)

High risk

Quote: "25 (20%) patients were considered dropouts"

Selective reporting (reporting bias)

Low risk

Authors seem to report all the outcomes irrespective of their statistical
significance

Other bias

Low risk

No other risk of bias was noted

Characteristics of excluded studies
Abdulkadir et al. (2016)
Reason for exclusion

Study conducted in a high income country (UK)

Abrahamse‐Berkeveld et al. (2016)
Reason for exclusion

Study conducted in a high income country (Germany and Italy)

Abrahamsson et al. (2005)
Reason for exclusion

No relevant outcomes were found

ADAPTS trial (2019)
Reason for exclusion

Wrong settings: Ongoing study in Australia

Agarwal et al. (2003)
Reason for exclusion
Agarwal (2018)

No relevant clinical outcomes were reported
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Study conducted in a high income country (Australia)

Ahmadipour et al. (2019)
Reason for exclusion

Study conducted to treat neonatal Jaundice.

Ahmadpour Kacho et al. (2005)
Reason for exclusion

No relevant outcomes were reported

Al‐Hosni et al. (2012)
Reason for exclusion

Study conducted in a high income country (USA)

Ala‐Houhala et al.(1988)
Reason for exclusion

Study conducted in a high income country (Finland)

Allen et al. (2010)
Reason for exclusion

Study conducted in high income country (UK)

Armanian et al. (2014)
Reason for exclusion

Study participants were given only Prebiotics and no probiotics

Arthur et al. (1992)
Reason for exclusion

Study population did not include Neonates

Aryayev et al. (2018)
Reason for exclusion

Study conducted in high income country

Athalye‐Jape et al. (2018)
Reason for exclusion

Study conducted in high income country

Awad et al. (2010)
Reason for exclusion

Study was retracted

Ayah et al. (2007)
Reason for exclusion

Vitamin A was given at 14 weeks

Aydin et al. (2012)
Reason for exclusion

Population included children with Congential Heart disease only

Baglatzi et al. (2016)
Reason for exclusion

Study conducted in a high income country

Bakker (2005)
Reason for exclusion

Study continued supplementation of probiotics for 4 months

Bakker Zierikzee (2005)
Reason for exclusion

Study conducted in a high income country (Netherland)

Bin‐Nun et al. (2005)
Reason for exclusion

Study conducted in Israel

Bocquet et al. (2013)
Reason for exclusion

Study conducted in a high income country (France)

Bonati (1993a)
Reason for exclusion

Study conducted in a high income country (Italy)

Bonati (1996b)
Reason for exclusion

Study conducted in a high income country (Italy)

Bora & Deori (2019)
Reason for exclusion

Study compared two forms of the same intervention

Cekola et al. (2015)
Reason for exclusion

Study conducted in a high income country (USA)

Chabra et al. (2013)
Reason for exclusion

Study conducted in a high income country (USA)

Chandel et al. (2017)
Reason for exclusion

No relevant clinical outcomes were available

Chi (2019)
Reason for exclusion
Chouraqui et al. (2008)

No clinical outcomes were available

IMDAD

|

ET AL.

Reason for exclusion

61 of 88

Study conducted in a high income country (France)

Chrzanowska‐Liszewska (2011)
Reason for exclusion

Study conducted in a high income country (Poland)

Chua et al. (2017)
Reason for exclusion

Study conducted in a high income country (Netherland)

Corkins & Kovacevich (2001)
Reason for exclusion

Study conducted UK

Costalos et al. (2003)
Reason for exclusion

Study conducted in a high income country (Greece)

Costeloe (2016)
Reason for exclusion

Study conducted in a high income country (UK)

Coutsoudis et al. (1996)
Reason for exclusion

No clinical outcomes were available

Dani et al. (2002)
Reason for exclusion

Study conducted in high income country (

Darboe et al. (2007)
Reason for exclusion

Study conducted on wrong study population (infants)

Delimont et al. (2019)
Reason for exclusion

Study conducted on older children and used Sorghum‐Based and
Corn‐Based Fortified Blended Foods

Delvin et al. (2000)
Reason for exclusion

Study conducted in a high income country (US)

Deng & Chen (2010)
Reason for exclusion

No abstract or full text available and no relevant outcomes were
available.

Denkel et al. (2017)
Reason for exclusion

Study conducted in a high income country (Germany)

Deshpande 2016
Reason for exclusion

Study conducted in high income country

Diaby et al. (2018)
Reason for exclusion

Observational study assessing the coverage of vitamin A
supplementation

Dilli et al. (2013)
Reason for exclusion

Study conducted on wrong patient population (infants with
congenital heart diseases)

Elom et al. (2019)
Reason for exclusion

Wrong study population

Escribano et al. (2018)
Reason for exclusion

Study conducted in a high income country (Spain)

Galderisi et al. (2016)
Reason for exclusion

The study investigated glucose monitoring and not the dextrose gel

Garg et al. (2017)
Reason for exclusion

Wrong study design (retrospective cohort study)

Garland et al. (2011)
Reason for exclusion

Study conducted in a high income country (Australia)

Garofoli et al. (2018)
Reason for exclusion

Wrong setting

Gomber (1996)
Reason for exclusion
Gomez‐Rodriguez et al. (2019)
Reason for exclusion

Wrong study design
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Compared two different regimens of probiotics. No placebo group
was included.
Gonchar et al. (2016)
Reason for exclusion

No relevant outcomes were available. Study only available in the
form of abstract. Authors were contacted for full text but no
response

Guo‐Qiang et al. (2016)
Reason for exclusion

Wrong study design

Hammerman & Bin‐nun (2007)
Reason for exclusion

Wrong intervention

Harris et al. (2016)
Reason for exclusion

Study conducted in New Zealand

Hays (2015)
Reason for exclusion

Study conducted in a high income country

Hoy‐Schulz et al. (2016)
Reason for exclusion

Study conducted on wrong patient population

Hoyos (1999)
Reason for exclusion

Wrong study design

Hua et al. (2014)
Reason for exclusion

Only abstract available and no relevant clinical outcomes were
available

Huang et al. (2016)
Reason for exclusion

No relevant outcomes were available

Hunter et al. (2012)
Reason for exclusion

Wrong study design

Härtel (2019)
Reason for exclusion

The study is being conducted in a high income country (Germany)

Idindili et al. (2007)
Reason for exclusion

Study conducted on wrong patient population

Indrio et al. (2008)
Reason for exclusion

Study conducted in a high income country

IRCT (2015)
Reason for exclusion

Wrong comparison

Jacobs (2017)
Reason for exclusion

Study conducted in a high income country

Janvier et al. (2014)
Reason for exclusion

Study conducted in a high income country

Kahbazi et al. (2019)
Reason for exclusion

Wrong study population

Kanic et al. (2015)
Reason for exclusion

Study conducted in a high income country

Karthikeyan & Bhat (2017)
Reason for exclusion

Study conducted in a high income country

Kiatchoosakun (2014)
Reason for exclusion

No relevant outcomes were available

Kirkwood et al. (2010)
Reason for exclusion

Wrong study design

Kliegman (2005)
Reason for exclusion

Wrong study design

Koksal et al. (2015)
Reason for exclusion

Only abstract was available and no analyzable data were reported
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Kukkonen et al. (2008)
Reason for exclusion

Wrong study design

Leele et al. (2015)
Reason for exclusion

Study conducted in a high income country (Singapore)

Li (2019)
Reason for exclusion

The intervention continued for 4 months

Lin (2009)
Reason for exclusion

Study conducted in a high income country (Taiwan)

Long & Dempsey (2018)
Reason for exclusion

Study conducted in a developed country

Lozano (2008)
Reason for exclusion

Study conducted in a high income country

Lund et al. (2014)

Reason for exclusion

The control group did not receive the placebo but polio vaccine. It is
difficult to tease out the effect of vitamin A supplementation vs.
No vitamin A supplementation.

Lundelin et al. (2017)
Reason for exclusion

Study conducted in a high income country

Mactier et al. (2012)
Reason for exclusion

Study conducted in a high income country

Maldonado‐Lobon (2015)
Reason for exclusion

Study conducted in a high income country

Manzano et al. (2017)
Reason for exclusion

Study conducted in a high income country (Spain)

Manzoni et al. (2006)
Reason for exclusion

Study conducted in a high income country (Italy)

Manzoni et al. (2009)
Reason for exclusion

Study conducted in a high income country (italy)

Marissen et al. (2019)
Reason for exclusion

This is an ongoing study in Germany which is a high income country.

Martins et al. (2009)
Reason for exclusion

Wrong study population

Materna (2010)
Reason for exclusion

Study conducted in a high income country

McCulloch et al. (2012)
Reason for exclusion

Study conducted in a high income country (UK)

McKinlay (2016)
Reason for exclusion

Study conducted in a high income country

Meyer & Gortner (2014)
Reason for exclusion

Study conducted in a high income country (Germany)

Mg (2011)
Reason for exclusion

Study conducted in a high income country (Italy)

Mihatsch et al. (2010)
Reason for exclusion

Study conducted in a high income country (Germany)

Millar (2017)
Reason for exclusion

Study conducted in a high income country

Moles et al. (2015)
Reason for exclusion

Study conducted in high income country

Nadella et al. (2019)
Reason for exclusion

Wrong intervention
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Nct (2006)
Reason for exclusion

Study conducted in high income country

Nct (2016)
Reason for exclusion
Papagaroufalis et al. (1991)

Wrong settings

Reason for exclusion

Study conducted in high income country (Greece)

Papagaroufalis et al. (2014)
Reason for exclusion

Study conducted in high income country (Greece)

Patole et al. (2016)
Reason for exclusion

Study conducted in a high income country (Australia)

Pearson et al. (1992)
Reason for exclusion

Study conducted in a high income country (USA)

Plummer et al. (2018)
Reason for exclusion

Study conducted in a high income country (Australia)

Puccio et al. (2007)
Reason for exclusion

Study conducted in a high income country (Italy)

Qiao et al. (2017)
Reason for exclusion

No relevant outcomes were available

Radke et al. (2017)
Reason for exclusion

Study conducted in a high income country (Germany)

Raguž et al. (2016)
Reason for exclusion

Wrong study design

Rakshasbhuvankar et al. (2017)
Reason for exclusion

Study conducted in a high income country (Australia)

Rawat et al. (2016)
Reason for exclusion

Study conducted in the USA

Repa et al. (2015)
Reason for exclusion

Study conducted in a high income country (Austria)

Robbins & Fletcher (1993)
Reason for exclusion

wrong comparator

Rodriguez‐Herrera et al. (2019)
Reason for exclusion

Study conducted in a high income country

Rodríguez (2015)
Reason for exclusion

Study compared two forms of Probiotics and no comparison with
placebo was available

Rohan (2016)
Reason for exclusion

Study conducted in a high income country (UK)

Ross et al. (1993)
Reason for exclusion

Study included children 6 months and older

Rouge et al. (2009)
Reason for exclusion

Study conducted in a high income country (France)

Rubaltelli et al. (2000)
Reason for exclusion

Study conducted in a high income country (Italy)

Sadowska‐Krawczenko et al. (2012)
Reason for exclusion

Study conducted in a high income country (Germany)

Samuels et al. (2016)
Reason for exclusion

Study conducted in a high income country (Netherland)

Shenai et al. (1987)
Reason for exclusion
Smilowitz et al. (2017)

Study conducted in a high income country (USA)
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Study conducted in a high income country (USA)

Storm et al. (2019)
Reason for exclusion

Study conducted in a high income country USA

Stratiki et al. (2007)
Reason for exclusion

Study conducted in a high income country (Greece)

Strus et al. (2018)
Reason for exclusion

Study conducted in a high income country (Poland)

Ter (2017)
Reason for exclusion

Study conducted in Australia

Thanhaeuser et al. (2014)
Reason for exclusion

Study conducted in a high income country (Austria)

Totsu et al. (2014)
Reason for exclusion

Study conducted in a high income country (Japan)

Tyson et al. (1999)
Reason for exclusion

Study conducted in a high income country (USA)

Venkatarao et al. (1996)
Reason for exclusion

Infant received vitamin A at 6 months

Vlieger et al. (2009)
Reason for exclusion

Study conducted in high income country (Netherland)

Wardle et al. (2001)
Reason for exclusion

Study conducted in high income country (UK)

West et al. (1991)
Reason for exclusion

Study included children 6‐59 months of age

Yang et al. (2011)
Reason for exclusion

Full text not available and no abstract was available either so no
relevant outcomes were available.

Characteristics of studies awaiting classification
Barclay et al. (2003)

Methods

Randomized controlled trial

Participants

Term infants

Interventions

Formula with pre‐pro and synbiotics

Outcomes

Growth

Notes

Study available only in the abstract form

Chubarova and Sharyafetdinova (2017)

Methods

Randomized Controlled trial

Participants

Preterm neonates

Interventions

Outcomes

A combination of freeze‐dried strains of lactobacilli and bifidobacteria: Lactobacillus rhamnosus, Bifidobacterium infantis,
Bifidobacterium longum, Lactobacillus acidophilus (at time of manufacture 2 billion CFUs per 3 g of the preparation), also
containing the additional component maltodextrin. The comparison group received placebo
NEC and stay in NICU and others

Notes

Only abstract available. It is not clear on where the study was done
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Characteristics of ongoing studies
DelPiano (2016)

Study name
Methods

Our open‐label, randomized controlled study has the primary endpoint of reducing diarrhea and infectious diseases
(number of episodes/severity) and the secondary endpoint of decreasing infant mortality
Randomized control trial

Participants

The trial is currently conducted in Luzira, a suburb of Kampala, the capital of Uganda, and in Gulu and Lira, in the north
of Uganda.The study is projected to enrol 4000 babies (control = 2000 and treatment=2000) who will be followed
till 1 year of life. As controls, 2000 babies of the same community are planned to be considered

Interventions

The probiotic product selected for the trial is composed of 3 designated microorganisms, namely Bifidobacterium breve
BR03 (DSM 16604), B. breve B632 (DSM 24706), and Lactobacillus delbrueckii subsp. delbrueckii LDD01 (DSM
22106)

Outcomes

Incidence of diarrhea and mortality

Starting date
Contact information

Gastroenterology Department, Santa Rita Hospital‐Policlinico di Monza †Department of Gynecology and Obstetrics,
Santa Rita Hospital‐Policlinico di Monza, Vercelli ‡Biolab Research Ltd, Novara, Italy

Notes

Goodman (2015)

Study name

Prevention of vitamin A deficiency by supplementation alongside routine vaccinations: a randomised controlled
trial in Ghana infants

Methods
Participants

Randomised controlled trial
Participant inclusion criteria
1. Mothers normally resident in the study area
2. Informed consent obtained from the mother
Participant exclusion criteria
1. Mothers unable to give informed consent
2. Mothers considered to be at high risk of adverse outcome in puerperal period
3. Multiple deliveries
4. Severe adverse reaction to vitamin A supplementation

Interventions

1st Group:
1. Mothers 200,000 IU vitamin A shortly after delivery
2. Infants: 25,000 IU vitamin A with each Diphtheria, Pertussis, Tetanus (DPT) vaccine 1, 2 and 3
2nd Group:
1. Mothers 200,000 IU vitamin A at infant's Bacillus Calmette‐Guerin (BCG) vaccine and another 200,000 IU
vitamin A at infant's 1st DPT
2. Infants: 50,000 IU vitamin A with each DPT 1, 2 and 3

Outcomes

Primary outcome measure
1. Serum retinol levels, assessed by carrying out mRDR testing of infants at 6 weeks, 6 and 9 months
2. Modified Retinol Dose Response (mRDR) tests
3. Incidence of side effects such as bulging of the anterior fontanel and vomiting
4. Incidence of severe morbidity
Secondary outcome measures
1. Breast milk retinol concentrations, assessed at 6 weeks, 6 and 9 months for an assessment of the impact of
the different supplementation regimes
2. mRDR testing of infants at 9 months of age

Starting date

01/01/2004

Contact information

World Health Organization
Geneva‐27
CH‐1211
Switzerland

Notes

No results are available

Heydarabad (2018)

Study name

Evaluation of the effect of probiotics on late‐onset sepsis in very preterm newborns

Methods

A randomized, triple blinded, placebo controlled clinical trial with two parallel groups

Participants

Inclusion criteria include: 1. Preterm infants weighting 1000‐1500 g and <32 weeks’ gestational age at birth 2.
Enrolled within 48 h of birth
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Exclusion criteria: (a) Major congenital anomalies (Esophageal atresia,omphalocele, imperforate anus). (2) Major
congenital heart malformations. (3) Genetic anomalies(e.g. Trisomy 21 or other trisomies). (4) Considered
likely to die within 72 h of birth. (5) Death before minimal entral feeding (10‐20cc/kg/day). (6) Parents from
whom informed consent cannot be obtained. (7) Sepsis in admission (CRP > 10 mg/dl in 1th day of
admission). (8) Asphyxia (grade II, III). (9) Maternal chorioamnionitis
Interventions

Very low‐birth‐weight preterm infants with a gestational age of <32 weeks and a weight of 1000‐1500 gr who
are admitted to the NICU of Shahid Motahari Hospital in Urmia during the first 48 h of their birth. Patients
are randomly divided into two groups; the intervention group receive probiotic and the control group
receive Dish water as placebo

Outcomes

Late onset sepsis

Starting date

2018‐03‐05

Contact information

Kamran Dehghan
Iran (Islamic Republic of)
dehghan.k@umsu.ac.ir

Notes

Kaur (2018)

Study name

Effect of probiotic supplementation on feed tolerance and weight gain in low birth weight infants on tube feeds

Methods

Randomized, parallel group trial

Participants

Inclusion criteria: All neonates with a birth weight between 1000 and 1800 gm admitted to the NICU in whom
enteral feeds can be started.
Exclusion criteria:
Neonates with weight <1000 gm
Neonates with gastrointestinal anomalies
Neonates with major congenital malformations
Neonates in whom the feed could not be started by day 14 of life

Interventions

Intervention 1: Probiotic: Probiotic containing Lactibacillus acidophilus, Lactibacillus rhamnosus, Bifidobacterium
longum, Saccharomyces boulardi in form of powdered sachet of 1 g each
Control Intervention 1: Nil: Nil

Outcomes

To compare the time taken (in days) to reach full enteral feeds (150 ml/kg/day) in low birth weight infants on
orogastric feeds between the probiotic and no probiotic group
To compare episodes of feed intolerance and weight gain in both the groups.Timepoint: Time taken to reach full
enteral feeds

Starting date

31‐07‐2018

Contact information

Neonatal Intensive Care Unit, Department of pediatrics,GGS medical college and hospital faridkot
Faridkot
PUNJAB
151203
India
dr.amarpreet12@gmail.com

Notes

Londhe (2019)

Study name

Use of zinc and pre‐probiotics as a therapeutic adjunct in neonatal sepsis in preterms‐ An Open label
randomized controlled trial

Methods

Randomized, parallel group, multiple arm trial

Participants

All intramural preterm neonates from 28 week 1day to 36 week 6 days admitted to NICU at GMCH
Aurangabad with proven sepsis during the study period, whose parents consented to be part of the study
were included
Diagnostic criteria for sepsis was
(a) Positive “sepsis screen,” that is, presence of at least two of the following three parameters, namely, Total
leucocyte count <5000/mm3, Low absolute neutrophil count (as per standard charts), C‐reactive
protein>1 mg/dl,
(b) Radiological evidence of pneumonia
(c) Culture positive sepsis
(d) Meningitis
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Interventions

Zinc and prebiotics: zinc and pre‐probiotic group was given both zinc 10 mg per day and pre‐probiotics as syrup
5 ml per day containing L. acidophilus (1.25 billion), B. longum (0.125 billion), B. bifidum (0.125 billion), B.
lactis (1 billion) and Inulin (25 mg) till discharge
Zinc: Zinc group was given oral zinc 10 mg once a day irrespective of age of newborn till discharge.
Pre‐biotic group: Pre‐probiotics group was given as Syrup 5 ml per day containing L. acidophilus (1.25 billion), B.
longum (0.125 billion), B. bifidum (0.125 billion), B. lactis (1 billion) and Inulin (25 mg) till discharge
Control: Not receiving any of the above

Outcomes

Reduction in mortality

Starting date

Date Completed: 31/08/2016

Contact information

Division of Neonatology Department of Pediatrics Govt Medical College Aurangabad
431001
Aurangabad, MAHARASHTRA
India
atul.londhe1982@gmail.com

Notes

Description results are available at the web site where the clinical trial was registered. We wrote to authors to
obtain the results

Mirmohammdi (2018)

Study name

Determination of the effect of probiotics on prevention of necrotizing enterocolitis in preterm infants

Methods

This randomized clinical trial will be conducted on preterm infants with low birth weight and very low birth
weight.

Participants

Inclusion criteria: VLBW infants (gestational age ≤34 weeks and birth weight ≤1500 g) survive until the onset of
oral nutrition
Exclusion criteria: (1) Severe asphyxia (stage III) (2) Congenital major anomalies (3) Babies who have not started
oral feeding for 3 weeks after birth. (4) Infants receiving antifungal treatment

Interventions

The intervention group consisted of newborn infants with probiotic podilakat made by Iran Fertilizer Company
in a quantity of 1 drops per kg of weight every 12 h with breast milk or milk powder
The control group is a neonate who will receive 0.5 cc normal saline every 12 h with breastfeeding or
breastfeeding

Outcomes

Baby weight at the end of the 3rd month

Starting date

2019‐07‐29

Contact information

mir farhad mirmohammdi
Ibn sina ave‐ imam reza hospital‐ mashhad‐ Iran
Emailmirmohammadif951@mums.ac.ir

Notes

Mukhtar, 2019

Study name

Role of prophylactic microbial supplements in prevention of blood stream infection and intestinal tract injury in
premature neonates

Methods
Participants

Randomized, parallel group trial
All infants admitted to our NICU with birth weight <2 kg or gestational age <35 weeks as assessed by EDD and
further confirmed by Ballards score who survive the first 24 hrs of life will be enrolled in the study

Interventions

Mixture of Lactobacillus acidophilus, Lactobacillus rhamnosus, Bifidobacterium longum, and Streptomyces boulardii in
a dose of 1.25 billion CFU twice daily started with the first feed which can be in the form of expressed
breast milk or preterm formula feed and continued till discharge
The control group will receive expressed breast milk or preterm formula feed with no supplements added

Outcomes

1. Necrotising colitis
2. Nosocomial sepsis
In preterm low birth weight babies

Starting date

01/12/2012

Contact information

Seniour resident, Department of Pediatrics and Neonatology, Sher‐i‐Kashmir Institute of Medical Sciences,
Soura Srinagar
Srinagar
JAMMU & KASHMIR
190005
India
gousiamukhtar@gmail.com,

Notes

Study started in 2012 but no results have been published yet
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Nandhini 2012

Study name

A clinical study to analyse the effectiveness of administration of harmless bacteria in preventing infection of
intestine in preterm babies

Methods

Randomized, parallel group trial

Participants

Inclusion criteria:
birth weight >1000 g
gestational age—28–34 weeks
enterally fed
Exclusion criteria:
surgical conditions of gastrointestinal tract
severe birth asphyxia
major congenital malformations
chromosomal anomalies

Interventions

Intervention 1: probiotics: Bifidobacterium and Lactobacilli species‐ capsule(available as pre pro HS capsules
marketed by fourrts limited) one capsule, administered twice a day orally mixed with breast milk for 7 days
Control Intervention 1: none

Outcomes

Incidence and severity of NEC. Timepoint: during period of hospital stay

Starting date

15‐02‐2011

Contact information

Department of pediatrics JIPMER, Dhanvanthri Nagar
605006
Pondicherry, PONDICHERRY
India
drnbiswal@yahoo.com

Notes

The web site said that the study is completed. We wrote to authors to ask for the results

Punnahitananda, 2011

Study name

Effect of oral probiotic supplementation on the rate of hospital acquired infection and necrotizing enterocolitis
in preterm very low birth weight infants

Methods

Randomized controlled study

Participants

Participant inclusion criteria
1. VLBW preterm infants (gestational age (GA) < 35 weeks, body weight (BW) < 1.5 kg)
2. Admitted to the neonatal intensive care unit (NICU) who survived the first 3 days of life
Participant exclusion criteria
1. Infants with chromosome abnormality
2. Infants with severe congenital defects
3. Infants with gastrointestinal anomalies (e.g., omphalocele, gastroschisis, intestinal obstruction)
4. Infants with unstable hemodynamic status

Interventions

Daily enteral probiotic supplementation of live Lactobacillus acidophilus and Bifidobacterium infantis at a dose of
2.5 ×108 CFU of each strain once a day for at least 28 days versus placebo

Outcomes

Primary outcome measure
Nosocomial Infections
Secondary outcome measures
1. Necrotizing enterocolitis (NEC)
2. Feeding tolerance
3. Time to reach full enteral feeding

Starting date

28/04/2011

Contact information

Rama IV Road
Pathumwan
Bangkok
10330
Thailand
grad@chula.ac.th

Notes

Rathod, 2019

Study name

Probiotics for prevention of necrotising enterocoilitis in preterm neonates

Methods

Randomized, parallel group, placebo controlled trial

Participants

1. gestational age 28–34 weeks
2. Birth weight of <2 kg
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Exclusion criteria: Preterm newborn
1. Birth weight >2 kg
2. Lethal Congenital malformation
3. Newborn on ventilator
Interventions

Intervention 1: giving probiotics: 50% of preterm newborn are given probiotics while rest 50% are not given
probiotics
Intervention 2: giving probiotics: 50% of preterm newborn are given probiotics while rest 50% are not given
probiotics
Control Intervention 1: not applicable

Outcomes

Occurrence of necrotising enterocolitis

Starting date

28/09/2017

Contact information

Mahendra Rathod
Department of Pediatrics,sir Takhtsinhji hospital, Bhavnagar
364001
Bhavnagar, GUJARAT
India
jayendragohil@gmail.com

Notes

It is not clear if the study is completed.

Razavi, 2014

Study name

Effect of probiotic in prevention of necroziting entrocolitis in preterm infants in Hafez hospital

Methods

Randomized, blinding: double blinded, placebo

Participants

Inclusion criteria: premature neonates with 1500 gr and below that are stable and tolerate (10cc/kg/day)
formula or breast milk.Exclusion criteria: decline to participate; severe congenital anomaly; death

Interventions

Intervention group: add probiotics (Probiotic drops Pedilact Manufacturing zist takhmir) milk at the rate of 0/
1cc/kg/day until hospital
Control group: The control group was used as control and did not receive drug

Outcomes

Sign and symptom of NEC

Starting date

2014‐05‐22

Contact information

Dr.Seyed Mostajab Razavi
Neonatal Research Center, Neonatal Department, Namazi Hospital, Zand Street, Shiraz Shiraz Iran (Islamic
Republic of)
porarish@sums.ac.ir

Notes

Shashidhar, 2019

Study name

A study of the effect of probiotic organism administration on feeding tolerance in very low birth weight
newborn babies

Methods

Randomized, parallel group, active controlled trial

Participants

Inclusion criteria: All neonates (infants in the first 28 days of life) with a birth weight <1.5 kg, admitted to NICU
SJMCH Bangalore. Postnatal age <2 wks and started enteral feeds.
Exclusion criteria: Neonates GI tract anomalies, severe congenital malformations.

Interventions

Intervention 1: probiotic sachets: Lactobacillus Spp, Bifidobacter Spp, Saccharomyces boulardi
oral 1 sachet once a day orally mixed in breast milk till discharge
Control Intervention 1: breast milk: breast milk only

Outcomes

Incidence of feed intolerance
Incidence of NEC stage 2 or more
Duration of hospital stay
Days on TPN
Weight gain
Mortality

Starting date

31‐08‐2012

Contact information

Senior resident Dept.of Neonatology St.Johns Medical College Koramangala Bangalore
Bangalore
KARNATAKA
560034
India
shashiishere@gmail.com

Notes
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Sinha, 2019

Study name

Phase III, multicentre, randomized, double‐blind, placebo‐controlled study to evaluate efficacy of probiotic
supplementation for prevention of neonatal sepsis in 0–2 months old low birth weight infants in India

Methods

Randomized, parallel group, placebo controlled trial

Participants

Inclusion criteria:
1. Birth weight: 1500 g to 500 g
2. Age of the new‐born Day 3‐7 on recruitment, that is, not later than 7th day
3. Stable clinical condition as assessed by physician and accepting feeds orally (where stable is defined as,
does not require intravenous fluids and vasopressor medication to maintain circulation and accepts oral
feeding or breastfeeding).
4. The mother (with the new‐born) is planning to stay in study area for a period of at least 2 months
Exclusion criteria:
1. New born with extreme prematurity, that is, <34 weeks
2. New born with illness requiring prolonged hospitalisation and interference with oral feeding
3. Presence of a gross congenital malformation incompatible with life
4. Parent or Legally authorized representative (LAR) not providing written consent

Interventions

Intervention 1: Vivomixx Drops, that is, Lactic acid bacteria and Bifidobacteria drop with medium chain
triglyderide oil.
1. Each bottle cap contains at least 50 Billion Lactic acid bacteria and Bifidobacteria
a. Streptococcus thermophilus DSM 24731
b. Bifidobacterium longum DSM 24736, B. breve DSM 24732 and B. infantis DSM 24737)
c. Lactobacillus acidophilus DSM 24735, L. plantarum DSM 24730, L. paracasei DSM 24733, and L. delbrueckii
subs. bulgaricus DSM 24734
2. Each bottle contains MCT, that is, Medium chain triglyceride oil 5 ml.
The contents of the cap should be mixed with MCT oil and shaken well prior to administration. Store in
refrigerator at 2–8°C: 1 ml per day for 30 days (corresponding to NLT 10 billion CFU per day)
Control Intervention 1: Placebo Drops
1. Each Bottle cap contains Maltodextrin
2. Each bottle contains MCT, that is, Medium chain triglyceride oil 5 ml
The contents of the cap should be mixed with MCT oil and shaken well prior to administration. Store in
refrigerator at 2‐ 8 degrees centigrade.: 1 ml per day for 30 days

Outcomes

1. Sepsis
2. Possible serious bacterial infections (PSBIs). Timepoint: 60 days

Starting date

Date of first enrolment: 01‐12‐2019

Contact information

Division of Reproductive, Maternal and Child Health
Ansari Nagar, New Delhi
South
DELHI
110029
India

Notes

Study started in Jan 2019

Summary of findings tables
Additional tables
DATA AND ANALYSES
1. Vitamin A versus control

Studies

Participants

Statistical method

Effect estimate

11. All‐cause neonatal mortality

Outcome or subgroup

6

126548

Risk ratio (IV, Random, 95% CI)

0.99 [0.90, 1.08]

12. All‐cause infant mortality at 6
months

12

154940

Risk ratio (IV, Random, 95% CI)

0.98 [0.89, 1.07]

13. All‐cause infant mortality at 12
months

8

118376

Risk ratio (IV, Random, 95% CI)

1.04 [0.94, 1.14]

14. Adverse events: bulging
fontanelle

6

100256

Risk ratio (IV, Random, 95% CI)

1.53 [1.12, 2.09]

15. Adverse events: vomiting

5

99582

Risk ratio (IV, Random, 95% CI)

1.00 [0.93, 1.07]

16. All‐cause neonatal mortality:
sensitivity analysis: fixed effect
model

5

126242

Risk ratio (IV, Fixed, 95% CI)

0.99 [0.90, 1.08]
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17. All‐cause infant mortality at 6
months: sensitivity analysis: fixed
effect model

12

154940

Risk ratio (IV, Fixed, 95% CI)

0.97 [0.91, 1.03]

18. All‐cause infant mortality at 12
months: sensitivity analysis: fixed
effect model

8

118376

Risk ratio (IV, Fixed, 95% CI)

1.02 [0.96, 1.08]

2. Probiotics versus control

Studies

Participants

Statistical method

Effect estimate

21. All‐cause mortality

Outcome or subgroup

26

10998

Risk ratio (IV, Random, 95% CI)

0.80 [0.66, 0.96]

22. All‐cause mortality: subgroup
analysis: settings

26

10998

Risk ratio (IV, Random, 95% CI)

0.80 [0.66, 0.96]

221. Hospital based

23

4691

Risk ratio (IV, Random, 95% CI)

0.78 [0.65, 0.94]

222. Community based

3

6307

Risk ratio (IV, Random, 95% CI)

1.25 [0.51, 3.05]

23. All‐cause mortality: subgroup
analysis: type of probiotics

26

10998

Risk ratio (IV, Random, 95% CI)

0.80 [0.66, 0.96]

231. Preparation contain a single
strain of probiotics

9

2242

Risk ratio (IV, Random, 95% CI)

0.80 [0.61, 1.05]

232. Preparation contained multiple
strains of probiotics

12

3050

Risk ratio (IV, Random, 95% CI)

0.80 [0.58, 1.09]

233. Preparation contained synbiotics
(prebiotics + probiotics)

5

5706

Risk ratio (IV, Random, 95% CI)

0.69 [0.29, 1.61]

24. All‐cause mortality: subgroup
analysis: type of participants

26

10998

Risk ratio (IV, Random, 95% CI)

0.80 [0.66, 0.96]

241. Study include preterm/low birth
weight babies

25

10587

Risk ratio (IV, Random, 95% CI)

0.79 [0.65, 0.95]

242. Study included term infants only

1

411

Risk ratio (IV, Random, 95% CI)

1.38 [0.31, 6.08]

25. All‐cause mortality: subgroup
analysis: type of feedings

26

10998

Risk ratio (IV, Random, 95% CI)

0.80 [0.66, 0.96]

251. Baby received breastmilk only

14

7721

Risk ratio (IV, Random, 95% CI)

0.81 [0.62, 1.05]

252. Baby received formula milk only

1

411

Risk ratio (IV, Random, 95% CI)

1.38 [0.31, 6.08]

253. Baby recieved both both
breastmilk and formula milk

8

2385

Risk ratio (IV, Random, 95% CI)

0.69 [0.48, 0.99]

254. Type of feeding was unclear

3

481

Risk ratio (IV, Random, 95% CI)

1.33 [0.63, 2.81]

26. All‐cause mortality: subgroup
analysis: probiotics preparation

26

10998

Risk ratio (IV, Random, 95% CI)

0.80 [0.66, 0.96]

261. Preparation contained
Lactobacillus

10

7002

Risk ratio (IV, Random, 95% CI)

0.82 [0.63, 1.05]

262. Preparation contained
Bifidobacterium

1

400

Risk ratio (IV, Random, 95% CI)

0.43 [0.17, 1.09]

263. Preparation contained both
Lactobacillus and Bifidobacterium

13

3110

Risk ratio (IV, Random, 95% CI)

0.71 [0.47, 1.08]

264. Preparation contained
Saccharomyces boulardii only

2

486

Risk ratio (IV, Random, 95% CI)

1.12 [0.46, 2.71]

27. All‐cause mortality: sensitivity
analysis: fixed effect models

26

10998

Risk ratio (IV, Fixed, 95% CI)

0.80 [0.66, 0.96]

28. All‐cause mortality: sensitivity
analysis: risk of bias

26

10998

Risk ratio (IV, Random, 95% CI)

0.80 [0.66, 0.96]

281. High Risk of bias for
randomisation/allocation
concealment

3

285

Risk ratio (IV, Random, 95% CI)

0.27 [0.05, 1.40]

282. Low or Unclear Risk of bias for
randomisation/allocation
concealment

23

10713

Risk ratio (IV, Random, 95% CI)

0.82 [0.68, 0.99]

IMDAD

|

ET AL.

73 of 88

29. Necrotizing enterocolitis
(any type)

30

5574

Risk ratio (IV, Random, 95% CI)

0.46 [0.35, 0.59]

210. Necrotizing enterocolitis:
subgroup analysis: probiotic
preparation

30

5574

Risk ratio (IV, Random, 95% CI)

0.46 [0.35, 0.59]

2101. Preparation contained
Lactobacillus

13

2738

Risk ratio (IV, Random, 95% CI)

0.39 [0.25, 0.61]

2102. Preparation contained
Bifidobacterium

1

400

Risk ratio (IV, Random, 95% CI)

0.20 [0.09, 0.47]

2103. Preparation contained both
Lactobacillus and
Bifidobacterium

14

1950

Risk ratio (IV, Random, 95% CI)

0.49 [0.36, 0.68]

2104. Preparation contained
Saccharomyces boulardii only

2

486

Risk ratio (IV, Random, 95% CI)

0.94 [0.45, 1.95]

211. Necrotizing enterocolitis:
subgroup analysis: type of
feeding

30

5574

Risk ratio (IV, Random, 95% CI)

0.46 [0.35, 0.59]

2111. Baby receieved breastmilk only

13

1945

Risk ratio (IV, Random, 95% CI)

0.43 [0.31, 0.59]

2112. Baby receieved formula
milk only

1

93

Risk ratio (IV, Random, 95% CI)

0.21 [0.03, 1.76]

2113. Baby received both breastmilk
and formula milk

9

2445

Risk ratio (IV, Random, 95% CI)

0.55 [0.33, 0.92]

2114. Type of feeding was unclear

7

1091

Risk ratio (IV, Random, 95% CI)

0.41 [0.17, 1.00]

212. Necrotizing enterocolitis:
subgroup analysis: type of
probiotics

30

5574

Risk ratio (IV, Random, 95% CI)

0.46 [0.35, 0.59]

2121. Preparation contained a single
strain of probiotics

12

2679

Risk ratio (IV, Random, 95% CI)

0.48 [0.30, 0.76]

2122. Preparation contained multiple
strains of probiotics

15

2156

Risk ratio (IV, Random, 95% CI)

0.48 [0.35, 0.67]

2123. Preparation contained
synbiotics
(prebiotics + probiotics)

3

739

Risk ratio (IV, Random, 95% CI)

0.28 [0.12, 0.67]

213. Necrotizing enterocolitis:
sensitivity analysis: fixed effect
models

30

5574

Risk ratio (IV, Fixed, 95% CI)

0.45 [0.37, 0.56]

214. Necrotizing enterocolitis:
sensitivity analysis: risk of bias

30

5574

Risk ratio (IV, Random, 95% CI)

0.46 [0.35, 0.59]

2141. Low or unclear risk of bias for
randomisation/allocation
concealment

27

5289

Risk ratio (IV, Random, 95% CI)

0.46 [0.35, 0.61]

2142. High risk of bias for
randomisation/allocation
concealment

3

285

Risk ratio (IV, Random, 95% CI)

0.33 [0.09, 1.13]

215. Neonatal sepsis

21

9105

Risk ratio (IV, Random, 95% CI)

0.78 [0.70, 0.86]

216. Neonatal sepsis: subgroup
analysis: settings

21

9105

Risk ratio (IV, Random, 95% CI)

0.78 [0.70, 0.86]

2161. Hospital based

19

3209

Risk ratio (IV, Random, 95% CI)

0.83 [0.76, 0.91]

2162. Community based

2

5896

Risk ratio (IV, Random, 95% CI)

0.67 [0.49, 0.91]

217. Neonatal sepsis: type of
probiotics

21

9105

Risk ratio (IV, Random, 95% CI)

0.78 [0.70, 0.86]

2171. Preparation contained single
strain of probiotics

8

1328

Risk ratio (IV, Random, 95% CI)

0.84 [0.74, 0.96]

2172. Preparation contained multiple
strains of probiotics

9

2482

Risk ratio (IV, Random, 95% CI)

0.81 [0.68, 0.97]

2173. Preparation contained
synbiotics
(prebiotics + probiotics)

4

5295

Risk ratio (IV, Random, 95% CI)

0.67 [0.54, 0.83]
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218. Neonatal sepsis: subgroup
analysis: type of feeding

21

9105

Risk ratio (IV, Random, 95% CI)

0.78 [0.70, 0.86]

2181. Baby received breastmilk only

8

6961

Risk ratio (IV, Random, 95% CI)

0.71 [0.61, 0.83]

2182. Baby received formula milk
o nly

2

218

Risk ratio (IV, Random, 95% CI)

0.59 [0.22, 1.56]

2183. Baby received both formula
and breastmilk only

7

1401

Risk ratio (IV, Random, 95% CI)

0.76 [0.64, 0.90]

2184. Type of feeding was unclear

4

525

Risk ratio (IV, Random, 95% CI)

0.95 [0.82, 1.09]

219. Neonatal sepsis: subgroup
analysis: probiotic preparation

21

9105

Risk ratio (IV, Random, 95% CI)

0.78 [0.70, 0.86]

2191. Preparation contained
Lactobacillus

11

7068

Risk ratio (IV, Random, 95% CI)

0.74 [0.62, 0.87]

2192. Preparation contained
Bifidobacterium

1

400

Risk ratio (IV, Random, 95% CI)

0.81 [0.60, 1.09]

2193. Preparation contained both
Bifidobacterium and
Lactobacillus

6

1026

Risk ratio (IV, Random, 95% CI)

0.83 [0.68, 1.02]

2194. Preparation contained
Saccharomyces boulardii only

3

611

Risk ratio (IV, Random, 95% CI)

0.73 [0.57, 0.94]

220. Neonatal Sepsis: Sensitivity
analysis: Fixed Effect Model

21

9105

Risk ratio (IV, Fixed, 95% CI)

0.79 [0.73, 0.85]

221. Neonatal sepsis: sensitivity
analysis: risk of bias

21

9105

Risk ratio (IV, Random, 95% CI)

0.78 [0.70, 0.86]

2211. Low or unclear risk of bias for
randomization/allocation
concealment

19

8892

Risk ratio (IV, Random, 95% CI)

0.79 [0.71, 0.87]

2212. High risk of bias due to
randomization/allocation
concealment

2

213

Risk ratio (IV, Random, 95% CI)

0.47 [0.25, 0.90]

222. Sepsis specifc mortality

2

4672

Risk ratio (IV, Random, 95% CI)

0.21 [0.04, 1.01]
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APPENDIX A
Literature Search Strategy
Medline Strategy using PubMed
Vitamin A
((((("Vitamin A"[Mesh]) OR (Vitamin A[tiab] OR Aquasol A[tiab]
OR Retinol[tiab] OR All Trans Retinol[tiab] OR All‐Trans‐Retinol[tiab]
OR Vitamin A1[tiab] OR Vitamin A 1[tiab] OR 11‐cis‐Retinol[tiab] OR
11 cis Retinol[tiab] OR Tretinoin[tiab]) AND Supplement*[tiab])) AND
(("Infant"[Mesh] OR "Premature Birth"[Mesh]) OR (Neonat*[tiab] OR
neo nat*[tiab]) OR (newborn* OR new Born*[tiab] OR newly born*
[tiab]) OR (preterm[tiab] OR preterms[tiab] OR pre term[tiab] OR pre
terms[tiab]) OR (premature*[tiab] AND (birth*[tiab] OR born[tiab]
OR deliver*[tiab])) OR (low[tiab] AND (birthweight*[tiab] OR birth
weight*[tiab])) OR (lbw[tiab] OR vlbw[tiab] OR elbw[tiab]) OR infant*
[tiab] OR (baby[tiab] OR babies[tiab])))) NOT ("Animals"[Mesh] NOT
("Animals"[Mesh] AND "Humans"[Mesh]))
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Glucose
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(MH "Infant" OR MH "Infant, Premature" OR MH "Infant,

(((((("Glucose"[Mesh]) OR (Dextrose OR Glucose[tiab]) AND

Newborn") OR TI ((Neonat* OR neo nat*) OR (newborn* OR new

supplement*)))) AND (("Infant"[Mesh] OR "Premature Birth"[Mesh])

Born* OR newly born*) OR (preterm OR preterms OR pre term OR

OR (Neonat*[tiab] OR neo nat*[tiab]) OR (newborn* OR new Born*

pre terms) OR (premature* AND (birth* OR born OR deliver*)) OR

[tiab] OR newly born*[tiab]) OR (preterm[tiab] OR preterms[tiab] OR

(low AND (birthweight* OR birth weight*)) OR (lbw OR vlbw OR

pre term[tiab] OR pre terms[tiab]) OR (premature*[tiab] AND (birth*

elbw) OR infant* OR (baby OR babies)) OR AB ((Neonat* OR neo

[tiab] OR born[tiab] OR deliver*[tiab])) OR (low[tiab] AND (birth-

nat*) OR (newborn* OR new Born* OR newly born*) OR (preterm OR

weight*[tiab] OR birth weight*[tiab])) OR (lbw[tiab] OR vlbw[tiab] OR

preterms OR pre term OR pre terms) OR (premature* AND (birth*

elbw[tiab]) OR infant*[tiab] OR (baby[tiab] OR babies[tiab])))) NOT

OR born OR deliver*)) OR (low AND (birthweight* OR birth weight*))

("Animals"[Mesh] NOT ("Animals"[Mesh] AND "Humans"[Mesh]))

OR (lbw OR vlbw OR elbw) OR infant* OR (baby OR babies))

Probiotics
((((("Probiotics"[Mesh] OR "Prebiotics"[Mesh] OR "Synbiotics"[Mesh]) OR (Probiotic*[tiab] OR prebiotic*[tiab] OR synbiotic*
[tiab]))) AND (("Infant"[Mesh]OR "Premature Birth"[Mesh]) OR
(Neonat*[tiab] OR neo nat*[tiab]) OR (newborn* OR new Born*[tiab]
OR newly born*[tiab]) OR (preterm[tiab] OR preterms[tiab] OR pre
term[tiab] OR pre terms[tiab]) OR (premature*[tiab] AND (birth*

NOT
(MH "Animals" NOT (MH "Animals" AND MH "Humans"))
Limiter: Exclude MEDLINE records
Probiotics
`(MH "Probiotics") OR (MH "Prebiotics") OR TI (probiotic* OR prebiotic* OR synbiotic*) OR AB (probiotic* OR prebiotic* OR synbiotic*)
AND

[tiab] OR born[tiab] OR deliver*[tiab])) OR (low[tiab] AND (birth-

(MH "Infant" OR MH "Infant, Premature" OR MH "Infant,

weight*[tiab] OR birth weight*[tiab])) OR (lbw[tiab] OR vlbw[tiab] OR

Newborn") OR TI ((Neonat* OR neo nat*) OR (newborn* OR new

elbw[tiab]) OR infant*[tiab] OR (baby[tiab] OR babies[tiab])))) NOT

Born* OR newly born*) OR (preterm OR preterms OR pre term OR

("Animals"[Mesh] NOT ("Animals"[Mesh] AND "Humans"[Mesh]))

pre terms) OR (premature* AND (birth* OR born OR deliver*)) OR

CINAHL Strategies
Vitamin A

(low AND (birthweight* OR birth weight*)) OR (lbw OR vlbw OR
elbw) OR infant* OR (baby OR babies)) OR AB ((Neonat* OR neo

(MH”Vitamin A") OR TI ("Vitamin A" OR "Aquasol A" OR Retinol

nat*) OR (newborn* OR new Born* OR newly born*) OR (preterm OR

OR "All Trans Retinol" OR "All‐Trans‐Retinol" OR "Vitamin A1" OR

preterms OR pre term OR pre terms) OR (premature* AND (birth*

"Vitamin A 1" OR "11‐cis‐Retinol" OR "11 cis Retinol" OR Tretinoin)

OR born OR deliver*)) OR (low AND (birthweight* OR birth weight*))

OR AB ("Vitamin A" OR "Aquasol A" OR Retinol OR "All Trans Re-

OR (lbw OR vlbw OR elbw) OR infant* OR (baby OR babies))

tinol" OR "All‐Trans‐Retinol" OR "Vitamin A1" OR "Vitamin A 1" OR

NOT

"11‐cis‐Retinol" OR "11 cis retinol" OR Tretinoin)

(MH "Animals" NOT (MH "Animals" AND MH "Humans"))

AND

Limiter: Exclude MEDLINE records

TI (Supplement*) OR AB (Supplement*) OR MH "Dietary Sup-

Scopus Strategies

plementation" OR MH "Dietary Supplements"
AND

Vitamin A
(TITLE‐ABS("Vitamin A" OR "Aquasol A" OR retinol OR "All

(MH "Infant" OR MH "Infant, Premature" OR MH "Infant,

Trans Retinol" OR "Vitamin A1" OR "11‐cis‐Retinol" OR tretinoin))

Newborn") OR TI ((Neonat* OR neo nat*) OR (newborn* OR new

AND (TITLE‐ABS(Supplement*)) AND (TITLE‐ABS ((neonat* OR "neo

Born* OR newly born*) OR (preterm OR preterms OR pre term OR

nat*") OR (newborn* OR "new born*" OR "newly born*") OR (preterm

pre terms) OR (premature* AND (birth* OR born OR deliver*)) OR

OR preterms OR "pre term" OR "pre terms") OR (premature*) AND

(low AND (birthweight* OR birth weight*)) OR (lbw OR vlbw OR

(birth* OR born OR deliver*) OR (low AND (birthweight* OR "birth

elbw) OR infant* OR (baby OR babies)) OR AB ((Neonat* OR neo

weight*")) OR (lbw OR vlbw OR elbow) OR infant* OR (baby OR

nat*) OR (newborn* OR new Born* OR newly born*) OR (preterm OR

babies))) AND NOT INDEX(medline)

preterms OR pre term OR pre terms) OR (premature* AND (birth*

Glucose

OR born OR deliver*)) OR (low AND (birthweight* OR birth weight*))
OR (lbw OR vlbw OR elbw) OR infant* OR (baby OR babies))

TITLE‐ABS (Glucose OR Dextrose) AND TITLE‐ABS (supplement*) AND TITLE‐ABS ((neonat* OR "neo nat*") OR (newborn* OR

NOT

"new born*" OR "newly born*") OR (preterm OR preterms OR "pre

(MH "Animals" NOT (MH "Animals" AND MH "Humans"))

term" OR "pre terms") OR (premature*) AND (birth* OR born OR

Limiter: Exclude MEDLINE records

deliver*) OR (low AND (birthweight* OR "birth weight*")) OR (lbw

Glucose
(MH "Glucose") OR TI (Dextrose OR Glucose) OR AB (Dextrose
OR Glucose)
AND
TI (Supplement*) OR AB (Supplement*) OR MH "Dietary Supplementation" OR MH "Dietary Supplements"
AND

OR vlbw OR elbow) OR infant* OR (baby OR babies)) AND NOT
INDEX (medline)
Probiotics
TITLE‐ABS (Probiotic* OR Prebiotic* OR Synbiotic*) AND TITLE‐
ABS ((neonat* OR "neo nat*") OR (newborn* OR "new born*" OR
"newly born*") OR (preterm OR preterms OR "pre term" OR "pre
terms") OR (premature*) AND (birth* OR born OR deliver*) OR (low
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AND (birthweight* OR "birth weight*")) OR (lbw OR vlbw OR elbow)
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Probiotics

OR infant* OR (baby OR babies)) AND NOT INDEX (medline)
CENTRAL
Vitamin A

1. 1 MeSH descriptor: [infant] explode all trees
2. MeSH descriptor: [Premature Birth] explode all trees
3. (Neonat*:ti,ab OR neo nat*:ti,ab) OR (newborn*:ti,ab OR new

1. 1 MeSH descriptor: [infant] explode all trees

Born*:ti,ab OR newly born*:ti,ab) OR (preterm:ti,ab OR pre-

2. MeSH descriptor: [Premature Birth] explode all trees

terms:ti,ab OR pre term:ti,ab OR pre terms:ti,ab) OR (prema-

3. (Neonat*:ti,ab OR neo nat*:ti,ab OR (newborn*:ti,ab OR new

ture*:ti,ab AND (birth*:ti,ab OR born:ti,ab OR deliver*:ti,ab)) OR

Born*:ti,ab OR newly born*:ti,ab) OR (preterm:ti,ab OR pre-

(low:ti,ab AND (birthweight*:ti,ab OR birth weight*:ti,ab)) OR

terms:ti,ab OR pre term:ti,ab OR pre terms:ti,ab) OR (prema-

(lbw:ti,ab OR vlbw:ti,ab OR elbw:ti,ab) OR infant*:ti,ab OR (ba-

ture*:ti,ab AND (birth*:ti,ab OR born:ti,ab OR deliver*:ti,ab)) OR

by:ti,ab OR babies:ti,ab)

(low:ti,ab AND (birthweight*:ti,ab OR birth weight*:ti,ab)) OR

4. #1 OR #2 OR #3

(lbw:ti,ab OR vlbw:ti,ab OR elbw:ti,ab) OR infant*:ti,ab OR (ba-

5. MeSH descriptor: [Animals] explode all trees

by:ti,ab OR babies:ti,ab)

6. MeSH descriptor: [Humans] explode all trees

4. #1 OR #2 OR #3

7. (#5 NOT (#5 AND #6))

5. MeSH descriptor: [Animals] explode all trees

8. MeSH descriptor: [Probiotics] explode all trees

6. MeSH descriptor: [Humans] explode all trees

9. MeSH descriptor: [Prebiotics] explode all trees

7. (#5 NOT (#5 AND #6))

10. MeSH descriptor: [Synbiotics] explode all trees

8. supplement*:ti,ab

11. #8 OR #9 OR #10

9. MeSH descriptor: [Vitamin A] explode all trees

12. Probiotic*:ti,ab OR prebiotic*:ti,ab OR synbiotic*:ti,ab

10. "Vitamin A":ti,ab OR "Aquasol A":ti,ab OR Retinol:ti,ab OR "All

13. #11 or #12

Trans Retinol":ti,ab OR "All‐Trans‐Retinol":ti,ab OR "Vitamin

14. #13 AND #4 NOT #7

A1":ti,ab OR "Vitamin A 1":ti,ab OR "11 cis Retinol":ti,ab OR

15. "accession number" near pubmed

"11‐cis‐Retinol":ti,ab OR Tretinoin:ti,ab

16. #14 NOT #15

11. #9 OR #10
12. #11 AND #8
13. #12 AND #4 NOT #7
14. "accession number" near pubmed
15. #13 NOT #14

LILACS
Vitamin A
(tw:(("Vitamin A"))) OR (ti:(("Aquasol A" OR retinol OR "All Trans
Retinol" OR "Vitamin A1" OR "11‐cis‐Retinol" OR tretinoin))) OR
(ab:(("Aquasol A" OR retinol OR "All Trans Retinol" OR "Vitamin A1"

Glucose

OR "11‐cis‐Retinol" OR tretinoin))) AND (ti:(supplement*)) OR (ab:(supplement*)) AND (tw:(Infant)) OR (tw:("Premature Birth")) OR

1. 1 MeSH descriptor: [infant] explode all trees

(ti:(((neonat* OR "neo nat*") OR (newborn* OR "new born*" OR

2. MeSH descriptor: [Premature Birth] explode all trees

"newly born*") OR (preterm OR preterms OR "pre term" OR "pre

3. (Neonat*:ti,ab OR neo nat*:ti,ab) OR (newborn*:ti,ab OR new

terms") OR (premature*) AND (born OR deliver*) OR (low AND

Born*:ti,ab OR newly born*:ti,ab) OR (preterm:ti,ab OR pre-

(birthweight* OR "birth weight*")) OR (lbw OR vlbw OR elbw) OR

terms:ti,ab OR pre term:ti,ab OR pre terms:ti,ab) OR (prema-

(baby OR babies)))) OR (ab:(((neonat* OR "neo nat*") OR (newborn*

ture*:ti,ab AND (birth*:ti,ab OR born:ti,ab OR deliver*:ti,ab)) OR

OR "new born*" OR "newly born*") OR (preterm OR preterms OR

(low:ti,ab AND (birthweight*:ti,ab OR birth weight*:ti,ab)) OR

"pre term" OR "pre terms") OR (premature*) AND (born OR deliver*)

(lbw:ti,ab OR vlbw:ti,ab OR elbw:ti,ab) OR infant*:ti,ab OR (ba-

OR (low AND (birthweight* OR "birth weight*")) OR (lbw OR vlbw

by:ti,ab OR babies:ti,ab)

OR elbw) OR (baby OR babies)))) AND db:("LILACS")

4. #1 OR #2 OR #3

Glucose

5. MeSH descriptor: [Animals] explode all trees

((tw:(glucose)) OR (ti:(dextrose)) OR (ab:(dextrose)) AND (ti:(supple-

6. MeSH descriptor: [Humans] explode all trees

ment*)) OR (ab:(supplement*))) AND ((tw:(infant)) OR (tw:(“premature

7. (#5 NOT (#5 AND #6))

birth”)) OR (ti:((neonat* OR "neo nat*") OR (newborn* OR "new born*"

8. supplement*:ti,ab

OR "newly born*") OR (preterm OR preterms OR "pre term" OR "pre

9. MeSH descriptor: [Glucose] explode all trees

terms") OR (premature*))) AND (ti:((born OR deliver*) OR (low AND

10. Dextrose:ti,ab OR Glucose:ti,ab

(birthweight* OR "birth weight*")) OR (lbw OR vlbw OR elbw) OR (baby

11. #9 OR #10

OR babies))) OR (ab:((neonat* OR "neo nat*") OR (newborn* OR "new

12. #11 AND #8

born*" OR "newly born*") OR (preterm OR preterms OR "pre term" OR

13. #12 AND #4 NOT #7

"pre terms") OR (premature*))) AND (ab:((born OR deliver*) OR (low

14. "accession number" near pubmed

AND (birthweight* OR "birth weight*")) OR (lbw OR vlbw OR elbw) OR

15. #13 NOT #14

(baby OR babies)))) AND (instance:"regional") AND (db:("LILACS"))
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'vitamin a 1':ti,ab OR '11‐cis‐retinol':ti,ab OR '11 cis retinol':ti,ab

((tw:(probiotics OR prebiotics OR synbiotics)) OR (ti:(probiotic*

OR tretinoin:ti,ab

OR prebiotic* OR synbiotic*)) OR (ab:(probiotic* OR prebiotic* OR

3. supplement*:ti,ab

synbiotic*))) AND ((tw:(infant)) OR (tw:(“premature birth”)) OR (ti:((-

4. 'supplementation'/exp

neonat* OR "neo nat*") OR (newborn* OR "new born*" OR "newly

5. #1 OR #2

born*") OR (preterm OR preterms OR "pre term" OR "pre terms") OR

6. #3 OR #4

(premature*))) AND (ti:((born OR deliver*) OR (low AND (birth-

7. #5 AND #6

weight* OR "birth weight*")) OR (lbw OR vlbw OR elbw) OR (baby

8. 'infant'/exp

OR

'prematurity'/exp

OR

'newborn'/exp

OR babies))) OR (ab:((neonat* OR "neo nat*") OR (newborn* OR "new

OR 'low birth weight'/exp OR 'very low birth weight'/exp OR

born*" OR "newly born*") OR (preterm OR preterms OR "pre term"

'extremely low birth weight'/exp OR 'premature labor'/exp

OR "pre terms") OR (premature*))) AND (ab:((born OR deliver*) OR

9. neonat*:ti,ab OR 'neo nat*':ti,ab OR newborn*:ti,ab OR 'new

(low AND (birthweight* OR "birth weight*")) OR (lbw OR vlbw OR

born*':ti,ab OR 'newly born*':ti,ab OR preterm:ti,ab OR pre-

elbw) OR (baby OR babies)))) AND (instance:"regional") AND

terms:ti,ab OR 'pre term':ti,ab OR 'pre terms':ti,ab OR (prema-

(db:("LILACS"))

ture*:ti,ab AND (birth*:ti,ab OR born:ti,ab OR deliver*:ti,ab)) OR

EMBASE
Vitamin A

(low:ti,ab AND (birthweight*:ti,ab OR 'birth weight*':ti,ab)) OR
lbw:ti,ab OR vlbw:ti,ab OR elbw:ti,ab OR infant*:ti,ab OR baby:ti,ab OR babies:ti,ab

1. 1 'retinol'/exp OR 'retinol palmitate'/exp OR '11 cis retinol'/exp
OR 'retinoic acid'/exp
2. 'vitamin a':ti,ab OR 'aquasol a':ti,ab OR retinol:ti,ab OR 'all trans
retinol':ti,ab OR 'all‐trans‐retinol':ti,ab OR 'vitamin a1':ti,ab OR

10. #8 OR #9
11. #7 AND #10
12. #11 NOT ([animals]/lim NOT [humans]/lim)
13. #12 NOT [medline]/lim

